

0000950170-24-12278010-Q Monte Rosa Therapeutics, Inc. 20241110720411070704780705007050 0 0000950170-24-122780 10-Q 76 20240930 20241107 20241107 Monte Rosa Therapeutics, Inc. 0001826457 2836 0000000000 DE 1231 10-Q 34 001-40522 241433117 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 10-Q 1 glue-20240930.htm 10-Q 10-Q Q3--12-31false00018264570001826457us-gaap:RestrictedStockMember2023-12-310001826457us-gaap:RetainedEarningsMember2023-07-012023-09-300001826457us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-09-300001826457us-gaap:LeaseholdImprovementsMember2023-12-310001826457us-gaap:FurnitureAndFixturesMember2024-09-300001826457us-gaap:AdditionalPaidInCapitalMember2024-03-3100018264572024-07-012024-09-300001826457us-gaap:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2024-01-012024-09-300001826457us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-09-300001826457us-gaap:RetainedEarningsMember2023-04-012023-06-300001826457us-gaap:RetainedEarningsMember2024-04-012024-06-300001826457us-gaap:FairValueInputsLevel1Memberglue:PensionPlanAssetsMember2024-09-300001826457us-gaap:FairValueInputsLevel3Memberglue:PensionPlanAssetsMember2023-12-310001826457us-gaap:RetainedEarningsMember2023-06-300001826457us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001826457us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001826457us-gaap:CommonStockMember2023-07-012023-09-300001826457glue:UnvestedStockOptionMember2024-09-300001826457us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001826457us-gaap:CommonStockMember2023-04-012023-06-300001826457us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001826457us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001826457glue:CollaborationAndLicenseAgreementMemberus-gaap:SubsequentEventMember2024-10-252024-10-250001826457glue:AtTheMarketOfferingMember2023-01-012023-09-300001826457glue:JefferiesLlcMember2022-07-312022-07-310001826457us-gaap:FurnitureAndFixturesMember2023-12-310001826457us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-300001826457glue:TwoThousandTwentyOneStockIncentivePlanMember2024-09-300001826457us-gaap:CommonStockMember2023-12-3100018264572022-12-310001826457us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2024-09-300001826457glue:JefferiesLlcMember2024-09-300001826457glue:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2024-09-300001826457glue:CollaborationAndLicenseAgreementMembersrt.MaximumMember2024-10-252024-10-250001826457us-gaap:ConstructionInProgressMember2023-12-310001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001826457us-gaap:MoneyMarketFundsMember2023-12-310001826457us-gaap:AdditionalPaidInCapitalMember2024-06-300001826457glue:CommonStockOptionsMember2023-01-012023-09-300001826457glue:NonCancelLeasesMember2024-09-300001826457us-gaap:FairValueInputsLevel3Memberglue:PensionPlanAssetsMember2024-09-300001826457us-gaap:WarrantMember2023-10-310001826457us-gaap:RetainedEarningsMember2023-01-012023-03-310001826457us-gaap:RestrictedStockMember2024-09-300001826457us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001826457us-gaap:USTreasurySecuritiesMember2023-12-310001826457us-gaap:AdditionalPaidInCapitalMember2023-06-300001826457us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001826457glue:PreFundedWarrantsMember2023-12-310001826457glue:UnderwrittenPublicOfferingMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001826457us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-09-300001826457us-gaap:FairValueInputsLevel2Memberglue:PensionPlanAssetsMember2024-09-300001826457srt:MinimumMemberglue:CollaborationAndLicenseAgreementMember2023-11-012023-11-300001826457us-gaap:WarrantMember2024-09-300001826457glue:UndesignatedPreferredStockMember2024-09-300001826457us-gaap:CommonStockMember2023-01-012023-03-310001826457glue:CollaborationAndLicenseAgreementMember2024-01-012024-09-300001826457us-gaap:USTreasurySecuritiesMember2024-09-300001826457us-gaap:CommonStockMember2024-01-012024-03-310001826457glue:TdSecuritiesUsaLlcMember2024-05-012024-05-310001826457glue:UnvestedStockOptionMember2024-01-012024-09-300001826457us-gaap:FairValueInputsLevel1Member2024-09-300001826457us-gaap:CommonStockMember2024-09-300001826457us-gaap:CommonStockMember2023-03-310001826457glue:AtTheMarketOfferingMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001826457us-gaap:RetainedEarningsMember2022-12-310001826457us-gaap:MoneyMarketFundsMember2024-09-300001826457us-gaap:RestrictedStockUnitsRSUMember2024-09-3000018264572023-09-300001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-3100018264572024-01-012024-03-310001826457us-gaap:FairValueInputsLevel2Member2024-09-300001826457glue:TwoThousandTwentyOneStockIncentivePlanMember2024-01-012024-09-300001826457glue:HochbergerstrasseMembersrt:MinimumMember2023-04-0300001826457us-gaap:RetainedEarningsMember2024-06-300001826457us-gaap:RetainedEarningsMember2023-09-3000018264572023-03-310001826457glue:HochbergerstrasseMember2023-04-012023-04-300001826457us-gaap:RestrictedStockMember2024-01-012024-09-300001826457us-gaap:CorporateDebtSecuritiesMember2023-12-310001826457us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001826457us-gaap:WarrantMember2023-10-012023-10-310001826457us-gaap:RestrictedStockMember2023-01-012023-09-300001826457us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001826457us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310001826457us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-09-300001826457glue:CommonStockOptionsMember2024-09-300001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-3000018264572023-01-012023-09-300001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001826457us-gaap:AdditionalPaidInCapitalMember2023-03-310001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001826457glue:LaboratoryEquipmentMember2023-12-310001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001826457us-gaap:AdditionalPaidInCapitalMember2022-12-310001826457us-gaap:LeaseholdImprovementsMember2024-09-300001826457us-gaap:FairValueInputsLevel2Member2023-12-310001826457glue:HarrisonStreetMember2021-12-140001826457us-gaap:ComputerEquipmentMember2024-09-300001826457us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001826457us-gaap:FairValueInputsLevel1Member2023-12-310001826457glue:CommonStockOptionsMember2024-01-012024-09-3000018264572023-10-012023-10-310001826457glue:AtTheMarketOfferingMember2024-01-012024-09-300001826457us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001826457us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001826457us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001826457us-gaap:CommonStockMember2024-06-300001826457glue:PensionPlanAssetsMember2023-12-310001826457us-gaap:RetainedEarningsMember2024-09-300001826457glue:JefferiesLlcMember2024-01-012024-09-300001826457us-gaap:CommonStockMember2024-03-310001826457us-gaap:USTreasurySecuritiesMember2024-09-300001826457glue:TdSecuritiesUsaLlcMember2024-05-310001826457us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001826457us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001826457us-gaap:CommonStockMember2023-06-300001826457us-gaap:CommonStockMember2023-09-300001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001826457us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310001826457us-gaap:RestrictedStockUnitsRSUMember2023-12-310001826457us-gaap:WarrantMemberglue:TdSecuritiesUsaLlcMember2024-05-310001826457us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100018264572024-06-300001826457us-gaap:AdditionalPaidInCapitalMember2023-09-300001826457us-gaap:RetainedEarningsMember2024-01-012024-03-310001826457us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001826457us-gaap:CorporateDebtSecuritiesMember2023-12-310001826457us-gaap:FairValueInputsLevel2Memberglue:PensionPlanAssetsMember2023-12-310001826457us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001826457us-gaap:CommonStockMemberglue:UnderwrittenPublicOfferingMember2024-04-012024-06-300001826457glue:HochbergerstrasseMember2021-03-010001826457us-gaap:ConstructionInProgressMember2024-09-300001826457us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300001826457us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-09-300001826457glue:HochbergerstrasseMembersrt.MaximumMember2023-04-0300001826457us-gaap:RestrictedStockMember2023-01-012023-09-300001826457us-gaap:RetainedEarningsMember2024-03-3100018264572023-07-012023-09-300001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001826457us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001826457us-gaap:CommonStockMember2022-12-310001826457glue:PreFundedWarrantsMember2024-09-300001826457us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-3100018264572024-09-3000018264572023-06-3000018264572023-01-012023-03-310001826457us-gaap:USTreasurySecuritiesMember2023-12-310001826457us-gaap:FairValueInputsLevel2Memberglue:TdSecuritiesUsaLlcMember2024-05-310001826457us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001826457glue:PensionPlanAssetsMember2024-09-300001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001826457us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001826457us-gaap:CorporateDebtSecuritiesMember2024-09-300001826457us-gaap:AdditionalPaidInCapitalMember2023-12-310001826457us-gaap:FairValueInputsLevel1Memberglue:PensionPlanAssetsMember2023-12-3100018264572023-01-012023-12-140001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001826457glue:UnderwrittenPublicOfferingMember2024-04-012024-06-300001826457us-gaap:RestrictedStockMember2024-09-300001826457us-gaap:ComputerEquipmentMember2023-12-310001826457us-gaap:CommonStockMember2024-05-012024-05-310001826457us-gaap:CommonStockMemberglue:AtTheMarketOfferingMember2024-04-012024-06-300001826457us-gaap:AdditionalPaidInCapitalMember2024-09-300001826457us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2023-12-310001826457us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001826457us-gaap:CommonStockMember2024-04-012024-06-300001826457us-gaap:RestrictedStockMember2024-01-012024-09-300001826457us-gaap:WarrantMemberglue:TdSecuritiesUsaLlcMember2024-05-012024-05-310001826457us-gaap:WarrantMember2024-01-012024-09-300001826457glue:LaboratoryEquipmentMember2024-09-300001826457us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001826457us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-3100018264572024-04-012024-06-300001826457us-gaap:RestrictedStockUnitsRSUMember2024-09-300001826457us-gaap:FairValueInputsLevel3Member2023-12-310001826457us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-09-300001826457us-gaap:RetainedEarningsMember2024-07-012024-09-300001826457glue:CollaborationAndLicenseAgreementMember2023-11-012023-11-300001826457us-gaap:RestrictedStockMember2023-12-310001826457us-gaap:CorporateDebtSecuritiesMember2024-09-300001826457us-gaap:RetainedEarningsMember2023-03-310001826457us-gaap:RetainedEarningsMember2024-09-3000018264572023-12-3100018264572024-01-012024-09-30iso4217:USDxbnrl:sharesxbnrl:pureutr:sgftxbnrl:sharesiso4217:USD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 A FORM 10-Q A (Mark One) a~" QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR a~" TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 A Monte Rosa Therapeutics, Inc. (Exact name of registrant as specified in its charter) A Delaware 84-3766197 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer identification No.) A A 321 Harrison Avenue, Suite 900Boston, Massachusetts 02118 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (617) 949-2643 A Securities registered pursuant to Section 12(b) of the Act: A Title of each class A TradingSymbol(s) A Name of each exchange on which registered Common stock, par value \$0.0001 per share A GLUE A The Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes a~" No a~" Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (A232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes a~" No a~" Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of a~large accelerated filer, a~accelerated filer, a~smaller reporting company, a~emerging growth companya~ in Rule 12b-2 of the Exchange Act. A Large accelerated filer a~ Accelerated filer a~ Non-accelerated filer a~ Smaller reporting company a~ A A A Emerging growth company a~ a~ A If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. a~ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes a~ No a~ As of November 4, 2024, the registrant had 61,436,740 shares of common stock, \$0.0001 per share, outstanding. A A A Special note regarding forward-looking statements This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as a~emay, a~will, a~should, a~expect, a~intend, a~plan, a~anticipate, a~believe, a~estimate, a~predict, a~potential, a~continue, or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about: a~the initiation, timing, progress, results, costs, and any expectations and/or predictions of success of our current and future research and development programs and preclinical studies, including our expectations for our molecular glue degraders, or MGDs, molecules, including our GSPT1-directed MGD MRT-2359, VAV1-directed MGD MRT-6160 and NEK7-directed MGD, MRT-8102; a~the initiation, timing, progress, results, costs, and any expectations and/or predictions of success of our current and any future clinical trials, including statements regarding the nature of or the timing for when any results of any clinical trials will become available; a~our ability to continue to develop our proprietary platform, called QuENTM, and to expand our proteomics and translational medicine capabilities; a~the potential advantages of our platform technology and product candidates; a~the extent to which our scientific approach and platform technology may target proteins that have been considered undruggable or inadequately drugged; a~our plans to submit Investigational New Drug, or IND applications to the U.S. Food and Drug Administration, or the FDA for current and future product candidates; a~the potential benefits of strategic collaborations and our ability to enter into strategic collaborations with third parties who have the expertise to enable us to further develop our biological targets, product candidates and platform technologies, including our agreement with Novartis AG, or Novartis, for MRT-6160; a~our ability to obtain and maintain regulatory approval of our product candidates; a~our ability to maintain and expand, including through third-party vendors, our library of MGDs; a~our ability to manufacture, including through third-party manufacturers, our product candidates for preclinical use, future clinical trials and commercial use, if approved; a~our ability to commercialize our product candidates, including our ability to establish sales, marketing and distribution capabilities for our product candidates; a~the rate and degree of market acceptance of our product candidates; a~the size and growth potential of the markets for our product candidates, and our ability to serve those markets; a~our ability to establish and maintain intellectual property rights covering our current and future product candidates and technologies; a~the implementation of our business model and strategic plans for our business, product candidates, and technology; a~estimates of our future expenses, revenues, capital requirements, and our needs for additional financing; a~our expected use of proceeds from sales of our common stock in "at-the-market" offerings and other offerings, and the period over which such proceeds, together with existing cash, will be sufficient to meet our operating needs; a~our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates; a~our financial performance; a~developments in laws

The third quarter interim condensed consolidated financial statements included additional funding will be necessary to fund future discovery research, pre-clinical and clinical activities. The Company will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although it has been successful in raising capital in the past, there is no assurance that the Company will be successful in obtaining such additional financing on terms acceptable to it, if at all, and the Company may not be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect the Company's business prospects, even the ability to continue operations. 2. Summary of significant accounting policies Basis of presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or GAAP, and are stated in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board, or FASB. All intercompany balances and transactions have been eliminated in consolidation.Unaudited Financial Information The Company's condensed consolidated financial statements included herein have been prepared in conformity with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. In the Company's opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Recently issued accounting pronouncements The Company has elected to use the extended transition period for complying with new or revised accounting standards as available under the Jumpstart Our Business Startups Act, or the JOBS Act. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024 and early adoption is permitted. The Company is currently in the process of evaluating the impact of this pronouncement on our related disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The impact of the adoption of this standard will be immaterial to the accompanying condensed consolidated financial statements.

3. Fair value measurements The following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):

	As of September 30, 2024	Level 1	Level 2	Level 3	Total
Current assets	\$ 125,006	\$ 125,006	\$ -	\$ -	\$ 125,006
Money market funds	\$ 125,006	\$ 125,006	\$ -	\$ -	\$ 125,006
Pension plan assets	\$ 57,386	\$ 57,386	\$ -	\$ -	\$ 57,386
Corporate debt securities	\$ 57,386	\$ 57,386	\$ -	\$ -	\$ 57,386
Total assets	\$ 251,169	\$ 251,169	\$ -	\$ -	\$ 251,169
Current liabilities	\$ 122,791	\$ 122,791	\$ -	\$ -	\$ 122,791
Unrealized gains	\$ 122,791	\$ 122,791	\$ -	\$ -	\$ 122,791
Losses	\$ 24,496	\$ 24,496	\$ -	\$ -	\$ 24,496
Total liabilities	\$ 122,791	\$ 122,791	\$ -	\$ -	\$ 122,791
Net assets	\$ 128,378	\$ 128,378	\$ -	\$ -	\$ 128,378

As of September 30, 2023:

	As of September 30, 2023	Level 1	Level 2	Level 3	Total
Current assets	\$ 125,006	\$ 125,006	\$ -	\$ -	\$ 125,006
Money market funds	\$ 125,006	\$ 125,006	\$ -	\$ -	\$ 125,006
Pension plan assets	\$ 57,386	\$ 57,386	\$ -	\$ -	\$ 57,386
Corporate debt securities	\$ 57,386	\$ 57,386	\$ -	\$ -	\$ 57,386
Total assets	\$ 251,169	\$ 251,169	\$ -	\$ -	\$ 251,169
Current liabilities	\$ 122,791	\$ 122,791	\$ -	\$ -	\$ 122,791
Unrealized gains	\$ 122,791	\$ 122,791	\$ -	\$ -	\$ 122,791
Losses	\$ 24,496	\$ 24,496	\$ -	\$ -	\$ 24,496
Total liabilities	\$ 122,791	\$ 122,791	\$ -	\$ -	\$ 122,791
Net assets	\$ 128,378	\$ 128,378	\$ -	\$ -	\$ 128,378

The Company's financial assets and liabilities are classified based on the fair value hierarchy. Level 1 consists of assets and liabilities that are quoted prices in active markets for identical securities. Level 2 consists of assets and liabilities that are valued using inputs that are observable either directly or indirectly, or derived from such observable inputs through correlation analysis. Level 3 consists of assets and liabilities that are valued using unobservable inputs. The Company's financial assets and liabilities are classified based on the fair value hierarchy. Level 1 consists of assets and liabilities that are quoted prices in active markets for identical securities. Level 2 consists of assets and liabilities that are valued using inputs that are observable either directly or indirectly, or derived from such observable inputs through correlation analysis. Level 3 consists of assets and liabilities that are valued using unobservable inputs. The Company's financial assets and liabilities are classified based on the fair value hierarchy. Level 1 consists of assets and liabilities that are quoted prices in active markets for identical securities. Level 2 consists of assets and liabilities that are valued using inputs that are observable either directly or indirectly, or derived from such observable inputs through correlation analysis. Level 3 consists of assets and liabilities that are valued using unobservable inputs.

exercise such Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, up to 19.99%) of the number of shares of the Company's common stock outstanding immediately after giving effect to such exercise. No pre-funded warrants have been exercised as of September 30, 2024. The holders of common stock are entitled to dividends when and if declared by the board of directors, subject to the preferences applicable to any outstanding shares of preferred stock. The board of directors has not declared any dividends and the Company has not paid any dividends. The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. The Company has issued restricted stock to founders, employees and consultants, and expense for this restricted stock is recognized on a straight-line basis (see Note 11). The restricted stock generally vests monthly over 4 years. As of September 30, 2024, and December 31, 2023, the Company has reserved the following shares of common stock for the vesting of restricted stock and exercise of stock options:

	September 30, 2024	December 31, 2023
Options to purchase common stock	11,591,425	9,394,930
Unvested restricted common stock awards	624	14,696
Unvested restricted common stock units	112,159	236,519
Pre-funded warrants	20,638,924	10,000,400
At-Market Offering	19,646,545	

In July 2022, the Company entered into a sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which the Company may offer and sell shares of its common stock having aggregate gross proceeds of up to \$100 million from time to time in after-the-market offerings through Jefferies, as the Company's sales agent. The Company agreed to pay Jefferies a commission of up to 3.0% of the gross proceeds of any shares sold by Jefferies under the Sales Agreement. During the nine months ended September 30, 2024, the Company sold 130,506 shares of common stock under the Sales Agreement for aggregate gross proceeds of \$1.0 million, or aggregate net proceeds of \$0.9 million after deducting sales agent discounts, commissions, and other offering costs. During the nine months ended September 30, 2023, the Company did not sell shares of its common stock under the Sales Agreement. Underwritten Public Offering: In May 2024, the Company entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.999 per pre-funded warrant, which represents the price per share at which shares of Common Stock were sold in this Offering, minus \$0.0001, which is the exercise price of each pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. A Registered Direct Offering: In October 2023, the Company sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the Company's common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share.

12 11. Stock-based compensation 2020 Stock incentive plan The Company's 2020 Stock Option and Grant Plan, or the 2020 Plan, provided for the Company to grant stock options, restricted stock and other stock awards, to employees, non-employee directors, and consultants. Upon the effectiveness of the 2021 Plan (as defined below), no further issuances were made under the 2020 Plan. The 2020 Stock incentive plan The Company's 2021 Stock Option and Incentive Plan, or the 2021 Plan, was approved by the Company's board of directors on May 28, 2021 and the Company's stockholders on June 17, 2021 and became effective on the date immediately prior to the date on which the registration statement for the Company's IPO was declared effective. The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company's officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2021 Plan was 4,903,145. Under the evergreen provision of the 2021 Plan, the shares available for issuance under the 2021 Plan will be automatically increased each January 1st by 5% of the outstanding number of shares of the Company's common stock on the immediately preceding December 31st or such lesser number of shares as may be determined by the Company's compensation, nomination and corporate governance committee. Effective January 1, 2024 the number of shares available under the 2021 Plan automatically increased by 2,507,011 shares pursuant to the evergreen provision of the 2021 Plan. As of September 30, 2024, 3,289,766 shares were available for issuance under the 2021 Plan. 2021 Employee stock purchase plan The Company's 2021 Employee Stock Purchase Plan, or the 2021 ESPP, was approved by the Company's board of directors on May 28, 2021 and the Company's stockholders on June 17, 2021 and became effective on the date immediately prior to the date on which the registration statement for the Company's IPO was declared effective. A total of 439,849 shares of the Company's common stock were initially reserved for issuance under the 2021 ESPP. The shares available for issuance under the 2021 ESPP will be automatically increased on each January 1st, through January 1, 2031, by the least of (i) 439,849 shares of the Company's common stock, (ii) 1% of the outstanding number of shares of the Company's common stock on the immediately preceding December 31st or (iii) such lesser number of shares of the Company's common stock as determined by the plan administrator of the 2021 ESPP. Effective January 1, 2024 the number of shares available under the 2021 ESPP automatically increased by 439,849 shares pursuant to the evergreen provision of the 2021 ESPP. As of September 30, 2024, 1,504,248 shares were available for issuance under the 2021 ESPP. Stock option activity The following summarizes stock option activity:

	Number of options	Weighted average exercise price	Weighted average remaining contractual term (years)	Aggregate intrinsic value (in thousands)	Outstanding
December 31, 2023	9,394,930	\$ 8.78	8.0	\$ 4,741	Granted
2024	2,945,540	\$ 5.48			Granted
Exercised	(238,304)	\$ 2.86			Exercised
Forfeited	(510,741)	\$ 7.99			Forfeited
September 30, 2024	11,591,425	\$ 8.10			Outstanding

The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company's common stock. Restricted stock award activity Unvested restricted stock awards were granted to employees under the 2020 Plan. Restricted stock awards generally vest over a four year period provided the individual remains in continuous service of the Company.

13 The following summarizes restricted stock award activity:

	Number of shares	Weighted average grant date fair value	Unvested restricted stock awards as of December 31, 2023	Unvested restricted stock awards as of September 30, 2024
December 31, 2023	14,696	\$ 2.19	14,072	
September 30, 2024	624	\$ 2.19		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	112,159	\$ 7.55		
Granted	236,519	\$ 8.00		
Vested	(122,034)	\$ 8.42		
Forfeited	(2,326)	\$ 7.55		
Unvested restricted stock units as of September 30, 2024	11			

announcing updated clinical data before the end of 2024. In October 2024, we announced a global exclusive development and commercialization license agreement with Novartis to advance VAV1 MGDs, including MRT-6160, currently in Phase 1 clinical development, for various immune-related conditions. In August 2024, we announced that the first participants had been dosed in an MRT-6160 Phase 1 single ascending dose/multiple ascending dose, or SAD/MAD, study. Initial clinical results, including safety, pharmacokinetics, VAV1 protein degradation, and key downstream pharmacodynamic markers, are anticipated by the first quarter of 2025. In addition, MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-1 β and the NLRP3 inflammasome, is now in IND-enabling studies, with an IND filing with the FDA planned for the first half of 2025. Further, our CDK2 and Cyclin E1-directed MGD programs are progressing and continue to advance towards development candidate nominations. We expect to nominate a development candidate for the CDK2-directed MGD program by year-end 2024. Liquidity To date, we have financed our operations primarily through the issuance and sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock, registered direct offerings, and through our collaboration with Roche. From our inception through the date hereof, there have been aggregate inflows of \$684.8 million of gross proceeds from such transactions. Since inception, we have had significant operating losses. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures and, to a lesser extent, general and administrative expenditures. Our net loss was \$135.4 million and \$108.5 million for the years ended December 31, 2023 and 2022, respectively, and our net loss was \$86.1 million and \$102.1 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of \$452.0 million and \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. Impact of global economic and political developments The development of our product candidates could be disrupted and materially adversely affected in the future by global economic or political developments. In addition, economic uncertainty in global markets caused by political instability and conflict, and economic challenges caused by global pandemics or other public health events, may lead to market disruptions, including significant volatility in commodity prices, credit and capital market instability and supply chain interruptions. Our business, financial condition and results of operations could be materially and adversely affected by negative impacts on the global economy and capital markets resulting from these global economic conditions, particularly if such conditions are prolonged or worsen. Components of operating results Collaboration Revenue Collaboration revenue represents amounts earned from our Collaboration and License Agreement with Roche. Research and development expenses Our research and development expenses include: $\bullet$ expenses incurred under agreements with consultants, third-party service providers that conduct research and development activities on our behalf; $\bullet$ personnel costs, which include salaries, benefits, pension and stock-based compensation; $\bullet$ laboratory and vendor expenses related to the execution of preclinical and clinical studies; $\bullet$ laboratory supplies and materials used for internal research and development activities; and $\bullet$ facilities and equipment costs. Most of our research and development expenses have been related to the development of our QuEENTM platform and advancement of our CSPT1 program, advancement of our disclosed and undisclosed programs including for CDK2, NEK7, VAV1, and CCNE1. With the exception of costs incurred for research and development on behalf of third parties, we have not reported program costs since our inception because we have not historically tracked or recorded our research and development expenses on a program-by-program basis. We use our personnel and infrastructure resources across the breadth of our research and development activities, which are directed toward identifying and developing product candidates. We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in manufacturing, as we advance our programs and conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects, the costs of related clinical development costs or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. General and administrative expenses Our general and administrative expenses consist primarily of personnel costs and other expenses for outside professional services, including legal fees relating to patent and corporate matters, professional fees for accounting, auditing, tax and administrative consulting services, insurance costs and other operating costs. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, and the potential commercialization of our product candidates and development of commercial infrastructure. We also anticipate our general and administrative costs will increase and with respect to the hiring of additional personnel, fees to outside consultants, lawyers and accountants, and costs associated with being a public company, such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC reporting requirements, insurance and investor relations costs. Non-operating income and (expense) Our non-operating income and (expense) includes (i) interest earned on our investments, including principally U.S. government-backed money-market funds and marketable securities; (ii) gains and losses on transactions of our Swiss subsidiary denominated in currencies other than the U.S. Dollar; (iii) proceeds from the sale of fixed assets; and (iv) realized losses on the sale of marketable securities. Results of operations for the three months ended September 30, 2024 and 2023 The following sets forth our results of operations:

|
 |
Three months ended September 30, 2024 | Three months ended September 30, 2023 | |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |

---------------------------------------|---|---
--
--|--|---------------------------------------

--
--|--|---------------------------------------

--
---|--|--------------------------------------|---
--
--|--|--------------------------------------|---
--
---|--|--------------------------------------|---
---|--|--------------------------------------

--|--|--------------------------------------
---|
| (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 9,216 Δ \$ Δ Δ \$ 9,216 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 27,616 Δ \$ 28,306 Δ \$ (690) Δ General and administrative Δ \$ 8,127 Δ \$ 8,662 Δ \$ (535) Δ Total operating expenses Δ \$ 35,743 Δ \$ 36,968 Δ \$ (1,225) Δ Loss from operations Δ \$ (26,527) Δ \$ (36,968) Δ Δ Δ 10,441 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ \$ 485 Δ Net loss before income taxes Δ \$ (23,788) Δ \$ (34,714) Δ Δ Δ 10,926 Δ Provision for income taxes Δ \$ (71) Δ \$ (170) Δ Δ 99 Δ Net loss Δ \$ (23,859) Δ \$ (34,884) Δ Δ 11,025 Δ 18 Collaboration revenue Collaboration revenue of \$9.2 million for the three months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 10,299 Δ \$ 12,227 Δ \$ (1,928) Δ Personnel costs Δ \$ 9,862 Δ \$ 9,208 Δ \$ 654 Δ Laboratory and related expenses Δ \$ 2,220 Δ \$ 2,284 Δ \$ (64) Δ Facility costs and other expenses Δ \$ 5,235 Δ \$ 4,587 Δ \$ 648 Δ Research and development expenses Δ \$ 27,616 Δ \$ 28,306 Δ \$ (690) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the three months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$2.6 million and \$2.3 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 5,702 Δ \$ 5,440 Δ \$ 262 Δ Professional services Δ \$ 572 Δ \$ 1,277 Δ \$ (705) Δ Facility costs and other expenses Δ \$ 1,853 Δ \$ 1,944 Δ \$ (91) Δ General and administrative expenses Δ \$ 8,127 Δ \$ 8,661 Δ \$ (534) Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the three months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$1.6 million and \$2.2 million, respectively. Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible
promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Three months ended September 30, 2024
 | Three months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 10,299 Δ \$ 12,227 Δ \$ (1,928) Δ Personnel costs Δ \$ 9,862 Δ \$ 9,208 Δ \$ 654 Δ Laboratory and related expenses Δ \$ 2,220 Δ \$ 2,284 Δ \$ (64) Δ Facility costs and other expenses Δ \$ 5,235 Δ \$ 4,587 Δ \$ 648 Δ Research and development expenses Δ \$ 27,616 Δ \$ 28,306 Δ \$ (690) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEEN Δ , Δ discovery engine. Research and development expenses for the three months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$2.6 million and \$2.3 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 5,702 Δ \$ 5,440 Δ \$ 262 Δ Professional services Δ \$ 572 Δ \$ 1,277 Δ \$ (705) Δ Facility costs and other expenses Δ \$ 1,853 Δ \$ 1,944 Δ \$ (91) Δ General and administrative expenses Δ \$ 8,127 Δ \$ 8,661 Δ \$ (534) Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the three months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$1.6 million and \$2.2 million, respectively. Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394
Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of
\$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Three months ended September 30, 2024 | Three months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 5,702 Δ \$ 5,440 Δ \$ 262 Δ Professional services Δ \$ 572 Δ \$ 1,277 Δ \$ (705) Δ Facility costs and other expenses Δ \$ 1,853 Δ \$ 1,944 Δ \$ (91) Δ General and administrative expenses Δ \$ 8,127 Δ \$ 8,661 Δ \$ (534) Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the three months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$1.6 million and \$2.2 million, respectively. Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ
Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing
costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Three months ended September 30, 2024 | Three months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and
administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023
 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the
date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023
 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEEN Δ , Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and
development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately
exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and
development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δ at-the-market Δ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table> | | Nine months ended September 30, 2024 | (in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may
develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If |
|
 |
Three months ended September 30, 2024 | Three months ended September 30, 2023 | |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |
| (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 10,299 Δ \$ 12,227 Δ \$ (1,928) Δ Personnel costs Δ \$ 9,862 Δ \$ 9,208 Δ \$ 654 Δ Laboratory and related expenses Δ \$ 2,220 Δ \$ 2,284 Δ \$ (64) Δ Facility costs and other expenses Δ \$ 5,235 Δ \$ 4,587 Δ \$ 648 Δ Research and development expenses Δ \$ 27,616 Δ \$ 28,306 Δ \$ (690) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEEN Δ , Δ discovery engine. Research and development expenses for the three months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$2.6 million and \$2.3 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 5,702 Δ \$ 5,440 Δ \$ 262 Δ Professional services Δ \$ 572 Δ \$ 1,277 Δ \$ (705) Δ Facility costs and other expenses Δ \$ 1,853 Δ \$ 1,944 Δ \$ (91) Δ General and administrative expenses Δ \$ 8,127 Δ \$ 8,661 Δ \$ (534) Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the three months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$1.6 million and \$2.2 million, respectively. Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement
and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Three months ended September 30, 2024
 | Three months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 5,702 Δ \$ 5,440 Δ \$ 262 Δ Professional services Δ \$ 572 Δ \$ 1,277 Δ \$ (705) Δ Facility costs and other expenses Δ \$ 1,853 Δ \$ 1,944 Δ \$ (91) Δ General and administrative expenses Δ \$ 8,127 Δ \$ 8,661 Δ \$ (534) Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the three months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$1.6 million and \$2.2 million, respectively. Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126
Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe
that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Three months ended September 30, 2024 | Three months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As
of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we
currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and
2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table>
 | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEEN Δ , Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of
10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023
 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and
related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δ at-the-market Δ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the
ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table> | | Nine months ended September 30, 2024 | (in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating
to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If | | |
 | |
|
 |
Three months ended September 30, 2024 | Three months ended September 30, 2023 | |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |
| (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 5,702 Δ \$ 5,440 Δ \$ 262 Δ Professional services Δ \$ 572 Δ \$ 1,277 Δ \$ (705) Δ Facility costs and other expenses Δ \$ 1,853 Δ \$ 1,944 Δ \$ (91) Δ General and administrative expenses Δ \$ 8,127 Δ \$ 8,661 Δ \$ (534) Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the three months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$1.6 million and \$2.2 million, respectively. Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Three months ended September 30, 2024</th><th>Three months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an
exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Three months ended September 30, 2024
 | Three months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study,
the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise
additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement
of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital
sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEEN Δ , Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on
sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table>
 | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately
exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table> | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023
 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δ at-the-market Δ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital
sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table> | | Nine months ended September 30, 2024 | (in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If |
 | | |
 |
 | | | |
|
 |
Three months ended September 30, 2024 | Three months ended September 30, 2023 | |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |
| (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 2,892 Δ \$ 2,227 Δ Foreign currency exchange gain (loss), net Δ \$ (153) Δ Δ 27 Δ Other income Δ \$ 2,739 Δ \$ 2,254 Δ Other income and expense for the three months ended September 30, 2024 and 2023 is primarily attributable to interest earned on marketable securities. 19 Results of operations for the nine months ended September 30, 2024 and 2023 The following sets forth our results of operations: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and
stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024
 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended
September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table>
 | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEEN Δ , Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023
Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table>
 | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of
September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table>
 | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δ at-the-market Δ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per
share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table>
 | | Nine months ended September 30, 2024 | (in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If |
 | | |
 |
 | | | |
 | | | |
|
 |
Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |
| (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Collaboration revenue Δ \$ 14,975 Δ \$ Δ Δ \$ 14,975 Δ Operating expenses: Δ Δ Δ Δ Δ Δ Δ Research and development Δ \$ 84,137 Δ \$ 84,137 Δ \$ (1,440) Δ General and administrative Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ Total operating expenses Δ \$ 109,091 Δ \$ 108,448 Δ \$ 643 Δ Loss from operations Δ \$ (94,116) Δ \$ (108,448) Δ Δ 14,332 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ \$ 1,677 Δ Net loss before income taxes Δ \$ (85,731) Δ \$ (101,740) Δ Δ 16,009 Δ Provision for income taxes Δ \$ (406) Δ \$ (360) Δ Δ 46 Δ Net loss Δ \$ (86,137) Δ \$ (102,100) Δ Δ 15,963 Δ Collaboration revenue Collaboration revenue of \$15.0 million for the nine months ended September 30, 2024 represents revenue recorded under the Roche License and Collaboration Agreement. As of September 30, 2024, \$18.9 million was classified as current deferred revenue on the condensed consolidated balance sheet. Research and development expenses Research and development expenses were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEENΔ, Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8
million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024
 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEEN Δ , Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table
border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table>
 | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table
border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table>
 | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of
our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δ at-the-market Δ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table>
 | | Nine months ended September 30, 2024 | (in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If |

 | | | |
 | | |
 |
 | | | |
 | | | |
|
 |
Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |
| (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ External research and development services Δ \$ 31,227 Δ \$ 35,698 Δ \$ (4,471) Δ Personnel costs Δ \$ 29,585 Δ \$ 28,126 Δ \$ 1,459 Δ Laboratory and related expenses Δ \$ 6,043 Δ \$ 6,812 Δ \$ (769) Δ Facility costs and other expenses Δ \$ 15,842 Δ \$ 13,501 Δ \$ 2,341 Δ Research and development expenses Δ \$ 82,697 Δ \$ 84,137 Δ \$ (1,440) Δ As of September 30, 2024, we had 105 employees engaged in research and development activities in our facilities in the U.S. and Switzerland. As of September 30, 2023, we had 107 research and development employees in our facilities in the U.S. and Switzerland. Most of our research and development expenses were driven by the successful achievement of key milestones in our research and development organization, including the continuation of the MRT-2359 clinical study, the advancement of MRT-6160 into the clinic, the progression of our preclinical pipeline, and the continued development of the Company's QuEEN Δ , Δ discovery engine. Research and development expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$7.9 million and \$6.7 million, respectively. General and administrative expenses General and administrative expenses to support our business activities were comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory
and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table></td></tr></tbody></table> | | Nine months ended September 30, 2024
 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily
of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table>
 | | Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385
Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δ at-the-market Δ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table>
 | | Nine months ended September 30, 2024 | (in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If |

 | | | |

 | | | |
 | | |
 |
 | | | |
 | | |
 |
|
 |
Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |
| (in thousands) Δ 2024 Δ 2023 Δ Dollar change Δ Personnel costs Δ \$ 16,443 Δ \$ 14,770 Δ \$ 1,673 Δ Professional services Δ \$ 3,850 Δ \$ 3,451 Δ \$ 399 Δ Facility costs and other expenses Δ \$ 6,101 Δ \$ 6,090 Δ \$ 11 Δ General and administrative expenses Δ \$ 26,394 Δ \$ 24,311 Δ \$ 2,083 Δ As of September 30, 2024 and 2023 we had 28 and 26 employees engaged in general and administrative activities, respectively, principally in our U.S. facility. General and administrative expenses for the nine months ended September 30, 2024 and 2023 included non-cash stock-based compensation expense of \$5.7 million and \$5.9 million, respectively. 20 Other income (expense) Other income (expense), net was comprised of: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>Nine months ended September 30, 2023</th></tr></thead><tbody><tr><td>(in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δat-the-marketΔ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table></td></tr></tbody></table>
 | | Nine months ended September 30, 2024
 | Nine months ended September 30, 2023 | (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into
a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δ at-the-market Δ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table>
 | | Nine months ended September 30, 2024 | (in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter
into such other arrangements when needed on favorable terms or at all. If |
 | | |
 |
 | | | |

 | | | |
 | | |
 |
 | | | |
 | | |
 |
|
 |
Nine months ended September 30, 2024 | Nine months ended September 30, 2023 | |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |
| (in thousands) Δ 2024 Δ 2023 Δ Interest income, net Δ \$ 7,971 Δ \$ 6,966 Δ Foreign currency exchange gain (loss), net Δ \$ 414 Δ \$ (151) Δ Gain on disposal of fixed assets Δ Δ 24 Δ Loss on sale of marketable securities Δ Δ Δ 131 Δ Other income Δ \$ 8,385 Δ \$ 6,708 Δ The increase in interest and other income for the nine months ended September 30, 2024, is due to the strengthening of the U.S. Dollar with respect to, principally, the Swiss Franc. Liquidity and capital resources Overview Due to our significant research and development expenditures, we have generated operating losses since our inception. We have funded our operations primarily through the sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock and through our collaboration with Roche. As of September 30, 2024, we had \$247.1 million in cash, cash equivalents, restricted cash and marketable securities. We have incurred losses since our inception and, as of September 30, 2024, we had an accumulated deficit of \$452.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. At-the-Market Offering On July 1, 2022, we filed a registration statement on Form S-3 (File No. 333-266003) with the SEC, which was declared effective on July 13, 2022, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$100.0 million of our common stock from time to time in Δ at-the-market Δ offerings, or the ATM Program, under the Shelf Registration Statement and subject to the limitations thereof. We will pay to the Jefferies cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. As of the date of this Quarterly Report on Form 10-Q, 2,612,514 shares have been sold pursuant to the ATM Program. Underwritten Public Offering In May 2024, we entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the \$0.0001 per share exercise price of such pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. Registered Direct Offering In October 2023, we sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the our common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. 21 Cash flows The following table summarizes our cash flows for the periods indicated: <table border="1"><thead><tr><th></th><th>Nine months ended September 30, 2024</th><th>(in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If</th></tr></thead></table>
 | | Nine months ended September 30, 2024
 | (in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |
|
 |
Nine months ended September 30, 2024 | (in thousands) Δ 2024 Δ 2023 Δ Net cash provided by (used in): Δ Δ Δ Δ Δ Operating activities Δ \$ (86,926) Δ \$ (73,436) Δ Investing activities Δ \$ (13,556) Δ \$ 74,504 Δ Financing activities Δ \$ 98,284 Δ \$ 2,319 Δ Net increase (decrease) in cash, cash equivalents and restricted cash Δ \$ (2,198) Δ \$ 3,387 Δ Operating activities Net cash used in operating activities of \$86.9 million during the nine months ended September 30, 2024, was attributable to our net loss of \$86.1 million and decreases in our working capital of \$18.3 million, partially off-set by non-cash charges of \$17.5 million principally with respect to depreciation expense and stock-based compensation. Net cash used in operating activities of \$73.4 million during the nine months ended September 30, 2023, was attributable to our net loss of \$102.1 million off-set by an increase in our working capital of \$14.8 million and non-cash charges of \$13.9 million principally with respect to depreciation expense and stock-based compensation. Investing activities Cash used in investing activities of \$13.6 million during the nine months ended September 30, 2024 was primarily attributable to proceeds from the maturity of marketable securities of \$152.6 million, offset by purchases of marketable securities of \$162.4 million and purchases of property and equipment of \$3.8 million. Cash provided by investing activities of \$74.5 million during the nine months ended September 30, 2023 was primarily attributable to proceeds from the maturity of marketable securities of \$121.8 million and proceeds from the sale of marketable securities of \$45.6 million, offset by purchases of marketable securities of \$75.6 million and purchases of property and equipment of \$17.4 million. Financing activities Net cash provided by financing activities of \$98.3 million for nine months ended September 30, 2024 was primarily due the net proceeds from our Offering of \$96.4 million. Funding requirements Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. Based upon our current operating plan, and the anticipated \$150 million upfront payment due from Novartis, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We base this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If | |

 | | |
 |
 | | |
 |
 | | |
 |
 | | | |

 | | | |
 | | | |
 | | |
 |

we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could 22 have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: the scope, progress, results and costs of researching, developing and manufacturing our current product candidates or any future product candidates, and conducting preclinical studies and clinical trials; the timing of, and the costs involved in, obtaining regulatory approvals or clearances for our lead product candidates or any future product candidates; the number and characteristics of any additional product candidates we develop or acquire; the cost of manufacturing our lead product candidate or any future product candidates and any products we successfully commercialize, including costs associated with building-out our manufacturing capabilities; our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into; the expenses needed to attract and retain skilled personnel; the costs associated with being a public company; the timing, receipt and amount of sales of any future approved or cleared products, if any; and the impact of global economic and political developments, future public health events and the corresponding responses of businesses and governments. Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs. Critical accounting policies and significant judgments and estimates Our unaudited interim condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U.S. The preparation of our unaudited interim condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. However, even though we believe we have used reasonable estimates and assumptions in preparing our interim condensed consolidated financial statements, the future effects of global economic and political developments and any future public health events on our results of operations, cash flows, and financial position are unclear. Our actual results may differ from these estimates under different assumptions or conditions. Revenue Recognition To date, our revenues have primarily consisted of consideration related to the License and Collaboration Agreement with Roche, which we are accounting for under ASC 606. In accordance with ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the assessment of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as we satisfy each performance obligation. As part of the accounting for arrangements under ASC 606, we must use significant judgment to determine the performance obligations based on the determination under step (ii) above. We also use judgment to determine whether 23 milestones or other variable consideration, except for royalties and sales-based milestones, should be included in the transaction price as described below. We recognize revenue based on those amounts when, or as, the performance obligations under the contract are satisfied. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. Determining the standalone selling price of each performance obligation requires significant judgment and is discussed in further detail in Note 9. We utilize judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and the resulting periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement, which are subject to review by the joint research committee, or JRC. Such a change could have a material impact on the amount of revenue we record in future periods. We concluded that the transfer of control to the customer for the performance obligation occurs over the time period that the research and development services are provided by us. We recognize revenue for the performance obligation as those services are provided using an input method, based on the cumulative costs incurred compared to the total estimated costs expected to be incurred to satisfy the performance obligation. The percentage of completion method is, in management’s judgment, the best measure of progress towards satisfying the performance condition. At the inception of each arrangement that includes research, development or regulatory milestone payments, we evaluate whether the milestones are considered likely to be met and estimate the amount to be considered for inclusion in the transaction price using the most-likely-amount method. If it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur, the associated milestone value is included in the transaction price. For milestone payments due upon events that are not within our control, such as regulatory approvals, we are not able to assert that it is likely that the regulatory approval will be granted and that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur until those approvals are received. In making this assessment, we evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone. There is considerable judgment involved in determining whether it is probable that a significant reversal in the amount of cumulative revenue recognized would not occur. We reevaluate the transaction price and our total estimated costs expected to be incurred at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research, development and manufacturing activities that we are responsible for, are resolved or other changes in circumstances occur. If necessary, we will adjust our estimate of the transaction price or our estimates of the total costs expected to be incurred. To date, we have not had any significant changes in our estimates. Other than the Company’s revenue recognition policy described above, there have been no significant changes to our critical accounting policies from those described in the Company’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2023 Annual Report. For a complete discussion of our significant accounting policies and recent accounting pronouncements, see Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report and Note 2 to our 2023 Annual Report. Recently issued and adopted accounting pronouncements Refer to Note 2, Summary of Significant Accounting Policies, in the accompanying notes to our and consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for a discussion of recent accounting pronouncements. 24 Contractual obligations and commitments During the three months ended September 30, 2024, there have been no material changes to our contractual obligations and commitments from those described under the Company’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 14, 2024. Off-balance sheet arrangements During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules. Emerging growth company status In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an emerging growth company may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Therefore, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we may adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-public companies instead of the dates required for other public companies. However, we may early adopt these standards. We will cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of \$1.235 billion or more, (ii) the last day of our fiscal year following the fifth anniversary of the date of the closing of our initial public offering, or our IPO, (iii) the date on which we have issued more than \$1.0 billion in nonconvertible debt during the previous three years or (iv) the date on which we are deemed to be a large, accelerated filer under the rules of the SEC. We are also a smaller reporting company, meaning that the market value of our stock held by non-affiliates plus the aggregate amount of gross proceeds to us as a result of our IPO is less than \$700 million and our annual revenue was less than \$100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company after our IPO if either (i) the market value of our stock held by non-affiliates is less than \$250 million or (ii) our annual revenue was less than \$100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than \$700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our annual reports on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. 25 Item 3. Quantitative and qualitative disclosures about market risk We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this Item 3. Item 4. Controls and procedures Evaluation of Disclosure Controls and Procedures Our management, with the participation of our principal executive officer and our principal financial officer have evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of September 30, 2024. The term “disclosure controls and procedures,” as defined in the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during three months ended September 30, 2024 that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations on Effectiveness of Controls Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving the desired control objectives. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. A 26 Part II – Other Information Item 1. Legal proceedings From time to time, we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of September 30, 2024, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk factors Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, those risks and uncertainties discussed in the Company’s Risk Factors included in our 2023 Annual Report, as amended and supplemented by the information in our subsequent Quarterly Reports on Form 10-Q, together with all of the other information contained in this Quarterly Report, including our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report. The risk factor disclosure in our 2023 Annual Report and subsequent Quarterly Reports on Form 10-Q is qualified by the information that is described in this Quarterly Report. If any of the risks described below or in our 2023 Annual Report actually occur, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment. Other than as set forth below, there have been no material changes to the risk factors set forth in our 2023 Annual Report. Risks related to our financial position and capital needs We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future. Since our inception, we have focused substantially all of our efforts and financial resources on developing our proprietary QuEENTM platform, our proprietary MGD library and our initial pipeline of product candidates. To date, we have financed our operations primarily through the issuance and sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock, registered direct offerings, and through our collaboration with Roche. From our inception through the date hereof, we raised an aggregate of \$684.8 million of gross proceeds from such transactions. As of September 30, 2024, our cash, cash equivalents, restricted cash and marketable securities were \$247.1 million. We have incurred net losses in each year since our inception, and we had an accumulated deficit of \$452.0 million as of September 30, 2024. For the years ended December 31, 2023 and 2022, we reported net losses of \$135.4 million and \$108.5 million, respectively. For the nine months ended September 30, 2024 and 2023, we reported a net loss of \$86.1 million and \$102.1 million, respectively. Substantially all of our operating losses have resulted from costs incurred in connection with our research and initial pipeline programs and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. We expect our expenses to significantly increase in connection with our ongoing activities, as we: conduct our clinical trial for MRT-2359, our MGD product candidate targeting GSPT1, and MRT-6160, our MGD product candidate targeting VAV1; continue preclinical activities for our VAV1, NEK7, CDK2, CCNE1, and other currently undisclosed programs; prepare and submit IND applications with the FDA for other current and future product candidates, including for MRT-8102, our MGD product candidate targeting NEK7; complete preclinical studies for current or future product candidates; progress MGD molecules from our initial programs through lead optimization to development candidates; initiate and complete clinical trials for current or future product candidates; expand and improve the capabilities of our QuEENTM platform; continue to build our proprietary library of MGDs; 27 contract to manufacture our product candidates; advance research and development related activities to expand our product pipeline; seek regulatory approval for our product candidates that successfully complete clinical development; develop and scale up our capabilities to support our ongoing preclinical activities and future clinical trials for our product candidates and commercialization of any of our product candidates for which we may obtain marketing approval; maintain, expand, and protect our intellectual property portfolio; hire additional staff, including clinical, scientific and management personnel; and secure facilities to support continued growth in our research, development and commercialization efforts. In addition, if we obtain marketing approval for our current or future product candidates, we will incur

significant expenses relating to our commercialization of such product candidates via our sales, marketing, product manufacturing and distribution efforts. Because of the numerous risks and uncertainties associated with developing pharmaceutical drugs, including in light of economic fluctuations, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we achieve profitability, we may not be able to sustain or increase our profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. 28 Item 2. Unregistered sales of equity securities, use of proceeds and issuer purchases of equity securities Recent sales of unregistered equity securities None. Issuer purchases of equity securities None. Item 3. Defaults upon senior securities None. Item 4. Mine safety disclosures Not Applicable. Item 5. Other information Rule 10b5-1 Trading Plans During the fiscal quarter ended on September 30, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Exchange Act Rule 10b5-1 trading arrangement," as those terms are defined in Item 408(a) of Regulation S-K. 29 Item 6. Exhibits A ExhibitNumber Description 3.1 A Fourth Amended and Restated Certificate of Incorporation of Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K (File No. 001-40522) filed on June 28, 2021). 3.2 A Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K (File No. 001-40522) filed on June 14, 2023). 3.3 A Second Amended and Restated By-laws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.3 of the Registrant's Quarterly Report on Form 10-Q (File No. 001-40522) filed on May 9, 2024) 31.1* Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1** Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. A A 101.INS* Inline XBRL Instance Document A "the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. 101.SCH* A Inline XBRL Taxonomy Extension Schema Document 104* A Cover Page Interactive Data File (embedded within the Inline XBRL document) A * Filed herewith. ** Deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference. A 30 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. A Monte Rosa Therapeutics, Inc. Date: November 7, 2024 By: /s/ Markus Warmuth Markus Warmuth Chief Executive Officer A A (Principal Executive Officer and Principal Financial Officer) A A 31 EX-31.1 2 glue-ex31.1.htm EX-31.1 EX-31.1 A Exhibit 31.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Markus Warmuth, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q for the period ending September 30, 2024 of Monte Rosa Therapeutics, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A Date: November 7, 2024 By: /s/ Markus Warmuth Markus Warmuth Chief Executive Officer A A (Principal Executive Officer and Principal Financial Officer) A A EX-32.1 3 glue-ex32.1.htm EX-32.1 EX-32.1 A Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Monte Rosa Therapeutics, Inc. (the "Company"), I certify, pursuant to 18 U.S.C. A§ 1350, as adopted pursuant to A§ 906 of the Sarbanes-Oxley Act of 2002, that: (1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. A Date: November 7, 2024 By: /s/ Markus Warmuth Markus Warmuth Chief Executive Officer A A (Principal Executive Officer and Principal Financial Officer) A A EX-101.SCH 4 glue-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 100020 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details) 2 link:presentationLink link:calculationLink link:definitionLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink link:definitionLink 100050 - Statement - Condensed Combined and Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 100060 - Statement - Condensed Combined and Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995455 - Disclosure - Description of business and liquidity link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995465 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995485 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995495 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995505 - Disclosure - Accrued expenses and other current liabilities link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995515 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995525 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995535 - Disclosure - Collaboration And License Agreements link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995545 - Disclosure - Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995555 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995565 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995575 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995585 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995595 - Disclosure - Employee Retirement Plan link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995605 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995615 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995625 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995635 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995645 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995655 - Disclosure - Accrued expenses and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995665 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995675 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995685 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995695 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995705 - Disclosure - Employee retirement plans (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995715 - Disclosure - Description of Business and Liquidity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995725 - Disclosure - Fair Value Measurements - Summary of Financial Assets Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995735 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995745 - Disclosure - Marketable Securities (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995755 - Disclosure - Marketable Securities - Summary of Marketable securities (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995765 - Disclosure - Property and Equipment, net - Schedule of Property, Plant and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995775 - Disclosure - Property and Equipment, net - Schedule of Depreciation Expense (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995785 - Disclosure - Property and Equipment, net (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995795 - Disclosure - Accrued expenses and other current liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995805 - Disclosure - Leases (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995815 - Disclosure - Leases - Components of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995825 - Disclosure - Leases - Summarizes lease expense (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995835 - Disclosure - Leases - Schedule of Lease Terms and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995845 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995855 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995865 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases under non-cancelable (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995875 - Disclosure - Commitments and Contingencies (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995885 - Disclosure - Collaboration and License Agreements (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995895 - Disclosure - Convertible Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995905 - Disclosure - Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995915 - Disclosure - Equity - Schedule of Common Stock for Potential Conversion Outstanding Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995925 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995935 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995945 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995955 - Disclosure - Stock-based compensation - Schedule of Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995965 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995975 - Disclosure - Income taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995985 - Disclosure - Net Loss Per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 995995 - Disclosure - Net Loss Per Common Share - Schedule of Anti-Dilutive Shares Excluded from Earnings Per Share Calculation (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 996005 - Disclosure - Employee Retirement Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 996015 - Disclosure - Employee retirement plans - Schedule of Pension Expense (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 996025 - Disclosure - Employee retirement plans - Schedule of Defined Contribution Expense (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 996035 - Disclosure - Subsequent events (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink Statement [Line Items] Potential Pre-Clinical, Clinical, Commercial, And Sales Milestones Potential Pre-Clinical, Clinical, Commercial, And Sales Milestones Potential pre-clinical, clinical, commercial, and sales milestones Increase (Decrease) in Accounts Receivable Accounts receivable Plan Name Plan Name [Domain] Entity Address Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation State Country Code Entity Incorporation, State or Country Code Unrecognized stock based compensation cost, units Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Other comprehensive income: Other Comprehensive Income (Loss), Tax [Abstract] Comprehensive loss: Weighted average exercise price, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted average exercise price, exercisable Weighted average remaining contractual term (years), balance Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Temporary Equity, Shares Issued Convertible preferred stock, shares issued Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of securities purchase agreement warrants Partners' Capital Account, Units, Sold in Public Offering 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Convertible Preferred Stock Preferred Stock [Text Block] Lessee, Operating Leases [Text Block] Leases Leases Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Increase in annual base rent (Percentage) Increase in annual base rent (Percentage) Increase in annual base rent (Percentage) Finite-Lived Intangible Assets by Major Class [Axis] Fair Value of Preferred Stock Tranche Obligation Fair Value of Preferred Stock Tranche Obligation Fair value of preferred stock tranche obligation. Accrued research and development Accrued Research And Development Accrued research and development. Equity [Text Block] Equity Net of underwriting Discount on issuance of common stock Net of underwriting Discount on issuance of common stock Underwriter's discount on issuance of common stock pursuant to the at-the-market sales agreement Unrealized loss on available-for-sale securities Debt Securities, Available-for-Sale, Unrealized Loss Unrealized loss on available-for-sale securities Unrealized loss on available-for-sale securities Operating Leases, Future Minimum Payments Due, Next 12 Months 2023 Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Increase In Future Issuance Reserved Share Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Increase In Future Issuance Reserved Share Increase in share percentage Sale of Stock [Domain] Cash and Cash Equivalents [Domain] Features of Convertible Preferred Stock [Abstract] Summarizes Lease Expense Operating Lease, Lease Income [Table Text Block] Pension Plan Assets [Member] Pension plan assets Member Pension Plan Assets [Member] Entity Central Index Key Entity Central Index Key Warrant [Member] Warrant [Member] Number of shares, forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Common stock shares issued Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Common stock, shares, issued Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Income Statement [Abstract] Entity Address State Or Province Entity Address, State or Province Proceeds from employee stock purchase plan Issuance of shares under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Net loss before income taxes Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Tenant improvements Payments for

Tenant Improvements Stock issuance costs of convertible securities. Stock issuance costs of convertible securities Agreement [Axis] Agreement [Axis] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Marketable Securities, Total Marketable Securities Marketable securities Debt Securities, Available-for-Sale, Unrealized Loss Position, Total Debt Securities, Available-for-Sale, Unrealized Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value, exercisable Cover [Abstract] Subsequent Event [Line Items] Non-Rule 10b5-1 Arrangement Modified Non Rule 10b51 Arr Modified Flag Non Rule 10b51 Arr Modified Flag Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gains Unrealized Gains Operating expenses: Operating Expenses [Abstract] Prior Settlement of Preferred Stock Tranch Obligation [Member] Prior Settlement Of Preferred Stock Tranch Obligation [Member] Prior Settlement of Preferred Stock Tranch Obligation Member. Current assets Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Investments, Debt and Equity Securities [Abstract] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Retained earnings accumulated deficit Retained earnings accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Plan Name Plan Name [Axis] Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis on Unobservable Inputs Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Number of options, beginning balance Number of options, ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Current assets: Assets, Current [Abstract] Issuance of common stock, net of issuance costs of \$984 Issuance of common stock, net of issuance costs of \$714 Issuance of common stock, net of issuance costs of \$714 Convertible preferred stock Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance Other Ownership Interests, Offering Costs Offering Costs Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Weighted average grant date fair value, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Lessee, Operating Lease, Term of Contract Initial lease term Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Vesting Vesting [Axis] Purchase price of stock Common Stock, Par or Stated Value Per Share Common stock, par or stated value per share Accounts Payable and Other Accrued Liabilities, Current Accrued expenses and other current liabilities Total other current liabilities Statement of Cash Flows [Abstract] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Unvested restricted common stock awards Restricted common stock Restricted Stock [Member] Equity Components Equity Components [Axis] Entity Address Address Line1 Entity Address, Address Line One Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Employee-related Liabilities, Current Compensation And Benefits Compensation and benefits Issued Pre Funded Warrants Issued Pre Funded Warrants Purchase of pre-funded warrants shares Number of shares, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Intangible Asset, Finite-Lived [Table] Computer Equipment [Member] Computer Hardware and Software Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Other receivables Other receivables Increase (Decrease) in Other Receivables Subsequent Event Type [Axis] TD Securities USA LLC Member TD Securities USA LLC [Member] TD Securities (USA) LLC [Member] Nonoperating Income (Expense) Total other income Schedule of Antidilutive Securities Excluded from Earnings Per Share Calculation Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] At-the-Market Offering [Member] At-the-Market Offering [Member] At-the-Market Offering Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable Securities Number of shares, Unvested restricted stock, beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares, Unvested, ending balance Subsidiary Or Equity Method Investee [Line Items] Subsidiary Or Equity Method Investee [Line Items] Amendment Flag Right-of-use assets and operating lease liabilities Increase (Decrease) in Operating Lease Liability Decrease in operating lease liability Operating Lease, Liability, Noncurrent Operating lease liability Corporate Debt Securities [Member] Corporate Debt Securities Member Additional Paid in Capital, Common Stock Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Additional paid-in capital Liquidity Consideration Policy [Policy Text Block] Liquidity consideration policy, Liquidity consideration Sale of Stock, Price Per Share Common stock, purchase price Common Stock sold to public Net income loss Net loss Lessee, Lease, Description [Table] Number of options, exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of common stock options, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number of options, exercisable Research and Development Expense [Member] Research and Development Options to purchase common stock Common Stock Options [Member] Common stock options member. Stock Options to Purchase Common Stock Shares of the preferred stock of the Company which are authorized under its Certificate of Incorporation, are not issued and outstanding, and have not been assigned to a series of preferred stock. Undesignated Preferred Stock [Member] Undesignated Preferred Stock Equity Component Equity Component [Domain] Statistical Measurement [Domain] General and administrative General and Administrative Expense General and Administrative Expense, Total General and administrative expense Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from Sale of Property, Plant, and Equipment Proceeds from the sale of property and equipment Aggregate net proceeds Issuance of common stock, net of issuance costs Issuance of common stock, net of issuance costs Furniture and Fixtures Furniture and Fixtures [Member] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Current deferred revenue Deferred Revenue, Current Deferred Revenue, Current, Total Preferred stock shares issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued, Total Interest Income [Member] Proceeds from exercise of employee stock options Proceeds from Stock Options Exercised Employee Retirement Plan Retirement Benefits [Text Block] Issuance of shares under employee stock purchase plan, Shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Total lease expense Operating Lease, Expense Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Weighted average exercise price, vested or expected to vest Weighted average exercise price, forfeited Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Restricted cash Restricted Cash, Noncurrent Class of Stock Class of Stock [Domain] Collaboration and license agreements Collaborative Arrangement Disclosure [Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Common stock shares outstanding Finite-Lived Intangible Assets, Major Class Name [Domain] 401(k) expense Postemployment Benefits, Period Expense Preferred stock price per share Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Accounts Payable and Accrued Liabilities, Current [Abstract] Operating Leases, Future Minimum Payments, Due Thereafter Thereafter Operating Leases, Future Minimum Payments, Due in Three Years 2025 Antidilutive Securities Antidilutive Securities [Axis] Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Gross Proceeds from sale of Common Stock Unrealized gain on available-for-sale securities Debt Securities, Available-for-Sale, Realized Loss Unrealized loss on available-for-sale securities Schedule of Restricted Stock Award Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Finite-Lived Intangible Assets [Line Items] Entity Interactive Data Current Entity Interactive Data Current Series B Convertible preferred stock, Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock Marketable Securities [Table] Document Quarterly Report Document Quarterly Report Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, vested Weighted average grant date fair value, Vested Cash, cash equivalents and restricted cash\$^ beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash-end of period Total cash, cash equivalents and restricted cash Total cash, cash equivalents and restricted cash Statistical Measurement [Axis] Operating Lease, Cost Operating lease expense Total assets measured at fair value Assets, Fair Value Disclosure Assets, Fair Value Disclosure, Total Related Party Related and Nonrelated Parties [Domain] Schedule of supplemental cash flow information related to leases. Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block] Schedule Of Supplemental Cash Flow Information Related To Leases Lease, Cost Total lease expense Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Future Minimum Payments Under Non -cancelable Operating Leases Schedule of Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Weighted average grant date fair value, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected remaining cost, weighted average period Income Statement Location Statement of Income Location, Balance [Axis] Cash and Cash Equivalents [Axis] Total assets Assets Reconciliation of cash, cash equivalents and restricted cash Restricted Cash and Cash Equivalents [Abstract] Issuance of pre-funded warrant, net of issuance costs Issuance of pre-funded warrant, net of issuance costs Issuance of pre-funded warrant, net of issuance costs of \$290 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Number of shares, Vested Number of shares, Vested Number of shares, Vested Dividends Payable Dividends declared Pension expense Pension Cost (Reversal of Cost) New Accounting Pronouncements, Policy [Policy Text Block] Recently issued accounting pronouncements Entity Address City Or Town Entity Address, City or Town AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Equity [Abstract] Payment of common stock issuance costs Payment of convertible preferred stock issuance costs Payments of stock issuance costs Stock issuance costs Operating Leases, Future Minimum Payments Due Total future minimum lease payments Total future minimum lease payments Number of shares, Forfeited Number of shares, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total Measure at fair value, transfers among Level 1, Level 2 or Level 3 Provision for pension benefit obligation Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual term (years), exercisable Depreciation expense Depreciation expense Depreciation Depreciation Share Price Common stock price Aggregate fair value of restricted stock vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Construction in Progress [Member] Construction in process Pre-Funded Warrants to Purchase Pre-Funded Warrants to Purchase Pre-funded warrants to purchase Company matching contributions to maximum employees eligible compensation Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate Fair Value Disclosures [Abstract] Public Offering of Share Public Offering Of Share Underwritten public offering Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases under non-cancelable Stock Issued During Period, Value, Stock Options Exercised Exercise of common stock options Lessee, Lease, Description [Line Items] Current liabilities: Liabilities, Current [Abstract] Document Type Document Type Security12b Title Title of 12(b) Security One Time Upfront Payment One Time Upfront Payment One Time Upfront Payment Cash and cash equivalents at carrying value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Component of Lease Expense Lease, Cost [Table Text Block] Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Aggregate intrinsic value, exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Research and development Research and Development Expense Research and Development Expense, Total Number of options, granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Expected remaining cost, weighted average period, units Expected remaining cost, weighted average period, units Restricted Cash and Cash Equivalents, Total Restricted Cash and Cash Equivalents Restricted Cash and Cash Equivalents Payments of Dividends Payments of Dividends, Total Dividends paid Series A-2 Convertible preferred stock, Series A-2 Convertible Preferred Stock Series A-2 Convertible Preferred Stock [Member] Asset Class [Domain] Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Total property and equipment, at cost Subsequent Event Type [Domain] Pre Funded Warrants [Member] Pre Funded Warrants [Member] Pre-funded warrants Operating Leases, Future Minimum Payments, Due in Two Years 2024 Potential clinical, commercial and sales milestones Potential Clinical, Commercial And Sales Milestones Potential Clinical, Commercial And Sales Milestones Payments for Rent Lease annual base rent per square foot Class of Warrant or Right, Exercise Price of Warrants or Rights Pre-funded warrants exercisable, exercise price Financial Instruments [Domain] Pre-Clinical Milestones Pre-clinical Milestones Pre-clinical milestones Sale of Stock [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Income taxes Income Tax Disclosure [Text Block] Underwritten Public Offering [Member] Underwritten Public Offering [Member] Underwritten Public Offering Two Thousand Twenty One Employee Stock Purchase Plan [Member] Two Thousand Twenty One Employee Stock Purchase Plan [Member] 2021 Employee Stock Purchase Plan Accounts payable Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable, Total Schedule Of Subsidiary Or Equity Method Investee [Table] Subsidiary Or Equity Method Investee, Sale of Stock [Table] Entity Address, Address Line Two Entity Address, Address Line Two Liabilities and Equity [Abstract] Liabilities and stockholders' equity Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change Defined benefit plan liability Defined benefit plan liability Antidilutive securities excluded from computation of EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Number of marketable securities held Number of marketable securities held Number of marketable securities held Deferred revenue, net of current Deferred Revenue Deferred Revenue, Total Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Gain (Loss) on Disposition of Property Plant Equipment, Total Gain (Loss) on Disposition of Property Plant Equipment Gain on disposal of property and equipment Trading Symbol Trading Symbol Equity, Attributable to Parent Total stockholders' equity Balance end period Balance beginning period Common stock shares issued Issuance of common stock, net of issuance costs Shares Issuance of common stock, net of issuance costs Shares Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Unvested restricted common stock units Restricted stock units Restricted Stock Units (RSUs) [Member] Deferred revenue Increase (Decrease) in Deferred Revenue Temporary Equity, Shares Authorized Convertible preferred stock, shares authorized Variable Lease, Cost Variable lease expense Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Land Subject to Ground Leases Land Subject to Ground Leases Schedule of Stock Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total company contributions to 401 (k) plan Defined Contribution Plan, Employer Discretionary Contribution Amount Defined contribution expense Geographical [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Aggregate intrinsic value, vested or expected to vest Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized Losses Unrealized Losses Unrecognized stock based compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Leases [Abstract] Reduction of right-of-use assets for lease incentives receivable Reduction Of Right Of Use Assets For Lease Incentives Receivable Reduction Of Right Of Use Assets For Lease Incentives Receivable Tabular disclosure of depreciation expenses. Schedule of Depreciation Expenses [Table Text Block] Schedule of Depreciation Expense Fair value measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Class Of Stock [Line Items] Class of Stock [Line Items] Scenario Scenario [Axis] Security Exchange Name Security Exchange Name Net loss per share-basic Income (Loss) from Continuing Operations, Per Basic

Share Net loss per share attributable to common stockholders-basic Net loss per share attributable to common stockholders-basic Total operating expenses Operating Expenses Collaboration and License Agreement [Member] Collaboration and License Agreement [Member] Collaboration and License Agreement Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Issuance of common stock Revenue recognition, development regulatory, sales milestones Revenue Recognition, Development, Regulatory, Sales Milestones Revenue Recognition, Development, Regulatory, Sales Milestones Class of Stock Class of Stock [Axis] Lessee Operating Lease Liability Payments Due Thereafter Lessee Operating Lease Liability Payments Due Thereafter Thereafter Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant fair value, granted Right of Use Assets Decreased Limit, Amount Right of Use Assets Decreased Limit, Amount Right of Use Assets Decreased Limit, Amount Right of Use Assets Decreased Limit, Amount Subsequent Event Subsequent Event [Member] Maximum [Member] Maximum [Member] Liabilities and Equity Total liabilities and stockholders' equity Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Number of options, vested or expected to vest Supplemental disclosure of noncash items Supplemental Cash Flow Information [Abstract] Retirement Benefits [Abstract] Leasehold Improvements Leasehold Improvements [Member] Schedule of Lease Terms and Discount Rate Table Text Block Schedule of Lease Terms and Discount Rate Table Text Block Schedule of Lease Terms and Discount Rate Entity Ex Transition Period Entity Ex Transition Period Total liabilities Liabilities Payment of Financing and Stock Issuance Costs, Total Payment of Financing and Stock Issuance Costs Payment of common stock and pre-funded warrant issuance costs Common Stock, Voting Rights Common stock, voting rights Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Total current assets Assets, Current Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan Proceeds from employee stock purchase plan Vesting term Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Entity Filer Category Entity Filer Category Property, Plant and Equipment [Abstract] Description of business and liquidity Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Payments to Acquire Marketable Securities Purchases of marketable securities Purchases of marketable securities Underwriter's Discount on Underwritten Public Offering Cost Underwriter's Discount on Underwritten Public Offering Cost Underwriter's discount on underwritten public offering cost Current Fiscal Year End Date Current Fiscal Year End Date Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Imputed interest Description of Pre Funded Warrants Description of Pre Funded Warrants Convertible Preferred Stock, Par or Stated Value Per Share Convertible preferred stock, par or stated value per share Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Noncash Expense, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, beginning balance Aggregate intrinsic value, ending balance Related Party Related and Nonrelated Parties [Axis] Entity Registrant Name Entity Registrant Name Noncash lease expense. Noncash Lease Expense Noncash lease expense Unaudited Financial Information Quarterly Financial Information [Text Block] Non-cancelable leases [Member] Non-cancelable leases [Member] Non-cancelable leases [Member] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Net Loss Per Common Share Earnings Per Share [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Gain (Loss) on Marketable Securities Gain (Loss) on Marketable Securities Loss on sale of marketable securities Loss on sale of marketable securities Money Market Funds [Member] Money Market Funds [Member] Other Liabilities, Current Other Weighted-average number of shares outstanding used in computing net loss per common share-basic Weighted Average Number of Shares Outstanding, Basic Weighted-average number of common shares used in computing net loss per share-basic Weighted-average number of common shares used in computing net loss per share-basic Vesting [Domain] Interest Income (Expense), Nonoperating Interest income Common Stock, Shares Authorized Common stock, shares authorized Aggregate net proceeds after deducting underwriter discounts and commissions Aggregate gross proceeds Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount of \$29 Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of marketable securities Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Weighted average exercise price, vested or expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average exercise price, granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortization of Intangible Assets Amortization of the ROU assets Financial Instrument [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term (years), balance General and Administrative Expense [Member] General and Administrative Share-Based Payment Arrangement [Abstract] Proceeds from maturities of marketable securities ProceedsFromMaturityOfMarketableSecurities ProceedsFromMaturityOfMarketableSecurities Proceeds From Maturity Of Marketable Securities Collaborative Arrangement and Arrangement Other than Collaborative [Table] Rule 10b5-1 Arrangement Modified Rule 10b51 Arr Modified Flag Rule 10b51 Arr Modified Flag Defined benefit plan liability Liability, Defined Benefit Pension Plan, Noncurrent Proceeds from Issuance of Warrants Proceeds from the issuance of pre-funded warrants Harrison street member. Harrison Street [Member] Laboratory Equipment Laboratory Equipment [Member] Laboratory equipment [Member] Debt Securities, Available-for-Sale Fair Value Fair Value Accounting Policies [Abstract] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Income Tax Disclosure [Abstract] Equity, Attributable to Parent [Abstract] Stockholders' equity Unvested Stock Option [Member] Unvested stock option member. Unvested Stock Option Jefferies LLC [Member] Jefferies LLC [Member] Statement [Table] Statement [Table] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Weighted average remaining contractual term (years), vested or expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Subsequent Event [Table] Series C Convertible preferred stock. Series C Convertible Preferred Stock [Member] Series C Convertible Preferred Stock Preferred stock, shares authorized Preferred Stock, Shares Authorized Collaboration Revenue Revenue from Contract with Customer, Including Assessed Tax Entity File Number Securities Act File Number Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Proceeds from Underwritten Public Offering Cost Proceeds from Underwritten Public Offering Cost Proceeds from underwritten public offering cost, net of underwriter's discount of \$3,000 Earnings Per Share [Abstract] Other receivables Other Receivables Statement of Financial Position [Abstract] Schedule of Defined Benefit Plans Disclosures [Table Text Block] Schedule of defined contribution expense incurred Loss from operations Operating Income (Loss) Loss from operations Shares Issued, Price Per Share Share exercise price Entity Shell Company Entity Shell Company Entity Tax Identification Number Entity Tax Identification Number Assets Assets [Abstract] Entity Current Reporting Status Entity Current Reporting Status Property, Plant and Equipment Disclosure [Text Block] Property and Equipment, net Subsequent Events [Abstract] Geographical [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Preferred stock, \$0.0001 par value, 10,000,000 shares authorized Preferred Stock, Value, Issued Net accretion of discounts/premiums on marketable securities. Accretion of Discounts Premiums on Marketable Securities Net Net accretion of discounts/premiums on marketable securities Purchases of property and equipment in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Proceeds from Issuance Initial Public Offering Proceeds from underwritten public offering cost, net of underwriter's discount of \$3,000 City Area Code City Area Code Total current liabilities Liabilities, Current Upfront payment receive Upfront Payment Received Upfront Payment Received Issuance of Common Stock Pursuant to the At-the-Market Sales Agreement Issuance of Common Stock Pursuant to the At-the-Market Sales Agreement Issuance of common stock pursuant to the at-the-market sales agreement Operating Leases, Future Minimum Payments, Due in Four Years 2026 Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stock Issued During Period, Shares, Other Common stock, shares, issued during the period Percentage of company's matching contribution with respect to each participant's contribution Defined Contribution Plan, Employer Matching Contribution, Percent of Match Agreement [Domain] Agreement [Domain] Commitments and Contingencies Disclosure [Abstract] Shares, Issued Shares Issued Percentage of Commission payable to Related Party Percentage of Commission payable to Related Party Convertible Preferred Stock [Member] Convertible Preferred Stock Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Amortized Cost Schedule of pension expense incurred Schedule of Costs of Retirement Plans [Table Text Block] Operating Lease, Liability, Current Current portion of operating lease liability Schedule of Conversions of Stock [Table Text Block] Common Stock Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options Share Based Compensation Arrangement By Share Based Payment Award Percentage of Increase In Future Issuance Reserve Share Number of share increase Share based compensation arrangement by share based payment award percentage of increase in future issuance reserve share. Convertible preferred stock converted to common stock Convertible Preferred Stock, Shares Issued upon Conversion Retained Earnings [Member] Accumulated Deficit Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Document Transition Report Document Transition Report Milestone Payments Milestone Payments Milestone Payments. 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Weighted average exercise price, exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Minimum [Member] Minimum [Member] Common Stock Common Stock Restricted Cash Restricted cash Restricted Cash, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Aggregate intrinsic value, vested or expected Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average grant date fair value, ending balance Weighted average grant date fair value, beginning balance Additional Paid-in Capital [Member] Additional Paid-in Capital Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income Statement Location Statement of Income Location, Balance [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Other Assets, Noncurrent Other long-term assets Cash Paid For Amount Included In Measurement Of Lease Liabilities, Cash Paid For Amount Included In Measurement Of Lease Liabilities Cash paid for amounts included in the measurement of lease liabilities Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Net loss per share-diluted Income (Loss) from Continuing Operations, Per Diluted Share Net loss per share attributable to common stockholders-diluted Net loss per share attributable to common stockholders-diluted Basis of Accounting, Policy [Policy Text Block] Basis of presentation Scenario Scenario [Domain] Stock issued during period shares restricted stock award vesting. Stock Issued During Period Shares Restricted Stock Award Vesting Restricted common stock vesting, Shares Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2022 Common stock, \$0.0001 par value; 500,000,000 shares authorized, 61,378,108 shares issued and 61,377,484 shares outstanding as of September 30, 2024; and 50,154,929 shares issued and 50,140,233 shares outstanding as of December 31, 2023 Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Gain (Loss) on Disposition of Assets, Total Gain (Loss) on Disposition of Assets Gain on disposal of fixed assets Lease Commencement Date Lease Commencement Date Lease commencement date Other income (expense): Other Nonoperating Income (Expense) [Abstract] CRT Cancer Research Technology Limited [Member] Cancer Research Technology Limited. Operating Lease, Liability Total operating lease liability Operating lease liability Total operating lease liability Debt Securities, Available-for-Sale [Table Text Block] Summary of Marketable securities Milestone Payments, Maximum Milestone Payments Maximum Milestone payments, Maximum. Schedule of Accrued Liabilities [Table Text Block] Schedule Of Accrued Expenses And Other Current Liabilities Commitments and contingencies (Note 8) Commitments and Contingencies Marketable Securities [Line Items] Two Thousand Twenty One Stock Incentive Plan [Member] Two Thousand Twenty One Stock Incentive Plan [Member] 2021 Stock Incentive Plan Weighted-average number of shares outstanding used in computing net loss per common share-diluted Weighted Average Number of Shares Outstanding, Diluted Weighted-average number of common shares used in computing net loss per share-diluted Weighted-average number of common shares used in computing net loss per share-diluted Summary of significant accounting policies Significant Accounting Policies [Text Block] Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable Lessee, Operating Lease, Renewal Term Renewal term Receivable in Tenant Improvements Receivable in Tenant Improvements Receivable in Tenant Improvements Number of options, vested or expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Lessee, Operating Lease, Liability, to be Paid Total undiscounted minimum lease payments Finance Lease, Liability Finance Lease Finance Lease Non-Refundable Upfront Payment Non-Refundable Upfront Payment Non-Refundable Upfront Payment Entity Small Business Entity Small Business Issuance of common stock, shares Stock Issued During Period, Shares, Issued for Services US Treasury Securities [Member] US Treasury Securities Member Foreign currency exchange gain (loss), net Gain (Loss), Foreign Currency Transaction, before Tax Foreign Currency Transaction Gain (Loss), before Tax, Total Sales Agreement For Aggregate Gross Proceeds Sales Agreement For Aggregate Gross Proceeds Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Weighted average exercise price, beginning balance Weighted average exercise price, ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses And Other Current Liabilities Asset Class [Axis] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for operating lease obligations Hochbergerstrasse member. Hochbergerstrasse [Member] Gross proceed from issuance of preferred stock Proceeds from Issuance of Preferred Stock and Preference Stock Temporary Equity, Shares Outstanding Convertible preferred stock, shares outstanding Balance (in shares) period end Balance (in shares) beginning Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term (years) Subsequent Events [Text Block] Subsequent events Accounts payable Accounts Payable, Current Accounts Payable, Current, Total Preferred Stock Tranche Obligation [Member] Preferred stock tranche obligation Member Preferred Stock Tranche Obligation [Member] Issuance of Common Stock Pursuant to the At-the-Market Sales Agreement, Shares Issuance of Common Stock Pursuant to the At-the-Market Sales Agreement, Shares Issuance of common stock pursuant to the at-the-market sales agreement, Shares Provision for pension benefit obligation Provision For Pension Benefit Obligation Provision for pension benefit obligation. Short-Term Lease, Cost Short-Term Lease XML 6 R1.htm IDEA: XBRL DOCUMENT v.324.3 Document and Entity Information 9 Months Ended Sep. 30, 2024 Cover [Abstract] A Document Type 10-Q Amendment Flag false Document Period End Date Sep. 30, 2024 Document Fiscal Year Focus 2024 Document Fiscal Period Focus Q3 Entity Registrant Name Monte Rosa Therapeutics, Inc. Entity Central Index Key 0001826457 Entity Current Reporting Status Yes Entity Interactive Data Current Yes Current Fiscal Year End Date -12-31 Entity Filer Category Non-accelerated Filer Entity Shell Company false Entity Small Business true Entity Emerging Growth Company true Entity Ex Transition Period false Title of 12(b) Security Common stock, par value \$0.0001 per share Trading Symbol GLUE Security Exchange Name NASDAQ Securities Act File Number 001-40522 Entity Incorporation, State or Country Code DE Entity Tax Identification Number 84-3766197 Entity Address, Address Line One 321 Harrison Avenue Entity Address, Address Line Two Suite 900 Entity Address, City or Town Boston Entity Address, State or Province MA Entity Address, Postal Zip Code 02118 City Area Code 617 Local Phone Number 949-2643 Document Quarterly Report true Document Transition Report false X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix:

dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:MonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:YearItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1:

[Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 28:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current, + ReferencesReference 1:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 10:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 11:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 12:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 13:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 14:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 15:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 16:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 17:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 18:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20:](#)
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap AssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available, + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into \(1\) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and \(2\) is exposed to potential losses or, less frequently, gains, arising from \(a\) possible claims against a company's resources due to future performance under contract terms, and \(b\) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1:](#)
[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Sub](#)

05(4)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 8 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - \$ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Å Å Preferred stock, par value \$ 0.0001 \$ 0.0001 Preferred stock, shares authorized 10,000,000 10,000,000 Common stock, par or stated value per share \$ 0.0001 \$ 0.0001 Common stock, shares authorized 500,000,000 500,000,000 Common stock, shares, issued 61,378,108 50,154,929 Common stock shares outstanding 61,377,484 50,140,233 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 9 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Å Å Å Collaboration Revenue \$ 9,216 \$ 0 \$ 14,975 \$ 0 Operating expenses: Å Å Å Research and development 27,616 28,306 82,697 84,137 General and administrative 8,127 8,662 26,394 24,311 Total operating expenses 35,743 36,968 109,091 108,448 Loss from operations (26,527) (36,968) (94,116) (108,448) Other income (expense): Å Å Å Interest income 2,892 2,227 7,971 6,966 Foreign currency exchange gain (loss), net (153) 27 414 (151) Gain on disposal of fixed assets 0 0 24 Loss on sale of marketable securities 0 0 (131) Total other income 2,739 2,254 8,385 6,708 Net loss before income taxes (23,788) (34,714) (85,731) (101,740) Provision for income taxes (71) (170) (406) (360) Net loss \$ (23,859) \$ (34,884) \$ (86,137) \$ (102,100) Net loss per share-basic \$ (0.29) \$ (0.7) \$ (1.21) \$ (2.06) Net loss per share-diluted \$ (0.29) \$ (0.7) \$ (1.21) \$ (2.06) Weighted-average number of shares outstanding used in computing net loss per common share-basic 82,011,670 49,814,903 71,173,647 49,533,143 Weighted-average number of shares outstanding used in computing net loss per common share-diluted 82,011,670 49,814,903 71,173,647 49,533,143 Other comprehensive income: Å Å Å Provision for pension benefit obligation \$ 37 \$ 14 \$ 107 \$ 42 Unrealized gain on available-for-sale securities 311 171 295 255 Comprehensive loss \$ (23,511) \$ (34,699) \$ (85,735) \$ (101,803) X - DefinitionGain (Loss) on Marketable Securities + ReferencesNo definition available. + Details Name: glue GainLossOnMarketableSecurities Namespace Prefix: glue Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProvision for pension benefit obligation. + ReferencesNo definition available. + Details Name: glue ProvisionForPensionBenefitObligation Namespace Prefix: glue Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/214747750/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/214747750/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9 + Details Name: us-gaap DebtSecuritiesAvailableForSaleRealizedLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap GeneralAndAdministrativeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7:

https://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/214746176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncomeStatementAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/

us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-32)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-55-48>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1> + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4) + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: [http://www.xbrl](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16)

50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(j\) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (j) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(k\) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (k) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11>Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1) + Details Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10:

2,233 Prepaid expenses and other current assets (4,940) 312 Accounts payable (7,056) (10) Accrued expenses and other current liabilities 487,268 Defined benefit plan liability 217 (3) Right-of-use assets and operating lease liabilities (897) 9,999 Deferred revenue (5,975) 0 Net cash used in operating activities (86,926) (73,436) Cash flows from investing activities: A A Purchases of property and equipment (3,805) (17,352) Proceeds from the sale of property and equipment 0 62 Purchases of marketable securities (162,400) (75,637) Proceeds from sale of marketable securities 0 45,631 Proceeds from maturities of marketable securities 152,649 121,800 Net cash provided by (used in) investing activities (13,556) 74,504 Cash flows from financing activities: A A Proceeds from underwritten public offering cost, net of underwriter's discount of \$3,000 47,001 0 Proceeds from the issuance of pre-funded warrants 50,000 0 Payment of common stock and pre-funded warrant issuance costs (641) 0 Proceeds from exercise of employee stock options 682 2,016 Proceeds from employee stock purchase plan 298 303 Net cash provided by financing activities 98,284 2,319 Net increase (decrease) in cash, cash equivalents and restricted cash (2,198) 3,387 Cash, cash equivalents and restricted cash\$~beginning of period 132,681 60,190 Cash, cash equivalents and restricted cash end-of period 130,483 63,577 Reconciliation of cash, cash equivalents and restricted cash A A Cash and cash equivalents 125,575 59,055 Restricted cash 4,908 4,522 Total cash, cash equivalents and restricted cash 130,483 63,577 Supplemental disclosure of noncash items A A Reduction of right-of-use assets for lease incentives receivable 0 5,128 Purchases of property and equipment in accounts payable and accrued expenses 131 1,270 At-the-Market Offering A A Cash flows from financing activities: A A Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount of \$29 \$ 944 \$ 0 X - DefinitionNet accretion of discounts/premiums on marketable securities. + ReferencesNo definition available. + Details Name: glue AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain (Loss) on Marketable Securities + ReferencesNo definition available. + Details Name: glue GainLossOnMarketableSecurities Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from Underwritten Public Offering Cost + ReferencesNo definition available. + Details Name: glue ProceedsFromUnderwrittenPublicOfferingCost Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceedsFromMaturityOfMarketableSecurities + ReferencesNo definition available. + Details Name: glue Proceedsfrommaturityofmarketablesecurities Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionReductionOfRightOfUseAssetsForLeaseIncentivesReceivable Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrli.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/214747401/830-230-45-1 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other. + ReferencesNo definition available. + Details Name: us-gaap DefinedBenefitPlanOtherChanges Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap Depreciation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrli.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in receivables classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInOtherReceivables Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1:

<http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-12> + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 11: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478009/946-205-45-3>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477314/942-235-S99-1>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 31: <http://www.xbrl.org/2003/role/exampleRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481175/810-10-55-4J>Reference 32: <http://www.xbrl.org/2003/role/exampleRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481175/810-10-55-4K>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 34: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-2>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1A>Reference 37: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1A> + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsiarySaleOfStockIssue=glue AtTheMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) \$ in Thousands 9 Months Ended Sep. 30, 2024 USD (\$) Statement of Cash Flows [Abstract] A Underwriter's discount on issuance of common stock pursuant to the at-the-market sales agreement \$ 29 Underwriter's discount on underwritten public offering cost \$ 3,000 X - DefinitionNet of underwriting Discount on issuance of common stock + ReferencesNo definition available. + Details Name: glue_NetOfUnderwritingDiscountOnIssuanceOfCommonStock Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUnderwriter's Discount on Underwritten Public Offering Cost + ReferencesNo definition available. + Details Name: glue_UnderwritersDiscountOnUnderwrittenPublicOfferingCost Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfCashFlowsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD (\$) \$ in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 30, 2023 Jun. 30, 2023 Sep. 30, 2023 Pay vs Performance Disclosure A A A A A A A A Net Income (Loss) \$ (23,859) \$ (30,310) \$ (31,968) \$ (34,884) \$ (35,178) \$ (32,038) \$ (86,137) \$ (102,100) X - ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvTable Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)

ASB -

and fixtures $\text{\$} 1,099 \text{ \AA} \text{ \AA} 1,099$ $\text{\AA}$ Leasehold improvements $\text{\$} 22,312 \text{ \AA} \text{ \AA} 20,893$ $\text{\AA}$ Construction in process $\text{\$} 126 \text{ \AA} \text{ \AA} 924$ $\text{\AA}$ Total property and equipment, at cost $\text{\$} 49,746 \text{ \AA} \text{ \AA} 46,047$ $\text{\AA}$ Less: accumulated depreciation $\text{\$} (18,304) \text{ \AA} (12,244)$ $\text{\AA}$ Property and equipment, net $\text{\$} 31,442 \text{ \AA} \text{ \AA} 33,803$ $\text{\AA}$ The following table summarizes depreciation expense incurred (in thousands): $\text{\AA}$ Three months ended September 30, $\text{\AA}$ Nine months ended September 30, $\text{\AA}$ $\text{\AA} 2024$ $\text{\AA} 2023$ $\text{\AA} 2024$ $\text{\AA}$ Depreciation expense $\text{\$} 2,103 \text{ \AA} \text{ \AA} 1,834$ $\text{\AA} \text{ \AA} 6,060$ $\text{\AA} \text{ \AA} 4,376$ $\text{\AA}$ X - References No definition available. + Details Name: us-gaap PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1) Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7> + Details Name: us-gaap PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration XML 20 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses and other current liabilities 9 Months Ended Sep. 30, 2024 Accounts Payable and Accrued Liabilities, Current [Abstract] $\text{\AA}$ Accrued Expenses And Other Current Liabilities 6. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following (in thousands): $\text{\AA}$ September 30, $\text{\AA}$ $\text{\AA}$ December 31, $\text{\AA}$ $\text{\AA} 2024$ $\text{\AA} 2023$ $\text{\AA}$ Compensation and benefits $\text{\$} 6,703 \text{ \AA} \text{ \AA} 7,593$ $\text{\AA}$ Accrued research and development $\text{\$} 7,093 \text{ \AA} \text{ \AA} 5,336$ $\text{\AA}$ Other $\text{\$} 1,303 \text{ \AA} \text{ \AA} 1,671$ $\text{\AA}$ Total other current liabilities $\text{\$} 15,099 \text{ \AA} \text{ \AA} 14,600$ $\text{\AA}$ X - Definition The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1> + Details Name: us-gaap AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap AccountsPayableAndAccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 21 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases [Abstract] $\text{\AA}$ Leases 7. Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use, or ROU, assets and operating lease liabilities in the condensed consolidated balance sheets. The Company has no finance leases as of September 30, 2024. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company $\text{\AA}$ ™s leases do not provide an implicit rate, management estimated the incremental borrowing rate based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Klybeckstrasse Lease In March 2021, the Company entered into an operating lease agreement for office and lab space with Wincasa AG, or the landlord, that occupies approximately 21,422 square feet located at Klybeckstrasse 191, 4057 Basel, Basel-City, Switzerland. In April 2023, the Company and the Landlord amended the Klybeckstrasse Lease which increased the office and lab space square footage from 21,422 square feet to 44,685 square feet and extended the term of the lease through June 30, 2027. The amendment was accounted for as a lease modification and resulted in an increase to the related ROU asset and operating lease liability of $\text{\$} 1.8$ million. Harrison Avenue Lease In December 2021, the Company entered into a non-cancelable lease agreement for 63,327 square feet of office and laboratory space to support its expanding operations, or the Harrison Avenue Lease. The term of the lease commenced on April 1, 2022 and the Company $\text{\AA}$ ™s obligation to pay rent began on December 21, 2022. The initial term of the lease is 128 months following the commencement date at which point the Company has the option to extend the lease an additional 5 years. As of the lease commencement date, the Company has determined that it is not reasonably certain to exercise the option to extend the lease and has not included the extension period in the lease term. The annual base rent under the Harrison Avenue Lease is $\text{\$} 95.00$ per square foot for the first year, which is subject to scheduled annual increases of 3%, plus certain costs, operating expenses and property management fees. Pursuant to the terms of the Harrison Avenue Lease, the landlord reimbursed the Company for $\text{\$} 13$ million of tenant improvements. The Company reduced the related ROU asset by the amounts reimbursed by the landlord and capitalized the leasehold improvements as fixed assets on the consolidated balance sheet. The components of lease expense for the three and nine months ended September 30, 2024 are as follows (in thousands): $\text{\AA}$ Three months ended September 30, $\text{\AA}$ $\text{\AA}$ Nine months ended September 30, $\text{\AA}$ $\text{\AA} 2024$ $\text{\AA} 2023$ $\text{\AA}$ $\text{\AA} 2024$ $\text{\AA} 2023$ $\text{\AA}$ Operating lease expense $\text{\$} 1,611 \text{ \AA} \text{ \AA} 1,569$ $\text{\AA} \text{ \AA} 4,860$ $\text{\AA} \text{ \AA} 5,552$ $\text{\AA}$ Variable lease expense $\text{\$} 912 \text{ \AA} \text{ \AA} 572$ $\text{\AA} \text{ \AA} 3,043$ $\text{\AA} \text{ \AA} 1,700$ $\text{\AA}$ Total lease expense $\text{\$} 2,523 \text{ \AA} \text{ \AA} 2,141$ $\text{\AA} \text{ \AA} 7,903$ $\text{\AA} \text{ \AA} 7,252$ $\text{\AA}$ The variable lease expenses generally include common area maintenance and property taxes. The following table summarizes lease expense incurred (in thousands): $\text{\AA}$ Three months ended September 30, $\text{\AA}$ $\text{\AA}$ Nine months ended September 30, $\text{\AA}$ $\text{\AA} 2024$ $\text{\AA} 2023$ $\text{\AA}$ $\text{\AA} 2024$ $\text{\AA} 2023$ $\text{\AA}$ Research and development $\text{\$} 2,099 \text{ \AA} \text{ \AA} 1,977$ $\text{\AA} \text{ \AA} 6,596$ $\text{\AA} \text{ \AA} 6,234$ $\text{\AA}$ General and administrative $\text{\$} 422 \text{ \AA} \text{ \AA} 350$ $\text{\AA} \text{ \AA} 1,306$ $\text{\AA} \text{ \AA} 1,204$ $\text{\AA}$ Total lease expense $\text{\$} 2,521 \text{ \AA} \text{ \AA} 2,327$ $\text{\AA} \text{ \AA} 7,902$ $\text{\AA} \text{ \AA} 7,438$ $\text{\AA}$ Short-term lease costs for the nine months ended September 30, 2024 and 2023 were immaterial. The weighted average remaining lease term and discount rate related to the Company's leases are as follows: $\text{\AA}$ September 30, 2024 $\text{\AA}$ $\text{\AA}$ December 31, 2023 $\text{\AA}$ Weighted average remaining lease term (years) $\text{\AA} 7.9 \text{ \AA} \text{ \AA} 8.6$ $\text{\AA}$ Weighted average discount rate $\text{\AA} 9.8 \text{ \AA} \text{ \AA} 9.8$ $\text{\AA}$ Supplemental cash flow information relating to the Company's leases for the nine months ended September 30, 2024 are as follows (in thousands): $\text{\AA}$ $\text{\AA}$ Nine months ended September 30, $\text{\AA}$ $\text{\AA} 2024$ $\text{\AA} 2023$ $\text{\AA}$ Right-of-use assets obtained in exchange for operating lease obligations $\text{\$} 108 \text{ \AA} \text{ \AA} 1,871$ $\text{\AA}$ Cash paid for amounts included in the measurement of lease liabilities $\text{\$} 2,325 \text{ \AA} \text{ \AA} 2,382$ $\text{\AA}$ The amortization of the ROU assets for the nine months ended September 30, 2024 and 2023 was $\text{\$} 1.6$ million and $\text{\$} 2.0$ million, respectively. Future minimum lease payments under non-cancelable leases as of September 30, 2024 for each of the years ending December 31 are as follows (in thousands): Undiscounted lease payments $\text{\$} \text{\AA} 2024$ $\text{\AA} 2025$ $\text{\AA} 2026$ $\text{\AA} 2027$ $\text{\AA} 2028$ $\text{\AA} 2029$ $\text{\AA}$ Thereafter $\text{\$} 31,010$ $\text{\AA}$ Total undiscounted minimum lease payments $\text{\$} 63,597$ $\text{\AA}$ Less: Imputed interest $\text{\$} (19,899)$ $\text{\AA}$ Total operating lease liability $\text{\$} 43,698$ $\text{\AA}$ X - References No definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent> + Details Name: us-gaap LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration XML 22 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] $\text{\AA}$ Commitments and Contingencies 8. Commitments and contingencies Legal Proceedings From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. As of September 30, 2024, the Company is not a party to any litigation and does not have a contingency reserve established for any litigation liabilities. X - References No definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for commitments and contingencies. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4) Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4) Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent> + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration XML 23 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration And License Agreements 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] $\text{\AA}$ Collaboration and license agreements 9. Collaboration and license agreements Roche Collaboration and License Agreement Description In October 2023, Monte Rosa Therapeutics AG, a wholly-owned subsidiary of Monte Rosa Therapeutics, Inc. or the Company, entered into a collaboration and license agreement, or the Roche Agreement, with F. Hoffman-La Roche Ltd. and Hoffman-La Roche Inc., or Roche. Pursuant to the agreement, the parties will seek to identify and develop molecular glue degraders, or MGDs, against cancer or neurological disease targets using the Company $\text{\AA}$ ™s proprietary drug discovery platform for an initial set of targets in oncology and neuroscience selected by Roche, with Roche having an option to expand the collaboration to include additional option targets, wherein a certain number of targets selected by Roche are subject to replacement rights owned by Roche. The Company will lead pre-clinical discovery and research activities with Roche leading late pre-clinical and clinical development activities. Under the Roche Agreement, Roche will have a worldwide, exclusive license under patents and know-how controlled by the Company to develop and commercialize products directed to applicable targets. The license exclusivity is subject to the Company $\text{\AA}$ ™s retained rights solely to fulfill its obligations under the arrangement. The research collaboration activities governed by the Roche Agreement will be overseen by a joint research committee. Unless earlier terminated, the Roche Agreement will remain in effect for each product licensed under the Agreement until expiration of the royalty term for the applicable product. The parties have included termination provisions in the Roche Agreement, allowing termination of the Roche Agreement in its entirety, on a country-by-country or a target-by-target basis. Pricing In November 2023, the Company received a $\text{\$} 50.0$ million non-refundable upfront payment for the initial set of targets. Pursuant to the terms of the Roche Agreement, the Company expects to be entitled to receive from Roche certain variable consideration including potential pre-clinical milestones up to $\text{\$} 172$ million, and potential clinical, commercial and sales milestones exceeding $\text{\$} 2$ billion. For the additional option targets, upon Roche $\text{\AA}$ ™s exercise of their option, the Company is entitled to receive an upfront payment of up to $\text{\$} 28$ million and potential pre-clinical, clinical, commercial and sales milestones exceeding $\text{\$} 1$ billion. The Company is also eligible to receive tiered royalties ranging from high-single-digits to low-teens on any products that are commercialized by Roche as a result of the collaboration. As of September 30, 2024, the Company has received $\text{\$} 9.0$ million related to Roche's decision to exercise its option rights for continued research and development services. The related payments are initially classified as deferred revenue in the accompanying condensed consolidated balance sheet and recognized in revenue as the related research and development services are performed. Accounting This agreement represents a transaction with a customer and therefore is accounted for under ASC 606 Revenue From Contracts With Customers. The Company determined that the development and commercialization licenses for each of the collaboration targets is neither capable of being distinct nor distinct within the context from the promised initial research services. In addition, the Company has determined that each target in the agreement is distinct from other targets because: (i) Roche can benefit from the license and research services for a given target on their own since the results related thereto can be evaluated discretely and (ii) the results of the research and development of each target does not affect either the Company $\text{\AA}$ ™s ability to perform or Roche $\text{\AA}$ ™s ability to assess the results for any other target. As such, the Company has identified certain performance obligations within the agreement as follows: $\text{\AA}$ $\text{\AA}$ Performance obligations for the research and development of initial targets $\text{\AA}$ $\text{\AA}$ Performance obligations for the research and development services related to Roche $\text{\AA}$ ™s option to replace certain targets The total transaction price of the Roche Agreement is allocated to the performance obligations based on their relative standalone selling price. The Company developed the standalone selling price for the performance obligations included in the Roche Agreement by determining the total estimated costs to fulfill each performance obligation identified with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The allocated transaction price is recognized as revenue from collaboration agreements in one of two ways: $\text{\AA}$ $\text{\AA}$ Research and development of the initial targets: The Company recognizes the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an input method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation related to said research and development target. The transfer of control occurs over this period and, in management $\text{\AA}$ ™s judgment, is the best measure of progress towards satisfying the performance obligation. $\text{\AA}$ $\text{\AA}$ Option rights: The transaction price allocated to the options rights, which are considered material rights, is deferred until the period that Roche elects to exercise or elects to not exercise its option right to license and commercialize the underlying research and development target. Upon Roche's exercise of an option right, the Company will recognize the portion of the transaction price allocated using the input method described above. Any payments made to exercise option rights will be added to the allocated value and recognized as the related services are performed. As of September 30, 2024, $\text{\$} 15.0$ million has been recognized as collaboration revenue in the condensed consolidated statements of operations and comprehensive loss and the remaining $\text{\$} 44.0$ million of the upfront payment and subsequent milestone payments related to customer options are recorded as deferred revenue in the liabilities section of the condensed consolidated balance sheets. X - Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1) Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent> + Details Name: us-gaap CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 24 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] $\text{\AA}$ Equity 10. Equity Undesignated Preferred Stock The Company had 10,000,000 shares authorized of undesignated preferred stock, par value of $\text{\$} 0.0001$, of which no shares were issued and outstanding as of September 30, 2024. Common Stock The Company had 500,000,000 shares of common stock authorized, of which 61,378,108 shares were issued and 61,377,484 shares were outstanding as of September 30, 2024. Additionally, the Company has issued pre-funded warrants to purchase 20,638,924 shares of the Company's common stock to an accredited investor. The pre-funded warrants are immediately exercisable at an exercise price of $\text{\$} 0.0001$ per share. The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of a Pre-Funded Warrant may not exercise such Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, up to 19.99%) of the number of shares of the Company $\text{\AA}$ ™s common stock outstanding immediately after giving effect to such exercise. No pre-funded warrants have been exercised as of September 30, 2024. The holders of common stock are entitled to dividends when and if declared by the board of directors, subject to the preferences applicable to any outstanding shares of preferred stock. The board of directors has not declared any dividends and the Company has not paid any dividends. The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. The Company has issued restricted stock to founders, employees and consultants, and expense for this restricted stock is recognized on a straight-line basis (see Note 11). The restricted stock generally vests monthly over 4 years. As of September 30, 2024, and December 31, 2023, the Company has reserved the following shares of common stock for the vesting of restricted stock and exercise of

stock options: [À](#) [September 30, 2024](#) [À](#) [December 31, 2023](#) [À](#) [Options to purchase common stock](#) [À](#) [11,591,425](#) [À](#) [9,394,930](#) [À](#) [Unvested restricted common stock awards](#) [À](#) [624](#) [À](#) [14,696](#) [À](#) [Unvested restricted common stock units](#) [À](#) [112,159](#) [À](#) [236,519](#) [À](#) [Pre-funded warrants](#) [À](#) [20,638,924](#) [À](#) [10,000,400](#) [À](#) [32,343,132](#) [À](#) [19,646,545](#) [À](#) [At-the-Market Offering](#) [In July 2022](#), the Company entered into a sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which the Company may offer and sell shares of its common stock having aggregate gross proceeds of up to \$100 million from time to time in [À](#) [eat-the-market](#) [À](#) offerings through Jefferies, as the Company's sales agent. The Company agreed to pay Jefferies a commission of up to 3.0% of the gross proceeds of any shares sold by Jefferies under the Sales Agreement. During the nine months ended September 30, 2024, the Company sold 130,506 shares of common stock under the Sales Agreement for aggregate gross proceeds of \$1.0 million, or aggregate net proceeds of \$0.9 million after deducting sales agent discounts, commissions, and other offering costs. During the nine months ended September 30, 2023, the Company did not sell shares of its common stock under the Sales Agreement. Underwritten Public Offering [In May 2024](#), the Company entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters, related to an underwritten public offering, or the Offering, of 10,638,476 shares of common stock at a price of \$4.70 per share, and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of Common Stock at a price of \$4.6999 per pre-funded warrant, which represents the price per share at which shares of Common Stock were sold in this Offering, minus \$0.0001, which is the exercise price of each pre-funded warrant. The pre-funded warrants are immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. Aggregate gross proceeds from the Offering were \$100 million, or aggregate net proceeds of \$96.4 million after deducting the underwriter discounts, commissions, and other offering costs. [À](#) [Registered Direct Offering](#) [In October 2023](#), the Company sold in a registered direct offering pursuant to a securities purchase agreement pre-funded warrants to purchase 10,000,400 shares of the Company's common stock to an accredited investor at a purchase price of \$2.4999 per pre-funded warrant for aggregate gross proceeds of \$25.0 million. The pre-funded warrants are immediately exercisable at an exercise price of \$0.0001 per share. X - References [No definition available.](#) + Details [Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for equity.](#) + References [Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748008/505-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details \[Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement \\[Abstract\\] À Stock-Based Compensation 11. Stock-based compensation 2020 Stock incentive plan The Company's 2020 Stock Option and Grant Plan, or the 2020 Plan, provided for the Company to grant stock options, restricted stock and other stock awards, to employees, non-employee directors, and consultants. Upon the effectiveness of the 2021 Plan \\(as defined below\\), no further issuances were made under the 2020 Plan. 2021 Stock incentive plan The Company's 2021 Stock Option and Incentive Plan, or the 2021 Plan, was approved by the Company's board of directors on May 28, 2021 and the Company's stockholders on June 17, 2021 and became effective on the date immediately prior to the date on which the registration statement for the Company's IPO was declared effective. The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company's officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2021 Plan was 4,903,145. Under the evergreen provision of the 2021 Plan, the shares available for issuance under the 2021 Plan will be automatically increased each January 1st by 5% of the outstanding number of shares of the Company's common stock on the immediately preceding December 31st or such lesser number of shares as may be determined by the Company's compensation, nomination and corporate governance committee. Effective January 1, 2024 the number of shares available under the 2021 Plan automatically increased by 2,507,011 shares pursuant to the evergreen provision of the 2021 Plan. As of September 30, 2024, 3,289,766 shares were available for issuance under the 2021 Plan. 2021 Employee stock purchase plan The Company's 2021 Employee Stock Purchase Plan, or the 2021 ESPP, was approved by the Company's board of directors on May 28, 2021 and the Company's stockholders on June 17, 2021 and became effective on the date immediately prior to the date on which the registration statement for the Company's IPO was declared effective. A total of 439,849 shares of the Company's common stock were initially reserved for issuance under the 2021 ESPP. The shares available for issuance under the 2021 ESPP will be automatically increased on each January 1st, through January 1, 2031, by the least of \\(i\\) 439,849 shares of the Company's common stock, \\(ii\\) 1% of the outstanding number of shares of the Company's common stock on the immediately preceding December 31st or \\(iii\\) such lesser number of shares of the Company's common stock as determined by the plan administrator of the 2021 ESPP. Effective January 1, 2024 the number of shares available under the 2021 ESPP automatically increased by 439,849 shares pursuant to the evergreen provision of the 2021 ESPP. As of September 30, 2024, 1,504,248 shares were available for issuance under the 2021 ESPP. Stock option activity The following summarizes stock option activity: À Number of options À Weighted average exercise price À Weighted average remaining contractual term \\(years\\) À Aggregate intrinsic value \\(in thousands\\) À Outstanding À December 31, 2023 À 9,394,930 À 8.78 À 8.0 À 4,741 À Granted À 2,945,540 À 5.48 À 5.8 À 2,384 À Exercised À \\(238,304\\) À 2.86 À 2.8 À 2.8 À Forfeited À \\(510,741\\) À 7.99 À 8.0 À 7.99 À Outstanding À September 30, 2024 À 11,591,425 À 8.10 À 7.8 À 4,122 À Vested or expected to vest À September 30, 2024 À 11,591,425 À 8.10 À 7.8 À 4,122 À Exercisable À September 30, 2024 À 5,871,488 À 8.98 À 7.0 À 3,190 À The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company's common stock. Restricted\]\(#\)](#)

as follows (in thousands except share and per share amounts):

	September 30, 2023	September 30, 2024	September 30, 2024	September 30, 2024
Net loss	\$ (23,859)	\$ (34,884)	\$ (86,137)	\$ (102,100)
Net loss per share attributable to common stockholders	\$ (0.29)	\$ (0.70)	\$ (1.21)	\$ (2.06)
Weighted-average number of common shares used in computing net loss	82,011,670	49,814,903	71,173,647	49,533,143

The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive:

	September 30, 2023	September 30, 2024
Stock options to purchase common stock	11,591,425	9,489,119
Restricted common stock	624	19,487
Restricted stock units	112,159	250,265

References: No definition available.

Details: Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 260 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (c) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef - Topic 260 - SubTopic 10 - Name Accounting Standards Codification - Publisher FASB - URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef - Topic 260 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 260 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap EarningsPerShareTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 28 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Retirement Plan 9 Months Ended Sep. 30, 2024 Retirement Benefits [Abstract] A Employee Retirement Plan 14. Employee retirement plans The Company, in compliance with Swiss Law, is contracted with the AXA Lehen AG for the provision of pension benefits in a defined benefit plan. All benefits are organized in a semi-autonomous collective foundation within the framework of the contract with AXA. Insurance benefits due are paid directly to the entitled persons by AXA in the name of and for the account of the collective foundation. The pension plan is financed by contributions of both employees and employer. The contract between the Company and the collective foundation can be terminated by either side. In the event of a termination, the Company would have an obligation to find alternative pension arrangements for its employees. Because there is no guarantee that the employee pension arrangements would be continued under the same conditions, there is a risk, albeit remote, that a pension obligation may fall on the Company. The pension assets are pooled for all affiliated companies; the investment of assets is done by the governing bodies of the collective foundation. The following table summarizes pension expense incurred (in thousands):

	Three months ended September 30, 2023	Nine months ended September 30, 2023	Three months ended September 30, 2024	Nine months ended September 30, 2024
Pension expense	\$ 279	\$ 251	\$ 822	\$ 702

In February 2021, the Company adopted a defined contribution plan intended to qualify under Section 401(k) of the Internal Revenue Code covering all eligible U.S. based employees of the Company. All employees are eligible to become participants of the plan immediately upon hire. Each active employee may elect, voluntarily, to contribute a percentage of their compensation to the plan each year, subject to certain limitations. The Company reserves the right, but is not obligated, to make additional contributions to this plan. The Company makes safe-harbor match contributions of 100% of the first 4% of each participant's eligible compensation. In January 2024, the Company adopted a defined contribution supplemental pension plan for eligible Swiss based employees defined by Swiss Law Art. 1e BVV 2, or the 1e Plan. Employees earning above a defined threshold are eligible and automatically enrolled in the 1e Plan and required contributions are determined by age and salary under Swiss Law. The Company and the employee share the costs of the 1e Plan. The following table summarizes defined contribution expenses incurred (in thousands):

	Three months ended September 30, 2023	Nine months ended September 30, 2023	Three months ended September 30, 2024	Nine months ended September 30, 2024
Defined contribution expense	\$ 164	\$ 99	\$ 701	\$ 488

References: No definition available.

Details: Name: us-gaap CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for retirement benefits. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480794/715-70-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 17 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480482/715-20-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (d)(iv)(03) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (d)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (g) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (l) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - Name Accounting Standards Codification - Publisher FASB - URI https://asc.fasb.org/715/tableOfContentReference 8: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (d)(iii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (o) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (p) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (r)(1) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (r)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 20 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef - Topic 715 - SubTopic 60 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Subparagraph (c) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480266/715-60-50-3 + Details Name: us-gaap PensionAndOtherPostretirementBenefitsDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 29 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] A Subsequent events 15. Subsequent events On October 25, 2024, Monte Rosa Therapeutics AG, a wholly owned subsidiary of Monte Rosa Therapeutics, Inc., or the Company, and Novartis Pharma AG, or Novartis, entered into a License Agreement, or the Novartis Agreement. Pursuant to the Novartis Agreement, the Company will grant to Novartis an exclusive, royalty-bearing, sublicensable and transferable license to develop, manufacture, and commercialize VAV1 MGDs, including MRT-6160, which is currently in Phase 1 clinical development for immune-mediated conditions. The Company is responsible for completing the ongoing Phase 1 clinical study and Novartis is responsible for all subsequent development and commercial activities starting at Phase 2. Development and commercial activities governed by the Agreement will be overseen by a Development Committee and a Commercialization Committee. Pursuant to the Novartis Agreement, the Company is entitled to receive from Novartis (1) an upfront payment of \$150 million, (2) up to \$2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies including (a) potential development and regulatory milestone payments, exceeding \$1.5 billion if multiple indications achieve regulatory approval in multiple territories, (b) potential sales milestones payments in connection with sales outside of the United States, and (3) tiered royalties on sales outside of the United States. The Company will continue to be responsible for costs associated with the ongoing Phase 1 clinical study and Novartis will be responsible for costs associated with any subsequent clinical studies. The Company and Novartis also agreed to a net profit and loss sharing arrangement, pursuant to which the Company will co-fund any global clinical development from Phase 3 onwards and will share 30% of any profits and losses associated with the manufacturing and commercialization of the licensed products in the United States. The Company has defined opportunities to opt out of the net profit and loss sharing arrangement, in such case, sales in the United States would be entitled to the potential sales milestones payments and tiered royalties on sales available outside of the United States. Any costs for any co-funded development and commercialization activities are subject to budgets reviewed by the Development Committee and Commercialization Committee, respectively. The Novartis Agreement is subject to customary closing conditions, including regulatory clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The parties have included customary termination provisions in the Agreement, including Novartis' ability to terminate the Novartis Agreement in its entirety. X - References No definition available. + Details Name: us-gaap SubsequentEventsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 855 - Name Accounting Standards Codification - Publisher FASB - URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef - Topic 855 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (a) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap SubsequentEventsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 30 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant

Level 1 [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [21](#) [22](#) [23](#) [24](#) [25](#) [26](#) [27](#) [28](#) [29](#) [30](#) [31](#) [32](#) [33](#) [34](#) [35](#) [36](#) [37](#) [38](#) [39](#) [40](#) [41](#) [42](#) [43](#) [44](#) [45](#) [46](#) [47](#) [48](#) [49](#) [50](#) [51](#) [52](#) [53](#) [54](#) [55](#) [56](#) [57](#) [58](#) [59](#) [60](#) [61](#) [62](#) [63](#) [64](#) [65](#) [66](#) [67](#) [68](#) [69](#) [70](#) [71](#) [72](#) [73](#) [74](#) [75](#) [76](#) [77](#) [78](#) [79](#) [80](#) [81](#) [82](#) [83](#) [84](#) [85](#) [86](#) [87](#) [88](#) [89](#) [90](#) [91](#) [92](#) [93](#) [94](#) [95](#) [96](#) [97](#) [98](#) [99](#) [100](#) [101](#) [102](#) [103](#) [104](#) [105](#) [106](#) [107](#) [108](#) [109](#) [110](#) [111](#) [112](#) [113](#) [114](#) [115](#) [116](#) [117](#) [118](#) [119](#) [120](#) [121](#) [122](#) [123](#) [124](#) [125](#) [126](#) [127](#) [128](#) [129](#) [130](#) [131](#) [132](#) [133](#) [134](#) [135](#) [136](#) [137](#) [138](#) [139](#) [140](#) [141](#) [142](#) [143](#) [144](#) [145](#) [146](#) [147](#) [148](#) [149](#) [150](#) [151](#) [152](#) [153](#) [154](#) [155](#) [156](#) [157](#) [158](#) [159](#) [160](#) [161](#) [162](#) [163](#) [164](#) [165](#) [166](#) [167](#) [168](#) [169](#) [170](#) [171](#) [172](#) [173](#) [174](#) [175](#) [176](#) [177](#) [178](#) [179](#) [180](#) [181](#) [182](#) [183](#) [184](#) [185](#) [186](#) [187](#) [188](#) [189](#) [190](#) [191](#) [192](#) [193](#) [194](#) [195](#) [196](#) [197](#) [198](#) [199](#) [200](#) [201](#) [202](#) [203](#) [204](#) [205](#) [206](#) [207](#) [208](#) [209](#) [210](#) [211](#) [212](#) [213](#) [214](#) [215](#) [216](#) [217](#) [218](#) [219](#) [220](#) [221](#) [222](#) [223](#) [224](#) [225](#) [226](#) [227](#) [228](#) [229](#) [230](#) [231](#) [232](#) [233](#) [234](#) [235](#) [236](#) [237](#) [238](#) [239](#) [240](#) [241](#) [242](#) [243](#) [244](#) [245](#) [246](#) [247](#) [248](#) [249](#) [250](#) [251](#) [252](#) [253](#) [254](#) [255](#) [256](#) [257](#) [258](#) [259](#) [260](#) [261](#) [262](#) [263](#) [264](#) [265](#) [266](#) [267](#) [268](#) [269](#) [270](#) [271](#) [272](#) [273](#) [274](#) [275](#) [276](#) [277](#) [278](#) [279](#) [280](#) [281](#) [282](#) [283](#) [284](#) [285](#) [286](#) [287](#) [288](#) [289](#) [290](#) [291](#) [292](#) [293](#) [294](#) [295](#) [296](#) [297](#) [298](#) [299](#) [300](#) [301](#) [302](#) [303](#) [304](#) [305](#) [306](#) [307](#) [308](#) [309](#) [310](#) [311](#) [312](#) [313](#) [314](#) [315](#) [316](#) [317](#) [318](#) [319](#) [320](#) [321](#) [322](#) [323](#) [324](#) [325](#) [326](#) [327](#) [328](#) [329](#) [330](#) [331](#) [332](#) [333](#) [334](#) [335](#) [336](#) [337](#) [338](#) [339](#) [340](#) [341](#) [342](#) [343](#) [344](#) [345](#) [346](#) [347](#) [348](#) [349](#) [350](#) [351](#) [352](#) [353](#) [354](#) [355](#) [356](#) [357](#) [358](#) [359](#) [360](#) [361](#) [362](#) [363](#) [364](#) [365](#) [366](#) [367](#) [368](#) [369](#) [370](#) [371](#) [372](#) [373](#) [374](#) [375](#) [376](#) [377](#) [378](#) [379](#) [380](#) [381](#) [382](#) [383](#) [384](#) [385](#) [386](#) [387](#) [388](#) [389](#) [390](#) [391](#) [392](#) [393](#) [394](#) [395](#) [396](#) [397](#) [398](#) [399](#) [400](#) [401](#) [402](#) [403](#) [404](#) [405](#) [406](#) [407](#) [408](#) [409](#) [410](#) [411](#) [412](#) [413](#) [414](#) [415](#) [416](#) [417](#) [418](#) [419](#) [420](#) [421](#) [422](#) [423](#) [424](#) [425](#) [426](#) [427](#) [428](#) [429](#) [430](#) [431](#) [432](#) [433](#) [434](#) [435](#) [436](#) [437](#) [438](#) [439](#) [440](#) [441](#) [442](#) [443](#) [444](#) [445](#) [446](#) [447](#) [448](#) [449](#) [450](#) [451](#) [452](#) [453](#) [454](#) [455](#) [456](#) [457](#) [458](#) [459](#) [460](#) [461](#) [462](#) [463](#) [464](#) [465](#) [466](#) [467](#) [468](#) [469](#) [470](#) [471](#) [472](#) [473](#) [474](#) [475](#) [476](#) [477](#) [478](#) [479](#) [480](#) [481](#) [482](#) [483](#) [484](#) [485](#) [486](#) [487](#) [488](#) [489](#) [490](#) [491](#) [492](#) [493](#) [494](#) [495](#) [496](#) [497](#) [498](#) [499](#) [500](#) [501](#) [502](#) [503](#) [504](#) [505](#) [506](#) [507](#) [508](#) [509](#) [510](#) [511](#) [512](#) [513](#) [514](#) [515](#) [516](#) [517](#) [518](#) [519](#) [520](#) [521](#) [522](#) [523](#) [524](#) [525](#) [526](#) [527](#) [528](#) [529](#) [530](#) [531](#) [532](#) [533](#) [534](#) [535](#) [536](#) [537](#) [538](#) [539](#) [540](#) [541](#) [542](#) [543](#) [544](#) [545](#) [546](#) [547](#) [548](#) [549](#) [550](#) [551](#) [552](#) [553](#) [554](#) [555](#) [556](#) [557](#) [558](#) [559](#) [560](#) [561](#) [562](#) [563](#) [564](#) [565](#) [566](#) [567](#) [568](#) [569](#) [570](#) [571](#) [572](#) [573](#) [574](#) [575](#) [576](#) [577](#) [578](#) [579](#) [580](#) [581](#) [582](#) [583](#) [584](#) [585](#) [586](#) [587](#) [588](#) [589](#) [590](#) [591](#) [592](#) [593](#) [594](#) [595](#) [596](#) [597](#) [598](#) [599](#) [600](#) [601](#) [602](#) [603](#) [604](#) [605](#) [606](#) [607](#) [608](#) [609](#) [610](#) [611](#) [612](#) [613](#) [614](#) [615](#) [616](#) [617](#) [618](#) [619](#) [620](#) [621](#) [622](#) [623](#) [624](#) [625](#) [626](#) [627](#) [628](#) [629](#) [630](#) [631](#) [632](#) [633](#) [634](#) [635](#) [636](#) [637](#) [638](#) [639](#) [640](#) [641](#) [642](#) [643](#) [644](#) [645](#) [646](#) [647](#) [648](#) [649](#) [650](#) [651](#) [652](#) [653](#) [654](#) [655](#) [656](#) [657](#) [658](#) [659](#) [660](#) [661](#) [662](#) [663](#) [664](#) [665](#) [666](#) [667](#) [668](#) [669](#) [670](#) [671](#) [672](#) [673](#) [674](#) [675](#) [676](#) [677](#) [678](#) [679](#) [680](#) [681](#) [682](#) [683](#) [684](#) [685](#) [686](#) [687](#) [688](#) [689](#) [690](#) [691](#) [692](#) [693](#) [694](#) [695](#) [696](#) [697](#) [698](#) [699](#) [700](#) [701](#) [702](#) [703](#) [704](#) [705](#) [706](#) [707](#) [708](#) [709](#) [710](#) [711](#) [712](#) [713](#) [714](#) [715](#) [716](#) [717](#) [718](#) [719](#) [720](#) [721](#) [722](#) [723](#) [724](#) [725](#) [726](#) [727](#) [728](#) [729](#) [730](#) [731](#) [732](#) [733](#) [734](#) [735](#) [736](#) [737](#) [738](#) [739](#) [740](#) [741](#) [742](#) [743](#) [744](#) [745](#) [746](#) [747](#) [748](#) [749](#) [750](#) [751](#) [752](#) [753](#) [754](#) [755](#) [756](#) [757](#) [758](#) [759](#) [760](#) [761](#) [762](#) [763](#) [764](#) [765](#) [766](#) [767](#) [768](#) [769](#) [770](#) [771](#) [772](#) [773](#) [774](#) [775](#) [776](#) [777](#) [778](#) [779](#) [780](#) [781](#) [782](#) [783](#) [784](#) [785](#) [786](#) [787](#) [788](#) [789](#) [790](#) [791](#) [792](#) [793](#) [794](#) [795](#) [796](#) [797](#) [798](#) [799](#) [800](#) [801](#) [802](#) [803](#) [804](#) [805](#) [806](#) [807](#) [808](#) [809](#) [810](#) [811](#) [812](#) [813](#) [814](#) [815](#) [816](#) [817](#) [818](#) [819](#) [820](#) [821](#) [822](#) [823](#) [824](#) [825](#) [826](#) [827](#) [828](#) [829](#) [830](#) [831](#) [832](#) [833](#) [834](#) [835](#) [836](#) [837](#) [838](#) [839](#) [840](#) [841](#) [842](#) [843](#) [844](#) [845](#) [846](#) [847](#) [848](#) [849](#) [850](#) [851](#) [852](#) [853](#) [854](#) [855](#) [856](#) [857](#) [858](#) [859](#) [860](#) [861](#) [862](#) [863](#) [864](#) [865](#) [866](#) [867](#) [868](#) [869](#) [870](#) [871](#) [872](#) [873](#) [874](#) [875](#) [876](#) [877](#) [878](#) [879](#) [880](#) [881](#) [882](#) [883](#) [884](#) [885](#) [886](#) [887](#) [888](#) [889](#) [890](#) [891](#) [892](#) [893](#) [894](#) [895](#) [896](#) [897](#) [898](#) [899](#) [900](#) [901](#) [902](#) [903](#) [904](#) [905](#) [906](#) [907](#) [908](#) [909](#) [910](#) [911](#) [912](#) [913](#) [914](#) [915](#) [916](#) [917](#) [918](#) [919](#) [920](#) [921](#) [922](#) [923](#) [924](#) [925](#) [926](#) [927](#) [928](#) [929](#) [930](#) [931](#) [932](#) [933](#) [934](#) [935](#) [936](#) [937](#) [938](#) [939](#) [940](#) [941](#) [942](#) [943](#) [944](#) [945](#) [946](#) [947](#) [948](#) [949](#) [950](#) [951](#) [952](#) [953](#) [954](#) [955](#) [956](#) [957](#) [958](#) [959](#) [960](#) [961](#) [962](#) [963](#) [964](#) [965](#) [966](#) [967](#) [968](#) [969](#) [970](#) [971](#) [972](#) [973](#) [974](#) [975](#) [976](#) [977](#) [978](#) [979](#) [980](#) [981](#) [982](#) [983](#) [984](#) [985](#) [986](#) [987](#) [988](#) [989](#) [990](#) [991](#) [992](#) [993](#) [994](#) [995](#) [996](#) [997](#) [998](#) [999](#) [1000](#) [1001](#) [1002](#) [1003](#) [1004](#) [1005](#) [1006](#) [1007](#) [1008](#) [1009](#) [1010](#) [1011](#) [1012](#) [1013](#) [1014](#) [1015](#) [1016](#) [1017](#) [1018](#) [1019](#) [1020](#) [1021](#) [1022](#) [1023](#) [1024](#) [1025](#) [1026](#) [1027](#) [1028](#) [1029](#) [1030](#) [1031](#) [1032](#) [1033](#) [1034](#) [1035](#) [1036](#) [1037](#) [1038](#) [1039](#) [1040](#) [1041](#) [1042](#) [1043](#) [1044](#) [1045](#) [1046](#) [1047](#) [1048](#) [1049](#) [1050](#) [1051](#) [1052](#) [1053](#) [1054](#) [1055](#) [1056](#) [1057](#) [1058](#) [1059](#) [1060](#) [1061](#) [1062](#) [1063](#) [1064](#) [1065](#) [1066](#) [1067](#) [1068](#) [1069](#) [1070](#) [1071](#) [1072](#) [1073](#) [1074](#) [1075](#) [1076](#) [1077](#) [1078](#) [1079](#) [1080](#) [1081](#) [1082](#) [1083](#) [1084](#) [1085](#) [1086](#) [1087](#) [1088](#) [1089](#) [1090](#) [1091](#) [1092](#) [1093](#) [1094](#) [1095](#) [1096](#) [1097](#) [1098](#) [1099](#) [1100](#) [1101](#) [1102](#) [1103](#) [1104](#) [1105](#) [1106](#) [1107](#) [1108](#) [1109](#) [1110](#) [1111](#) [1112](#) [1113](#) [1114](#) [1115](#) [1116](#) [1117](#) [1118](#) [1119](#) [1120](#) [1121](#) [1122](#) [1123](#) [1124](#) [1125](#) [1126](#) [1127](#) [1128](#) [1129](#) [1130](#) [1131](#) [1132](#) [1133](#) [1134](#) [1135](#) [1136](#) [1137](#) [1138](#) [1139](#) [1140](#) [1141](#) [1142](#) [1143](#) [1144](#) [1145](#) [1146](#) [1147](#) [1148](#) [1149](#) [1150](#) [1151](#) [1152](#) [1153](#) [1154](#) [1155](#) [1156](#) [1157](#) [1158](#) [1159](#) [1160](#) [1161](#) [1162](#) [1163](#) [1164](#) [1165](#) [1166](#) [1167](#) [1168](#) [1169](#) [1170](#) [1171](#) [1172](#) [1173](#) [1174](#) [1175](#) [1176](#) [1177](#) [1178](#) [1179](#) [1180](#) [1181](#) [1182](#) [1183](#) [1184](#) [1185](#) [1186](#) [1187](#) [1188](#) [1189](#) [1190](#) [1191](#) [1192](#) [1193](#) [1194](#) [1195](#) [1196](#) [1197](#) [1198](#) [1199](#) [1200](#) [1201](#) [1202](#) [1203](#) [1204](#) [1205](#) [1206](#) [1207](#) [1208](#) [1209](#) [1210](#) [1211](#) [1212](#) [1213](#) [1214](#) [1215](#) [1216](#) [1217](#) [1218](#) [1219](#) [1220](#) [1221](#) [1222](#) [1223](#) [1224</](#)

gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML R38 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Common Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] A Schedule of Earnings Per Share, Basic and Diluted Basic and diluted net loss per share are as follows (in thousands except share and per share amounts): A A Three months endedSeptember 30, A A Nine months endedSeptember 30, A A A 2024 A A 2023 A A 2024 A A 2023 A Net loss A \$ (23,859) A \$ (34,884) A \$ (86,137) A \$ (102,100) Net loss per share attributable to common stockholdersA basic and diluted A \$ (0.29) A \$ (0.70) A \$ (1.21) A \$ (2.06) Weighted-average number of common shares used in computing net lossA A per shareA basic and diluted A A 82,011,670 A A 49,814,903 A A 71,173,647 A A 49,533,143 A Schedule of Antidilutive Securities Excluded from Earnings Per Share Calculation The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive: A A September 30, A A September 30, A A A 2024 A A 2023 A Stock options to purchase common stock A 11,591,425 A A 9,489,119 A Restricted common stock A 624 A A 19,487 A Restricted stock units A 112,159 A A 250,265 A X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: <http://www.xbrl.org/2003/role/commonPracticeRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Employee retirement plans (Tables) 9 Months Ended Sep. 30, 2024 Retirement Benefits [Abstract] A Schedule of pension expense incurred The following table summarizes pension expense incurred (in thousands): A A Three months endedSeptember 30, A A Nine months endedSeptember 30, A A A 2024 A A 2023 A A 2024 A A 2023 A Pension expense A \$ 279 A A \$ 251 A A \$ 822 A A \$ 702 A Schedule of defined contribution expense incurred The following table summarizes defined contribution expenses incurred (in thousands): A A Three months endedSeptember 30, A A Nine months endedSeptember 30, A A A 2024 A A 2023 A A 2024 A A 2023 A Defined contribution expense A \$ 164 A A \$ 99 A A \$ 701 A A \$ 488 A X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the costs related to the various types of retirement plans including defined benefit pension plan cost, defined contribution plan cost, other postretirement benefit plan cost, and net periodic benefit cost. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 715 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480506/715-20-50-1> + Details Name: us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 715 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480506/715-20-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Section 55 -Paragraph 17 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480482/715-20-55-17>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480506/715-20-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480506/715-20-50-4>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480506/715-20-50-2> + Details Name: us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Liquidity - Additional Information (Details) - USD \$ (\$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Subsidiary Or Equity Method Investee [Line Items] A A A A A A Restricted Cash and Cash Equivalents A 242,200 A A A A \$ 242,200 A A Accumulated deficit (452,025) A A A A (452,025) A A \$ (365,888) Net Income (Loss) A \$ (23,859) A \$ (30,310) A \$ (31,968) A \$ (34,884) A \$ (35,178) A \$ (32,038) A \$ (86,137) A \$ (102,100) A X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Summary of Financial Assets Liabilities Measured on Recurring Basis (Details) - USD \$ (\$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current

À À Total assets measured at fair value \$ 251,169 \$ 236,420 Level 3 [Member] À À Current assets À À Total assets measured at fair value 125,006 122,791 Level 2 [Member] À À Current assets À À Total assets measured at fair value 126,163 113,629 Level 3 [Member] À À Current assets À À Total assets measured at fair value 0 0 US Treasury Securities Member À À Current assets À À Total assets measured at fair value 59,225 24,496 US Treasury Securities Member | Level 1 [Member] À À Current assets À À Total assets measured at fair value 0 0 US Treasury Securities Member | Level 2 [Member] À À Current assets À À Total assets measured at fair value 59,225 24,496 US Treasury Securities Member | Level 3 [Member] À À Current assets À À Total assets measured at fair value 0 0 Money Market Funds [Member] À À Current assets À À Total assets measured at fair value 125,006 122,791 Money Market Funds [Member] | Level 1 [Member] À À Current assets À À Total assets measured at fair value 125,006 122,791 Money Market Funds [Member] | Level 2 [Member] À À Current assets À À Total assets measured at fair value 0 0 Pension Plan Assets [Member] À À Current assets À À Total assets measured at fair value 9,552 9,317 Pension Plan Assets [Member] | Level 1 [Member] À À Current assets À À Total assets measured at fair value 0 0 Pension Plan Assets [Member] | Level 2 [Member] À À Current assets À À Total assets measured at fair value 9,552 9,317 Pension Plan Assets [Member] | Level 3 [Member] À À Current assets À À Total assets measured at fair value 0 Corporate Debt Securities Member À À Current assets À À Total assets measured at fair value 57,386 79,816 Corporate Debt Securities Member | Level 1 [Member] À À Current assets À À Total assets measured at fair value 0 Corporate Debt Securities Member | Level 2 [Member] À À Current assets À À Total assets measured at fair value 57,386 79,816 Corporate Debt Securities Member | Level 3 [Member] À À Current assets À À Total assets measured at fair value \$ 0 \$ 0 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1:

glue_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 47 R442.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Additional Information) (Details) 1 Months Ended 9 Months Ended Dec. 14, 2021 USD (\$) ftA² Apr. 30, 2023 USD (\$) ftA² Sep. 30, 2024 USD (\$) Sep. 30, 2023 USD (\$) Mar. 01, 2021 ftA² Lessee, Lease, Description [Line Items] Å Å Å Å Å Finance Lease Å Å 0 Å Å Amortization of the ROU assets Å Å 1,600,000 Å 2,000,000 Å Tenant improvements Å Å 13,000,000 Å Hochbergerstrasse [Member] Å Å Å Å Å Lessee, Lease, Description [Line Items] Å Å Å Å Land Subject to Ground Leases | ftA² Å Å Å 21,422 Right of Use Assets Decreased Limit, Amount Å Å 1,800,000 Å Å Å Hochbergerstrasse [Member] | Maximum [Member] Å Å Å Å Lessee, Lease, Description [Line Items] Å Å Å Å Land Subject to Ground Leases | ftA² Å Å 44,685 Å Å Å Hochbergerstrasse [Member] | Minimum [Member] Å Å Å Å Lessee, Lease, Description [Line Items] Å Å Å Å Land Subject to Ground Leases | ftA² Å 21,422 Å Å Harrison Street [Member] Å Å Å Å Lessee, Lease, Description [Line Items] Å Å Å Å Land Subject to Ground Leases | ftA² 63,327 Å Å Å Lease commencement date Apr. 01, 2022 Å Å Å Å Initial lease term 128 months Å Å Å Renewal term 5 years Å Å Å Lease annual base rent per square foot 95 Å Å Å Increase in annual base rent (Percentage) 3.00% Å Å Å X - DefinitionIncrease in annual base rent (Percentage) + ReferencesNo definition available. + Details Name: glue_IncreaseInAnnualBaseRentPercentage Namespace Prefix: glue_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLease Commencement Date + ReferencesNo definition available. + Details Name: glue_LeaseCommencementDate Namespace Prefix: glue_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionRight of Use Assets Decreased Limit, Amount + ReferencesNo definition available. + Details Name: glue_RightOfUseAssetsDecreasedLimitAmount Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 40-Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(2\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(2)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2> + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionArea of land subject to a ground lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)\(1\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (a)(1)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3) + Details Name: us-gaap_LandSubjectToGroundLeases Namespace Prefix: us-gaap_Data Type: dtr-types:arealItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7A-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7A-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3> + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)\(3\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (a)(3)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3) + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)\(3\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (a)(3)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3) + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionCash payments to lessor's for use of assets under operating leases. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(g\)-SubTopic 10-Topic 230-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (g)-SubTopic 10-Topic 230-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/230-10-45-25) + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy. + ReferencesNo definition available. + Details Name: us-gaap_PaymentsForTenantImprovements Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=glue_HochbergerstrasseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=glue_HarrisonStreetMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Components of Lease Expense (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Leases [Abstract] Å Å Å Operating lease expense \$ 1,611 \$ 1,569 \$ 4,860 \$ 5,552 Variable lease expense 912 572 3,043 1,700 Total lease expense \$ 2,523 \$ 2,141 \$ 7,903 \$ 7,252 X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(d\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (d)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 49 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Summarizes lease expense (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Å Å Å Total lease expense \$ 2,521 \$ 2,327 \$ 7,902 \$ 7,438 Research and Development Å Å Å Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Å Å Å Total lease expense \$ 2,099 \$ 1,977 \$ 6,596 \$ 6,234 General and Administrative Å Å Å Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Å Å Å Total lease expense \$ 422 \$ 350 \$ 1,306 \$ 1,204 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4) + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Lease Terms and Discount Rate (Details) Sep. 30, 2024 Dec. 31, 2023 Leases [Abstract] Å Å Weighted average remaining lease term (years) 7 years 10 months 24 days 8 years 7 months 6 days Weighted average discount rate 9.80% 9.80% X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(g\)\(4\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g)(4)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(g\)\(3\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g)(3)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 51 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Leases [Abstract] Å Å Right-of-use assets obtained in exchange for operating lease obligations \$ 108 \$ 1,871 Cash paid for amounts included in the measurement of lease liabilities \$ 2,325 \$ 2,382 X - DefinitionCash Paid For Amount Included In Measurement Of Lease Liabilities. + ReferencesNo definition available. + Details Name: glue_CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(g\)\(2\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g)(2)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 52 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details) - Non-cancelable leases [Member] \$ in Thousands Sep. 30, 2024 USD (\$) \$ Finite-Lived Intangible Assets [Line Items] Å 2024 \$ 1,891 2025 7,746 2026 7,943 2027 7,651 2028 7,356 Thereafter 31,010 Total undiscounted minimum lease payments 63,597 Less: Imputed interest (19,899) Total operating lease liability \$ 43,698 X - DefinitionLessee Operating Lease Liability Payments Due Thereafter + ReferencesNo definition available. + Details Name: glue_LesseeOperatingLeaseLiabilityPaymentsDueThereafter Namespace Prefix: glue_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 40-Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)\(2\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(2)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)\(1\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(1)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(d\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (d)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 8:

number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. No pre-funded warrants have been exercised as of September 30, 2024

À À Dividends declared À À \$ 0 À Dividends paid À À \$ 0 À Gross Proceeds from sale of Common Stock À \$ 25,000 À À Common stock, voting rights À À one À Warrant [Member] À À À À Class of Stock [Line Items] À À À Pre-Funded Warrants to Purchase À À 10,000,400 20,638,924 À À Pre-funded warrants exercisable, exercise price À À \$ 0.0001 À À Share exercise price À À \$ 0.0001 À À Common stock price À À \$ 2.4999 À À Common Stock À À À À Class of Stock [Line Items] À À À À Underwritten public offering À 10,638,476 À À Unvested restricted common stock awards À À À À Class of Stock [Line Items] À À À À Vesting term À À 4 years À À Jefferies LLC [Member] À À À À Class of Stock [Line Items] À À À À Common stock, shares, issued during the period À À 130,506 À À Percentage of Commission payable to Related Party 3.00% À À À À Offering Costs À À \$ 900 À À Gross Proceeds from sale of Common Stock \$ 100,000 À À \$ 1,000 À À TD Securities (USA) LLC [Member] À À À À À Class of Stock [Line Items] À À À À Offering Costs À \$ 96,400 À À À Gross Proceeds from sale of Common Stock À \$ 100,000 À À À TD Securities (USA) LLC [Member] | Warrant [Member] À À À À Class of Stock [Line Items] À À À À Purchase of pre-funded warrants shares À 10,638,524 À À À Common stock price À \$ 4.6999 À À À TD Securities (USA) LLC [Member] | Common Stock À À À À Class of Stock [Line Items] À À À À Share exercise price 0.0001 À À À Common stock price À \$ 4.7 À À À Undesignated Preferred Stock À À À À Class of Stock [Line Items] À À À À Preferred stock, shares authorized À À 10,000,000 À À Preferred stock, par value À À \$ 0.0001 À À Preferred stock shares issued À À 0 À À Preferred stock, shares outstanding À À 0 À À - DefinitionDescription of Pre Funded Warrants + ReferencesNo definition available. + Details Name: glue DescriptionOfPreFundedWarrants Namespace Prefix: glue Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIssued Pre Funded Warrants + ReferencesNo definition available. + Details Name: glue IssuedPreFundedWarrants Namespace Prefix: glue Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of Commission payable to Related Party + ReferencesNo definition available. + Details Name: glue PercentageOfCommissionPayableToRelatedParty Namespace Prefix: glue Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPre-Funded Warrants to Purchase + ReferencesNo definition available. + Details Name: glue PreFundedWarrantsToPurchase Namespace Prefix: glue Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPublic Offering of Share + ReferencesNo definition available. + Details Name: glue PublicOfferingOfShare Namespace Prefix: glue Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/exampleRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(7\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(7)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3) + Details Name: us-gaap ClassOfStockLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity’s charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm’s shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap CommonStockVotingRights Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(24\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(15\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(15)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 405-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147478790/946-405-45-2>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(15\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(15)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap DividendsPayableCurrentAndNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemBalance Type: credit Period Type: instant X - DefinitionThe cumulative amount of offering costs allocated to the other unit holders. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 5-Subparagraph \(SAB Topic 4.F\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 5-Subparagraph (SAB Topic 4.F)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5) + Details Name: us-gaap OtherOwnershipInterestsOfferingCosts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemBalance Type: debit Period Type: instant X - DefinitionCash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 15-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 15-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap PaymentsOfDividends Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity’s charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3) + Details Name: us-gaap ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionPeriod over which grantee’s right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in ‘PnYmMnDTnHnMnS’ format, for example, ‘P1Y5M13D’ represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap Data Type: xbrl:durationItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap SharePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap SharesIssuedPricePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap Data Type: xbrl:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AwardTypeAxis=us-gaap RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RelatedPartyTransactionsByRelatedPartyAxis=glue JefferiesLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RelatedPartyTransactionsByRelatedPartyAxis=glue TdSecuritiesUsaLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=glue UndesignatedPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=glue UnvestedRestrictedCommonStockAwards Axis=glue Class Of Stock [Line Items] A Common stock reserved for future issuance 32,343,132 19,646,545 Options to purchase common stock A Common stock reserved for future issuance 11,591,425 9,394,930 Unvested restricted common stock awards A Common stock reserved for future issuance 112,159,236,519 Pre-funded warrants A Common stock reserved for future issuance 624 14,696 Unvested restricted common stock units A Common stock reserved for future issuance 210,638,924 100,400 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(ii)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(ii)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(ii)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap ClassOfStockLineItems Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap Data Type: xbrl:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap StatementClassOfStockAxis=glue CommonStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=glue RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=glue PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=glue ExpectedRemainingCostWeightedAveragePeriodUnits Namespace Prefix: glue Data Type: xbrl:durationItemType Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award percentage of increase in future issuance reserve share. + ReferencesNo definition available. + Details Name: glue ExpectedRemainingCostWeightedAveragePeriodUnits Namespace Prefix: glue Data Type: xbrl:durationItemType Balance Type: na Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award percentage of increase in future issuance reserve share. + ReferencesNo definition available. + Details Name: glue ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInFutureIssuanceReserveShare Namespace Prefix: glue Data Type: xbrl:sharesItemType Balance Type: na Period Type: duration X - DefinitionShare Based Compensation Arrangement By Share Based Payment Award Percentage Of Increase In Future Issuance Reserved Share + ReferencesNo definition available. + Details Name: glue ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInFutureIssuanceReservedShare Namespace Prefix: glue Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap Data Type: xbrl:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYmMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap Data Type: xbrl:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference

Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(03) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(03) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (d)(1) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (d)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (e)(1) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (e)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(ii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(iii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(iv) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(v) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (d)(1) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification - Section 50 - Paragraph 2 - SubTopic 10 - Topic 505 - Publisher FASB - URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap SharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - Details Name: us-gaap AwardTypeAxis=us-gaap RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AwardTypeAxis=us-gaap RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PlanNameAxis=glue TwoThousandTwentyOneEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap PlanNameAxis=glue TwoThousandTwentyOneEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DOCUMENT v3.24.3 Stock-Based Compensation - Schedule of Stock Option Activity (Details) \$ / shares in Units, \$ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 USD (\$) \$ / shares shares Dec. 31, 2023 USD (\$) \$ / shares shares Share-Based Payment Arrangement [Abstract] Å Number of options, beginning balance | shares 9,394,930 Å Number of options, granted | shares 2,945,540 Å Number of options, exercised | shares (238,304) Å Number of shares, forfeited | shares (510,741) Å Number of options, ending balance | shares 11,591,425 9,394,930 Number of options, vested or expected to vest | shares 11,591,425 Å Number of options, exercisable | shares 5,871,488 Å Weighted average exercise price, beginning balance | \$ / shares \$ 8.78 Å Weighted average exercise price, granted | \$ / shares 5.48 Å Weighted average exercise price, exercised | \$ / shares 2.86 Å Weighted average exercise price, forfeited | \$ / shares 7.99 Å Weighted average exercise price, ending balance | \$ / shares 8.1 Å 8.78 Weighted average exercise price, vested or expected to vest | \$ / shares 8.1 Å Weighted average exercise price, exercisable | \$ / shares \$ 8.98 Å Weighted average remaining contractual term (years), balance 7 years 9 months 18 days 8 years Weighted average remaining contractual term (years), vested or expected to vest 7 years 9 months 18 days Å Weighted average remaining contractual term (years), exercisable 7 years Å Aggregate intrinsic value, beginning balance | \$ 4,741 Å Aggregate intrinsic value, ending balance | \$ 4,122 Å 4,741 Aggregate intrinsic value, vested or expected to vest | \$ 4,122 Å Aggregate intrinsic value, exercisable | \$ 3,190 Å X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv)(03) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - Definition Gross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv)(01) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification - Topic 718 - SubTopic 10 - Section 50 - Paragraph 2 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemBalance Type: debit Period Type: instant X - Definition Number of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(ii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - Definition Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (e)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemBalance Type: debit Period Type: instant X - Definition Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (e)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv)(02) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - Sub

value, beginning balance | \$ / shares 2.19 Weighted average grant date fair value, vested | \$ / shares 2.19 Weighted average grant date fair value, ending balance | \$ / shares 2.19 X - Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 1D-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12:

Section 50 - Paragraph 2 - Subparagraph (c)(2)(ii) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16:

https://asc.fasb.org/1943274/214748524/220-10-50-1Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(20\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(20))) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/220-10-50-1 + Details Name: us-gaap IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(13\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(13))) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-50-9-2Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-50-9-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-50-9-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-99-1Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-50-9-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-50-9-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-99-1Reference 13:

Contribution Expense (Details) - USD (\$) \$ in Thousands Starts 3 Months Ended 9 Months Ended Sep 30, 2023 Sep 30, 2023 Sep 30, 2023 Retirement Benefits [Abstract] X X X
Defined contribution expense \$ 164 \$ 99 \$ 701 \$ 488 X - ReferencesNo definition available. + Details Name: us-gaap CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of discretionary contributions made by an employer to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration XML 69 R64.htm IDEA: XBRL DOCUMENT Y3.24.3 Subsequent events (Additional Information) (Details) - Collaboration and License Agreement - USD (\$) \$ in Millions 1 Months Ended Oct. 25, 2024 Nov. 30, 2023 Subsequent Event [Line Items] A A Upfront payment receive A \$ 28 Maximum [Member] A A Subsequent Event [Line Items] A A Revenue Recognition, Development, Regulatory, Sales Milestones \$ 2,100 A Subsequent Event A A Subsequent Event [Line Items] A A Upfront payment receive 150 A Revenue Recognition, Development, Regulatory, Sales Milestones \$ 1,500 A X - DefinitionRevenue Recognition, Development, Regulatory, Sales Milestones + ReferencesNo definition available. + Details Name: glue RevenueRecognitionDevelopmentRegulatorySalesMilestones Namespace Prefix: glue Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionUpfront Payment Received + ReferencesNo definition available. + Details Name: glue UpfrontPaymentReceived Namespace Prefix: glue Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147481764/830-30-50-2>-Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483399/855-10-50-2> + Details Name: us-gaap SubsequentEventLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: glue AgreementAxis=glue CollaborationAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsequentEventTypeNamespace Prefix: us-gaap SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 70 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial Report.xlsx M4\$!#1!0 / (OX9UDU04UB+<+ 0 \$9 Jc4C)>< ,O871P+GAM M;S/VOL,I1\$ IQO;=IP4B0J2L+(/> QLOd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lAJ4IPI DOE&I+&3&K;=@SWVVOM(G(WXVJZMOFUCP MH5A)VHX\$KS.QIXSGYJ/LJ/14;1JIE6W*.7614EQC?-*HU+>,76>j7 V< M/ITI3LV4*P9IAI@S M&L%&KQMUAVC2/K^?F<-OHACA^FNVB<5@ \$9Y>PTGI/Z+>+9OVXH;5,VPLCO=U!=*Y FIS LCO' MHIY9;V\$5FJ?JH,@H%;D>/N5Z>HWL4^FZ>P T=HWJPJXOGL U M?RYJSZ7ON?9AH>=W-RJ93BUO=1FY;Q/N=N,-K?X8HU=RTSLS0LS=R2^JVE+ZUICA M J]+<\$X-RPPJ9SRJ;9WHIU? =9=NC0313ET X.D&*+ VVZG=>ZJB,D; MXJ0/O,VYZ<SX&N(YVOY2?9)?>78T?=Y1M1/OJ8=XQRHBH/NH8:85# MAWE|YAGE<90-J1E,M;PD+S=W8+C72PAX&1@+> .@ZJ|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dLI7^W-773RP13WAHK 2#2V)OI\$#@MUJTUWS3 MALKRJWKJ? ELEG RBR9YC 9 "XB\$U VSQHGDH6M).9%;CISND(G5B^4B2J DDWU MJG8/VAC4SKP8?0BSJSZ][KAM@M0/<4H4I6G?)7 RHKIYEADPLE-T39MT- M7115+4LG& G,ALMR-@E|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|TI(VN%=M5 M3#VJZ05OQBQ<1I1W& ;?;:GW>L^M PWGYEK\W6KOI1 5K[60-5+V[F+Q MC1Q=IMV SN(OPI 29P6RH=O?<?>? Y6<+1+&Q\$N>+&M^PN9?LG+TGHH^M] MIXOIJ?PY7. Z^|=I#, +=&4B) B)L+A, I'A CKG6E 2>??>J Q'UEM2 M _= <CQJX6+U#>.>B.K?C @J\$2] &40I4SPJO95W 1-\$@BLM2U\$P SO M6H>H5&C3YM9^M9?>CSEO\$UNUJ M|^I=>OYV;SLQJXYM3%. EHIBC<AN&Z N%7/(PAII+L) J01;YJ.[15#.75? MW8BIT7AO\$M;8SUCQ;IV\$;=>VQ9WIANT7@6%+2G/UPJ*KGWBJ,7[KBNX].3N* M=C^OBK/R9WB#X.BBW% QK^QY8<[<IO +65+2YLFWA84UH%71^>KA,I27 M64HPV9L (0BBW2\$,OT@);>?&W98<9ZWZACIG2BW.N+#Z4<S\$J Z3#38#4 M&6VBT1QEY47I6Q1LYI^P.A&6ZDFCQ\$APV.W.CB||;8B^U&H; OYO MCSWINOONL@<Y6V[W,P9.&-I2I GAH^O=J],J2L2+1,T^KPI&OR^XT MQI(FENNV19OX^X,S,B,H=>EIQ8RE+V,R2RJ2GF GL9M,TJ4\$? 762%RSZAM;WJX-K MRI+W&M&1UXFR,121QYHU&4&3(3H .88>#)JI3F1@ M(A*B^9+P6Y%5,W) <2+Z-I+&*& 00'DI0RLB/90MT8KV9&G?&24 MJHLF=2VB 7<_TA,A;C 85K^1#T^*X*8.<7K?N5\$9C^09F5-3.89;R5RC&ZB+&LAE|I61MJ.R.M&L M1 UZE^LG) PINT&3^K TRXX&C6JA8V];JAZ\$[*#W2(R\$1@.LX =&:(VZ4""U\$^! IF>-%.B6UW M-M0<,&WUT^Q?T2+ [<@>E9 [NP(GT&4[GKJE4]&8/&@&EN1M,

Q94EH3GD8DI7)EM3!&.%Y9IG6!+&S+&C'; GUN8T]]&9RE&M+O0O(U01K9JPS9V"X I*^N^RPQ0Q:[A~"12UGJ9F;Ms](4/W)N3QC5IX\$X\$8K2\$1<8R7?JGQVZ1>1C*E? ML"VUOF+J&"7C.A.M *9 JP]38T1+2;WJ6@JH\$F\$3H517E4#X J^D~D.PI1D64*D6;G<^DC1 MX1F6G;Z@E-Q-14-~>?P6P8P' JWAL<[3].69015E \$%&L38@BNKJZ YI]B MI"LA18,X9CV3BJC2P8RJ.(RTG.BC@L~.J)R1;U1 M~Y;Y3J]OSL"W#N#XJ[UF J~&C-A\$B85 M%<@>=L2A+@NOMMH+7QE(=N@37C@N'29ZF; .K4R%\$+M+U.V5 GLSNMX% V MTLF@.96=5+2;1VX3G+ZDA"~"F@=2; =@-02P.% M% @>[A@G66]9MU@ @ P@<1 @E I%J;JW;WJ^K'&G1<? .S?J-Z-8ACE5=08W4G&NIFIA'R MQMIT91FK1@ (F+JF+@9HDHJ[C&E\$] 9U(VM9385646PUHBU+8UEN+4&(WBWMI1 M8@~)E1GV W\$V;7 JSZ! -L~M%K&G\$H#5U1P'&B7>?PVB]U[L%/RGLU%\$; M4VPVOKS;S1;HLO~8-6<P(VGRT F,69#11'1YF1W] 06K0S?>0FF6[187VUUL0B?\$]; =+3T~?V5H+K2]SOG W~ M-SXV9EXO/>@MTB#P\$89HJ[UN4]JID@P'OI]U.M.U[.34JFC=HXZ6G; M2UF MI~N(H/34'MN'E2#I[04T1YX4](7KVU#) (M0SOT.M= M.Z.Y\$8W~OAB=;AA88#8@<@.T8L@YO|O@MU?A&+7Y\$9>;G15U5 FE.\$58P MF9?~JW?U7M5H+0@&DXV'Q.OF4V1V>3JRH7LPM25M1~O1 M05J#&+WKH5 N6J2P1';J@=JWMW+? Y=WKJL*RY)RA1@4)C2Y&YMC+L7H^MH MT;A;>B.TN?=-LS*+\$\$B[P.7P0NA#QV|@G^WL#U!+ P04 #.T.E=-9+^+8 ME-8' \$]s@ &O 'AL+W=O9.>M?7&XR<~>_ZH7.?(('18@P" # :!47 :JL@&KQ>+U+&36ZO9>UCN+VW7;+&T<~>@8M&#>~>JWJ3#UO?E~J~JN/PHI3NA.N&N4H.IF1OE5V[SW IN+B;7J.) MT1B7 67W@/BB+U.PX?7 EN/-!0*=>30KV.OBM^K'VOA'3151#@<..@ M O X.R~7;=Q2+8%KQD' 4NH08\$?2KE36? Y;.=+N>IYP%O.BU(MT15;J/V M1 71NU1';J.K3R6GP/EB+U,UXK? O:CP@=J9NEA,U6JQNGU|W5HJ7HNSB M[XZH?>2<1O1UT5M34KSEJ|J|JMU3 J4Y1]3F=JEZ2U>~VB.TNZ&:'XH@4GFAR M~JTWRI>+GUY>SFB0Q7U? ?[?1?1 5G@;JL= 9RZY9YUW~0~<=<C5K54\$W\$5? M3J&GZTKR1J1 3JV3U3434EN V.G~ZUV.U3JUBAY21UJ0JH3"Y.XXF* MC;96-1XEW%62P%&888;2H0.AZM4Z2ZH..W'X9K4V1> [Z2Y6BU ~"DJIU,7 M-#3;U,~>?7JYX2< CV 1=5HLN~L[DION J4:]9P]X;~F;J~JHMM+~N~X M=RI8@=QVOQ(2T.2E3KBIC..N.#@VBP P1)~#T; H\$ MGRJ 4Z8Y~\$0]2J~VVO*Q. 2S]~>O,+O~N> F135MO.P2OFM #48K2;J.G M J.EY?>?WZ;.<87UG9L~2?;STK0~HUI=4; 4 RMZ~3L@&SZ&G(5YRZ.X@J.(EU=E+~WJ1U02[PAJ=21 M. B72KEGQ[C[<~8<1OCC6LTO<~#=@DAS%M% [#WYV4 51QZB+&NF1V-DFU8K~ M28>B'BQ\$AK\$&S\$D'OQ<29J@H=G=GIHT\$S]8ZPPSBM3CO|U@.XPY~2+G|E1PW3 M4\$~|1%R%[#N.RXAC@J]\$(3Y)88T6W.- +!~=J8(5%R&G+CU0IF9(V,ETA))VG16W)S;@/O'~<1+2 & MPFZDP@QG A1?B- 9D;G<3<~< 5 IR8T&~?%U|H8K9?7TSE&9UP5~HS MO.~%G15?2@W.K%T 6ES~>ES3Z^~%3;:J9~> R'E3C1~X27%1]] L0J;PYO M3.*JZ|(RV8M%)P4\$J9..QY7518D<~<Q6N9P%|?%|@JUS7.<7<3C|QAPWM^KT074+V>+O< HOJ;M5RL#M8J|D; M+=\$ HY343@<?%XP7;1B\$X\$J1ARJ;|A]X0~|JYS .@S#H|V9'H1@'<('A'VE+ MFJFCBP2HJQ;.<H~#?>G7WRK'G982CB9ZP8L~.~.YK1<9V@M'R.R;~F^2L~DM04?SZA?B[M(G'CB~L3H MP3)?~XCI P-Z.WYJF|&~> M~2ICMY\$>Q1XM?>G8VL~R#86@&25 I9%> M4=Z'ZTZX M@>=7VE,73Q?6FT=5U2)PBO821'J](\$8,Q%&+GYY9N8MZEFOV869-U8X<~<M.ABK8! BCAD;=(64E/Q%<~\$2P2LQ7L/HOOSB+BU-G<|C)U6>2/W1=V|Y6I M~9EKWE=^H6K1V49~1'J(1~F=F2M1~T B56UCW624]Q@%~#MVMW..R] M[SR31O@J;|T;YTS+J|QJ]~>=UY W?MIM=7@ O H-~\$5AI<~<O~%6< M'3 \$W.7O OM~2O.IQTV>?~T'9U007#51(79R3XJ)U (I P-HU<~&E- M@3@?>4QT74W?~X>~>KVOU!+ P04 #.T.E=-9Q1~\$M&S? \$0 \$0 M'AL+W=O~%04?> 40I|-8E%63H/4M~2P4 GOZ(37L0G1Y-N1:FQ ML5~M.LT~<9+LYD13JH|C8-8T;Y~D>~WY~|@R+~PRFSQKPNB MK-4;6E;Z~\$WV.F:CE=(TY*+Q3@6JSB?+XJ>7IRPO K;N|HU[|SXH|67O_E5> ME~>3.0.B2T5B*Q6 [H|B;|D08|S1VYR;|I+B O O~ 9WX%E 6.M*5M |T9;K| M|Z|FJJ1~S9J|K= |JZ?7%VRO~#?7W6;94|J|KH8O~KPP\$C7Y5|_U|P|MO|I| 0V'1R4P\$=SY(4+ |125~.VZC66,8BF>SA/-H;TMB \$~<4W;|L|GB7J|C> MN1+>O T9<Y@%P/RB613E!43M7) \$~MYHO3?~R=C.Z.ZB+V3;J|A;|KR|KU4 M_UJN8R|E(G YG'V= |JXZ2|U@'519U'AL+1P18F5\$~ K'YY=|FCB2P7J|D|<~ UR323.0=|JZG M-F7=!! WT?72/F@?ETNKK~4=J6^27RN'&+~&KVU.LI2I6J|B;|B4R714VXB0 MG\$X)7FEVQ9|Z4EM|G=C44@M1#3@WVW1Y0~<6W~JL\$P7?~ 2@=507(|R MK%LE&.AC.K%LE&.AC.F407E3JIF4RHSBW7-WP0R4VXWVL|J|WZ?C66|6JTNX M'&O) |J|~ #8+&L5Y6ADZ MOXN:NN9~B~<~"PIIUPP(395-TYWI+4)93W+&1@M(3PNF\$ OJ;|J@'<@N X~+~X~R~O+&W-F|5|;~1D|A|>P M&3C.~\$D7Z\$YO@ CES?>@G'E33BLT.Z~<&CMC%;\$ABE D+L/FAYB3J07+M~N3B(V|,HR|B?<GZVONM1~4%~BK~2~M?73~<4Z?5 J)N|H5F|SSZ5XKR<~ M16K=|807A;~R'LYP;O@'AU (Q;M%Q|<#11+|0FRQ M'J~<10FY@D+4~9451 M3%;A*~A;7K%Y&H4|IFM|["(#?19'1~>+SPOH(KS|OW~< M'54~&UEC1! MS~NE+~22H@'6'S)D5W~+~#2Z|(OM44>+Y>|N;~?NL|QCQ|J|ODML+~S MTS|PVP|14|@2NQJ- 2FY4~F<I~N9N~K+A|Q'SC'Y|Y(~1~1~N~Y~<~B'836 M~<GAX&S'Q|J'~T~5G M..GEQFUNJ2~G~<G~JYA~K>L>..@P;9'0Q03HH/EF~#~>~>GB1*~S-(N\$GSG-E|BKWJ+GZ MLADX 7<(|J|<K>V)~K&W&AC@S%.#C3/W~'R'@Q;Z,~7A^2FAV5'E4;JM3' MG~98>T.%D?OU! V5@Jc4N5 JY.@+~R! |B%~\$6QO+C19S,\$E4IDCAVP4 MI'|=CTM0IK'UON'GAKCOOM'3\$/>H.O IT,|J\$C5NBNR~M&~|6FJ|BWGG.M3C MFFG1P1' *E*FR+R(SNO./4- LAT&NSX); M3Z('1~\$547RV2~<1~>U%7.F;~2D MY08&'G/V;|XZC'O?|U>P~Q Y8A|G0K~3L56S7BD9>~>E~H>~.ACRB\$HA^T7 M.SP5~N+&PG1X|F~W86VWV8Y~#3H2D|78YGYK8H1HMPY~P..B~3<~ 1~ M-7PS<304| U~>+<4EJO|T?~;2Y'YU|L~>3;+~M1O/K~N~&IUT|F Y6MGN M80=4AIR&.(%&@ ~Y7'9;|X0& XE< 1=-02P.% @ #1ACG60 +|-(I~O V@<I D M I X;|JW;WJ&KUL5~M|L\$V|[N77~XJ|P|BFW M~A~XG30\$1>VJW ~@1~VW78|H6&S8A1B21)*J|WZV=2'K| M'~%5;ZGSM77@Z~

[illegible][illegible]

[illegible]

Rendertexter was created by staff of the U.S.C. 105; var ShowLastAR=()=>{ShowLastAR=null>Show.showAR=function(f,r,w){if(ShowLastAR)show.hideAR()var e=a.whiled(e,c,e,nodeName)=e.nextSibiling;if(!c||!e.nodeName===TABLE)}[var ref=(window).w=document.document.getElementsByTagName(i);ref[e=e-ref.cloneNode(10);e.removeAttribute(id)];a.parentNode.appendChildChild(a)] if(c.e.style.display='block';ShowLastAR=e];Show.hideAR=function(t)(ShowLastAR.style.display='none');Show.toggleNext=function(a)[var e=a.whiled(e,c,e,nodeName)=DIV]le=e.nextSibiling;if(!e||!(e.c)||!(e.c)){}else{var d=p.if(e.style.display==='none'){d='block;p='}'}else{d='none;d+=+}}
e.style.display=d;if(a.textContent!=f.a.textContent.substring(p+a.textContent.substring(1)))else{a.innerHTMLText+p+a.innerHTMLText.substring(1)}} XML 72 report.css IDEA: XBRL DOCUMENT * Updated 2009-11-04 % v2.2 20 24 % DefRefStyles % Report table.authRefData Background-color: #def; border: 2px solid #2F4A97; font-size: 1em; position: absolute: } report table.authRefData { display: block; font-weight: bold; } report table.authRefData p { margin-top: 0px; } report table.authRefData hide { background-color: #2F4A97; padding: 1px 3px 0px 0px; text-align: right; } report table.authRefData .hide a:hover { background-color: #2F4A97; } report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } report table.authRefData table { font-size: 1em; } / Report Styles % pl.a.pl.visited { color: black; text-decoration: none; } / table % report { background-color: white; border: 2px solid #ac6; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } report hr { border: 1px solid #ac6; } / Top labels % report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } report td { vertical-align: top; background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } report pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; word-wrap: break-word; } report td.pl.a { cursor: pointer; display: block; font-weight: bold; width: 200px; overflow: hidden; } report td.pl.div.a { width: 200px; } report td.pl.a.hover { background-color: #ffc; } / Header rows...% report tr.th { background-color: #acf; color: black; font-weight: bold; } / Calendars...% report rc { background-color: #fff0f0; } / Even rows...% report re { background-color: #def; } report ru { border-bottom: 1px solid black; } / Odd rows...% report ro { background-color: white; } report row.td { border-bottom: 1px solid black; } report row.tb.td { border-bottom: 0px solid black; } / styles for footnote marker % report fn { white space: nowrap; } / styles for numeric types % report num { text-align: right; white space: nowrap; } report nump { padding-left: 2em; } report nump { padding: 0px 0.4em 0px 2em; } / styles for text types % report text { text-align: left; white space: normal; } report text.big { margin-bottom: 1em; width: 17em; } report text.more { display: none; } report text.note { font-style: italic; font-weight: bold; } report text.small { width: 10em; } report sup { font-style: italic; } report outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html 196 272 1 false 45 0 false 5 false false R1.htm 100000 Document - Document and Entity Information Sheet
[http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformationSheet](#) http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100030 Statement - Condensed Consolidated Balance Sheets (Unaudited) Parenthetical Sheet
[http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical](#) Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Statements 3 false false R4.htm 100040 Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet
[http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss](#) Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100050 Statement - Condensed Combined and Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) Sheet
[http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited](#) Condensed Combined and Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 100070 Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet
[http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited](#) Condensed Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 100080 Statement - Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) Sheet
[http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical](#) Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) Statements 7 false false R8.htm 995410 Disclosure - Pay vs Performance Disclosure Sheet
[http://xbri.sec.gov/ced/role/PvpDisclosurePayvsPerformanceDisclosureNotes 8 false false R9.htm 995445 Disclosure - Insider Trading Arrangements Sheet](#) [http://xbri.sec.gov/ced/role/InsiderTradingArrangementsInsiderTradingArrangementsNotes 9 false false R10.htm 995455 Disclosure - Description of business and liquidity Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidity](#) Description of business and liquidity Notes 10 false false R11.htm 995465 Disclosure - Summary of significant accounting policies Sheet
[http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies](#) Summary of significant accounting policies Notes 11 false false R12.htm 995475-Disclosure - Fair Value Measurements Sheet
[http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueMeasurementsNotes 12 false false R13.htm 995495-Disclosure - Marketable Securities Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesMarketableSecuritiesNotes 13 false false R14.htm 995495-Disclosure - Property and Equipment, net Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyandEquipmentnetNotes 14 false false R15.htm 995505-Disclosure - Accrued expenses and other current liabilities Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities](#) Accrued expenses and other current liabilities Notes 15 false false R16.htm 995515-Disclosure - Leases Sheet
[http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesLeasesNotes 16 false false R17.htm 995525-Disclosure - Commitments and contingencies Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies](#) Commitments and contingencies Notes 17 false false R18.htm 995535-Disclosure - Collaboration And License Agreements Sheet
[http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationAndLicenseAgreementsNotes 18 false false R19.htm 995555-Disclosure-Equity Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityEquityNotes 19 false false R20.htm 995565-Disclosure - Stock-Based Compensation Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationNotes 20 false false R21.htm 995575-Disclosure - Income taxes Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIIncome TaxesNotes 21 false false R22.htm 995585-Disclosure - Net Loss Per Common Share Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareNNet Loss Per Common ShareNotes 22 false false R23.htm 995595-Disclosure - Employee Retirement Plan Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureEmployeeRetirementPlanEmployeeRetirementPlanNotes 23 false false R24.htm 995605-Disclosure - Subsequent events Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureSubsequentEventsSubsequent EventsNotes 24 false false R25.htm 995615-Disclosure - Summary of significant accounting policies \(Policies\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesPoliciesNotes 25 false false R26.htm 995625-Disclosure - Fair Value Measurements \(Tables\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTablesFairValueMeasurements\(Tables\)Tables](#) [http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements26 false false R27.htm 995635-Disclosure - Marketable Securities \(Tables\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTablesMarketableSecurities\(Tables\)Tables](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecurities27 false false R28.htm 995645-Disclosure - Property and Equipment, net \(Tables\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTablesPropertyandEquipmentnet\(Tables\)Tables](#) [http://monterosatx.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet28 false false R29.htm 995655-Disclosure - Accrued expenses and other current liabilities \(Tables\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTablesAccruedexpensesandothercurrentliabilities\(Tables\)Tables](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities29 false false R30.htm 995665-Disclosure - Leases \(Tables\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesTablesLeases\(Tables\)Tables](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureLeases30 false false R31.htm 995675-Disclosure - Equity \(Tables\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityTablesEquity\(Tables\)Tables](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureEquity131 false false R32.htm 995685-Disclosure - Stock Based Compensation \(Tables\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTablesStockBasedCompensation\(Tables\)Tables](#) [http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensation32 false false R33.htm 995695-Disclosure - Net Loss Per Common Share \(Tables\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareTablesNetLossPerCommonShare\(Tables\)Tables](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShare133 false false R34.htm 995705-Disclosure - Employee retirement plans \(Tables\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlansTablesEmployeeretirementplans\(Tables\)Tables34 false false R35.htm 995715-Disclosure - Description of Business and Liquidity - Additional Information \(Details\) Sheet](#) [http://monterosatx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidityAdditionalInformationDetailsDescriptionofBusinessandLiquidity-AdditionalInformation\(Details\)Details](#) Details 35 false false R36.htm 995725-Disclosure - Fair Value Measurements - Summary of Financial Assets Liabilities Measured on Recurring Basis (Details) Sheet
[http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetailsFairValueMeasurements-SummaryofFinancialAssetsLiabilitiesMeasuredonRecurringBasis\(Details\)Details](#) Details 36 false false R37.htm 995735-Disclosure - Fair Value Measurements - Additional Information (Details) Sheet
[http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetailsFairValueMeasurements-AdditionalInformation\(Details\)Details](#) Details 37 false false R38.htm 995755-Disclosure - Marketable Securities - Summary of Marketable securities

[illegible]

["reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R19": { "role": "http://monterosax.com/20240930/taxonomy/role/DisclosureEquity", "longName": "095555-Disclosure-Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R20": { "role": "http://monterosax.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensation", "longName": "095565-Disclosure-Stock-Based-Compensation", "shortName": "Stock-Based-Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R21": { "role": "http://monterosax.com/20240930/taxonomy/role/DisclosureIncomeTaxes", "longName": "095575-Disclosure-Income-taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R22": { "role": "http://monterosax.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShare", "longName": "095585-Disclosure-Net Loss Per Common Share", "shortName": "Net Loss Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R23": { "role": "http://monterosax.com/20240930/taxonomy/role/Role-DisclosureEmployeeRetirementPlan", "longName": "095595-Disclosure-Employee Retirement Plan", "shortName": "Employee Retirement Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R24": { "role": "http://monterosax.com/20240930/taxonomy/role/DisclosureSubsequentEvents", "longName": "095605-Disclosure-Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R25": { "role": "http://monterosax.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "095615-Disclosure-Summary of significant accounting policies \(Policies\)", "shortName": "Summary of significant accounting policies \(Policies\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:LiquidityConsiderationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:LiquidityConsiderationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R26": { "role": "http://monterosax.com/20240930/taxonomy/role/Role-DisclosureFairValueMeasurementsTables", "longName": "095625-Disclosure-Fair Value Measurements \(Tables\)", "shortName": "Fair Value Measurements \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R27": { "role": "http://monterosax.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTables", "longName": "095635-Disclosure-Marketable Securities \(Tables\)", "shortName": "Marketable Securities \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["uniqueAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-20240930.htm", "first": true, "unique": true } }](#), ["R28": { "role": "http://monterosax.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetTables", "longName": "095645-Disclosure-Property and Equipment-net \(Tables\)", "shortName": "Property and Equipment-net \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C 7d5dfcea-1c5a-44f1-b9ea-83da1c2c6930", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": 1, "reportCount": 1, "baseRef": "glue-](#)

```
summary of Marketable securities (Details)" , "shortName": "Marketable Securities - Summary of Marketable securities (Details)" , "isDefault": "false" , "groupType": "disclosure" , "subGroupType": "details" , "menuCat": "Details" , "order": "38" , "firstAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" , "div": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } , "uniqueAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" , "div": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } } , "R30": { "role": "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail" , "longName": "995765 - Disclosure - Property and Equipment - net - Schedule of Property, Plant and Equipment (Detail)" , "shortName": "Property and Equipment - net - Schedule of Property, Plant and Equipment (Detail)" , "isDefault": "false" , "groupType": "disclosure" , "subGroupType": "details" , "menuCat": "Details" , "order": "39" , "firstAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:PropertyPlantAndEquipmentGross" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:PropertyPlantAndEquipmentTableTextBlock" , "div": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } , "uniqueAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:PropertyPlantAndEquipmentGross" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:PropertyPlantAndEquipmentTableTextBlock" , "div": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } } , "R40": { "role": "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" , "longName": "995775 - Disclosure - Property and Equipment - net - Schedule of Depreciation Expense (Details)" , "shortName": "Property and Equipment - net - Schedule of Depreciation Expense (Details)" , "isDefault": "false" , "groupType": "disclosure" , "subGroupType": "details" , "menuCat": "Details" , "order": "40" , "firstAnchor": { "contextRef": "C 8af1da63-89a3-490d-b6a0-c41d655f8bc3" , "name": "us-gaap:Depreciation" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "glue:ScheduleOfDepreciationExpensesTableTextBlock" , "div": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } , "uniqueAnchor": null } , "R41": { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" , "longName": "995795 - Disclosure - Accrued expenses and other current liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details)" , "shortName": "Accrued expenses and other current liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details)" , "isDefault": "false" , "groupType": "disclosure" , "subGroupType": "details" , "menuCat": "Details" , "order": "41" , "firstAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" , "div": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } , "uniqueAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" , "div": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } } , "R42": { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" , "longName": "995805 - Disclosure - Leases (Additional Information) (Details)" , "shortName": "Leases (Additional Information) (Details)" , "isDefault": "false" , "groupType": "disclosure" , "subGroupType": "details" , "menuCat": "Details" , "order": "42" , "firstAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:FinanceLeaseLiability" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:LeasesOperatingLeasesTableTextBlock" , "div": "body" , "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } , "uniqueAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:FinanceLeaseLiability" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:LeasesOperatingLeasesTableTextBlock" , "div": "body" , "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } } , "R43": { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" , "longName": "995815 - Disclosure - Leases - Components of Lease Expense (Details)" , "shortName": "Leases - Components of Lease Expense (Details)" , "isDefault": "false" , "groupType": "disclosure" , "subGroupType": "details" , "menuCat": "Details" , "order": "43" , "firstAnchor": { "contextRef": "C 8af1da63-89a3-490d-b6a0-c41d655f8bc3" , "name": "us-gaap:OperatingLeaseCost" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:LeaseCostTableTextBlock" , "div": "us-gaap:LesseeOperatingLeasesTableTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } , "uniqueAnchor": { "contextRef": "C 8af1da63-89a3-490d-b6a0-c41d655f8bc3" , "name": "us-gaap:OperatingLeaseCost" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:LeaseCostTableTextBlock" , "div": "us-gaap:LesseeOperatingLeasesTableTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } } , "R44": { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesSummarizesLeaseExpenseDetails" , "longName": "995825 - Disclosure - Leases - Summarizes lease expense (Details)" , "shortName": "Leases - Summarizes lease expense (Details)" , "isDefault": "false" , "groupType": "disclosure" , "subGroupType": "details" , "menuCat": "Details" , "order": "44" , "firstAnchor": { "contextRef": "C 8af1da63-89a3-490d-b6a0-c41d655f8bc3" , "name": "us-gaap:OperatingLeaseExpense" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:OperatingLeaseExpenseTableTextBlock" , "div": "us-gaap:LesseeOperatingLeasesTableTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } , "uniqueAnchor": { "contextRef": "C 8af1da63-89a3-490d-b6a0-c41d655f8bc3" , "name": "us-gaap:OperatingLeaseExpense" , "unitRef": "U USD" , "xsiNil": "false" , "lang": null , "decimals": "3" , "ancestors": { "span": "p" , "td": "tr" , "table": "us-gaap:OperatingLeasesTableTextBlock" , "div": "us-gaap:LesseeOperatingLeasesTableTextBlock" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } } , "R45": { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermsAndDiscountRateDetails" , "longName": "995835 - Disclosure - Leases - Schedule of Lease Terms and Discount Rate (Details)" , "shortName": "Leases - Schedule of Lease Terms and Discount Rate (Details)" , "isDefault": "false" , "groupType": "disclosure" , "subGroupType": "details" , "menuCat": "Details" , "order": "45" , "firstAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm" , "unitRef": "en-US" , "decimals": null , "ancestors": { "span": "p" , "td": "tr" , "table": "ix-continuation" , "div": "ix-continuation" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } , "uniqueAnchor": { "contextRef": "C 4ee636d5-69ec 4260-b73f-8c1e50cfb97e" , "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm" , "unitRef": "en-US" , "decimals": null , "ancestors": { "span": "p" , "td": "tr" , "table": "ix-continuation" , "div": "ix-continuation" , "body": "html" } , "reportCount": 1 , "baseRef": "glue 20240930.htm" , "first": true , "unique": true } } , "R46": { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" , "longName": "995845 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)" , "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)" , "isDefault": "false" , "groupType": "disclosure" , "subGroupType": "details" , "menuCat": "Details" , "order": "46" , "firstAnchor
```

"decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix-continuation", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "unique", true], "uniqueAnchor": { "contextRef": "C 76121d76 78df 429b 9d50 77d280a7face", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix-continuation", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "unique", true } }, "R56", { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitActivityDetails", "longName": "995955 - Disclosure - Stock based compensation - Schedule of Restricted Stock Unit Activity (Details)", "shortName": "Stock based compensation - Schedule of Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C 7d5dfcea 1c5a 44f1 b9ea 83da1e2c6930", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "uniqueAnchor": { "contextRef": "C 2027e1d1 79f3 4fd2 9a35 89b8f53dda0ec", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix-continuation", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "unique", true } }, "R57", { "role": "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails", "longName": "995965 - Disclosure - Stock Based Compensation - Schedule of Stock Based Compensation Expense (Details)", "shortName": "Stock Based Compensation - Schedule of Stock Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C 7d5dfcea 1c5a 44f1 b9ea 83da1e2c6930", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix-continuation", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "unique", true } }, "uniqueAnchor": { "contextRef": "C 7d5dfcea 1c5a 44f1 b9ea 83da1e2c6930", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix-continuation", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "unique", true } }, "R58", { "role": "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "995975 - Disclosure - Income taxes - Additional Information (Details)", "shortName": "Income taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C 8af1da63 89a3 490d b6a0 c41d655f8be3", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix-continuation", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "uniqueAnchor": null }, "R59", { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "longName": "995985 - Disclosure - Net Loss Per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "shortName": "Net Loss Per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C 8af1da63 89a3 490d b6a0 c41d655f8be3", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "uniqueAnchor": null }, "R60", { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails", "longName": "995995 - Disclosure - Net Loss Per Common Share - Schedule of Anti Dilutive Shares Excluded from Earnings Per Share Calculation (Details)", "shortName": "Net Loss Per Common Share - Schedule of Anti Dilutive Shares Excluded from Earnings Per Share Calculation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C 025efe7d 55e0 43b9 8684 2aff48b2b1e4", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "unique", true } }, "uniqueAnchor": { "contextRef": "C 025efe7d 55e0 43b9 8684 2aff48b2b1e4", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "unique", true } }, "R61", { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails", "longName": "996005 - Disclosure - Employee Retirement Plan - Additional Information (Details)", "shortName": "Employee Retirement Plan - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C 7d5dfcea 1c5a 44f1 b9ea 83da1e2c6930", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "unique", true } }, "R62", { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlansScheduleOfPensionExpenseDetails", "longName": "996015 - Disclosure - Employee retirement plans - Schedule of Pension Expense (Details)", "shortName": "Employee retirement plans - Schedule of Pension Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C 8af1da63 89a3 490d b6a0 c41d655f8be3", "name": "us-gaap:PensionExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "unique", true } }, "R63", { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlansScheduleOfDefinedContributionExpenseDetails", "longName": "996025 - Disclosure - Employee retirement plans - Schedule of Defined Contribution Expense (Details)", "shortName": "Employee retirement plans - Schedule of Defined Contribution Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C 8af1da63 89a3 490d b6a0 c41d655f8be3", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "unique", true } }, "R64", { "role": "http://monterosatx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "996035 - Disclosure - Subsequent events (Additional Information) (Details)", "shortName": "Subsequent events (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C 74292bba 54e0 4a39 97fa b8bc81ca2fec", "name": "glue:UpfrontPaymentReceived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "6", "ancestors": ["span", "p", "td", "tr", "ix-continuation", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "uniqueAnchor": { "contextRef": "C a9275ded 01ab 46c2 a795 20cb8e89207f", "name": "glue:RevenueRecognitionDevelopmentRegulatorySalesMilestones", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "8", "ancestors": ["span", "p", "td", "tr", "ix-continuation", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "uniqueAnchor": { "contextRef": "C a9275ded 01ab 46c2 a795 20cb8e89207f", "name": "glue:RevenueRecognitionDevelopmentRegulatorySalesMilestones", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "8", "ancestors": ["span", "p", "td", "tr", "ix-continuation", "div", "body", "html", "reportCount", "baseRef", "glue 20240930.htm", "first", true, "uniqueAnchor": { "contextRef": "C a9275ded 01ab 46c2 a795 20cb8e89207f", "name": "glue:RevenueRecognitionDevelopmentRegulatorySalesMilestones", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "8", "ancestors": ["span", "p", "td", "tr", "ix-continuation", "div", "body", "html", "reportCount

"ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": {
"r761"} } }, "us-gaap-AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock",
"crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "label":
"Additional Paid in Capital, Common Stock", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "periodEndLabel": "Additional Paid in Capital, Common Stock,
Ending Balance", "terseLabel": "Additional paid in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated
value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in
excess of par, capital surplus, or paid in capital." } } }, "auth_ref": { "r59"} } }, "us-gaap-AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited": { "lang": {
"en-us": { "role": { "label": "Additional Paid in Capital [Member]", "terseLabel": "Additional Paid in Capital", "documentation": "Excess of issue price over par or stated value of the entity's
capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r565", "r839", "r840", "r841", "r843", "r905", "r970"} } },
"ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": {
"lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": { "r774"} } }, "ecd_AdjToCompAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": {
"label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation." } } }, "auth_ref": { "r774"} } }, "ecd_AdjToNonPeeoNeoCompFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": {
"role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote." } } }, "auth_ref": { "r774"} } },
"ecd_AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoCompFnTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation,
Footnote" } } }, "auth_ref": { "r774"} } }, "us-gaap-AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited": { "lang": {
"en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "totalLabel": "APIC, Share-based
Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid in capital (APIC) for recognition of cost for award under share-based
payment arrangement." } } }, "auth_ref": { "r43", "r44", "r321"} } }, "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile
net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": {
"r774"} } }, "ecd_AggtChngPnsnValInSummryCompstnTblForApblyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValInSummryCompstnTblForApblyrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Change in Present
Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All
Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": { "r807"} } }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount",
"terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r733", "r743", "r753", "r785"} } }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {
"lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } },
"auth_ref": { "r736", "r746", "r756", "r788"} } }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]",
"terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": { "r808"} } }, "glue-AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://monterosatx.com/20240930/
"localname": "AgreementAxis", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails":
"http://monterosatx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Agreement [Axis]", "label":
"Agreement [Axis]" } } }, "auth_ref": { } }, "glue-AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "AgreementDomain",
"presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails":
"http://monterosatx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Agreement [Domain]", "label":
"Agreement [Domain]" } } }, "auth_ref": { } }, "ecd-AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember",
"presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to
Compensation" } } }, "auth_ref": { "r774"} } }, "ecd-AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All
Executive Categories" } } }, "auth_ref": { "r781"} } }, "ecd-AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember",
"presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements":
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": { "r737", "r747", "r757", "r781",
"r789", "r793", "r801"} } }, "ecd-AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading
Arrangements" } } }, "auth_ref": { "r799"} } }, "us-gaap-AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement.
Excludes amount capitalized." } } }, "auth_ref": { "r350", "r355"} } }, "dei-AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"AmendmentFlag", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Amendment
Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { } }, "us-
gaap-AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation":
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel":
"Amortization of the ROU assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a
systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used
in operations using the indirect method." } } }, "auth_ref": { "r7", "r246", "r252", "r676"} } }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Antidilutive securities excluded from computation of EPS", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation":
"Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not
included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": {
"r178"} } }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": { "r25"} } }, "us-
gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Antidilutive Securities Excluded From Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per
Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap-AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesNameDomain", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not
included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r25"} } }, "us-
gaap-Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets",
"documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r86", "r108", "r132", "r153", "r181", "r187", "r192", "r193", "r232", "r266", "r267",
"r268", "r269", "r270", "r271", "r272", "r273", "r274", "r383", "r387", "r418", "r524", "r603", "r672", "r673", "r700", "r724", "r873", "r874", "r923"} } }, "us-gaap-AssetsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets
[Abstract]" } } }, "auth_ref": { } }, "us-gaap-AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit",
"presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Total current
assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r126", "r138", "r153", "r232",
"r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r383", "r387", "r418", "r700", "r873", "r874", "r923"} } }, "us-gaap-AssetsCurrentAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label":
"Assets, Current [Abstract]" } } }, "auth_ref": { } }, "us-gaap-AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsFairValueDisclosure", "crdr": "debit", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureFairValueMeasurementsSummaryOfFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Total assets measured at fair value", "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets, Fair Value Disclosure, Total", "documentation": "Fair value portion of asset
recognized for present right to economic benefit." } } }, "auth_ref": { "r400", "r401", "r689"} } }, "glue-AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://monterosatx.com/20240930", "localname": "AtTheMarketOfferingMember", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails":
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentetical":
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited":
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "documentation": "At the Market Offering
[Member]", "label": "At the Market Offering [Member]", "terseLabel": "At the Market Offering" } } }, "auth_ref": { } }, "us-
gaap-AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for
Sale, Accumulated Gross Unrealized Gain, before Tax", "totalLabel": "Unrealized Gains", "terseLabel": "Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in
accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)."
" } } }, "auth_ref": { "r205"} } }, "us-gaap-AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Debt Securities, Available for
Sale, Accumulated Gross Unrealized Loss, before Tax", "totalLabel": "Unrealized Losses", "negatedLabel": "Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in
accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)."
" } } }, "auth_ref": { "r206"} } }, "us-gaap-AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": {

[http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails](#)"}}, {"lang": "en-us", "role": "label", "Debt Securities, Available for Sale, Amortized Cost", "totalLabel": "Amortized Cost", "terseLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)."}}, {"auth_ref": "r202", "r240", "r523"}}, {"us_gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", {"xbrltype": "monetary/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "order": "debit", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"}, {"lang": "en-us", "role": "negatedTerseLabel": "Unrealized loss on available-for-sale securities", "label": "Debt Securities, Available for Sale, Unrealized Loss", "terseLabel": "Unrealized loss on available-for-sale securities", "negatedLabel": "Unrealized loss on available-for-sale securities", "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)."}}, {"auth_ref": "r858"}}, {"us_gaap_AvailableForSaleSecuritiesDebtSecurities", {"xbrltype": "monetary/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "order": "debit", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"}, {"lang": "en-us", "role": "label", "Debt Securities, Available for Sale", "totalLabel": "Fair Value", "terseLabel": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)."}}, {"auth_ref": "r203", "r240", "r400", "r518", "r689", "r692", "r852", "r909", "r910", "r911"}}, {"ecd_AwardExercPrice", {"xbrltype": "perShare/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExercPrice", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Award Exercise Price", "terseLabel": "Exercise Price"}}, {"auth_ref": "r796"}}, {"ecd_AwardGrantDateFairValue", {"xbrltype": "monetary/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date"}}, {"auth_ref": "r797"}}, {"ecd_AwardTmgDiscLineItems", {"xbrltype": "string/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": "en-us", "role": "label", "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered"}}, {"auth_ref": "r792"}}, {"ecd_AwardTmgMnpiDiscTextBlock", {"xbrltype": "text/Block/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered"}}, {"auth_ref": "r792"}}, {"ecd_AwardTmgMethodTextBlock", {"xbrltype": "text/Block/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method"}}, {"auth_ref": "r792"}}, {"ecd_AwardTmgMnpiCnsrdFlag", {"xbrltype": "boolean/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsrdFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered"}}, {"auth_ref": "r792"}}, {"ecd_AwardTmgMnpiDiscTextBlock", {"xbrltype": "text/Block/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure"}}, {"auth_ref": "r792"}}, {"ecd_AwardTmgPredtrmdFlag", {"xbrltype": "boolean/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmdFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined"}}, {"auth_ref": "r792"}}, {"us_gaap_AwardTypeAxis", {"xbrltype": "string/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockUnitActivityDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement."}}, {"auth_ref": "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349"}}, {"ecd_AwardUndrlygSecuritiesAmt", {"xbrltype": "decimal/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Award Underlying Securities Amount", "terseLabel": "Underlying Securities"}}, {"auth_ref": "r795"}}, {"ecd_AwardsCloseToMnpiDiscIndName", {"xbrltype": "string/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name"}}, {"auth_ref": "r794"}}, {"ecd_AwardsCloseToMnpiDiscTable", {"xbrltype": "string/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures"}}, {"auth_ref": "r793"}}, {"ecd_AwardsCloseToMnpiDiscTableTextBlock", {"xbrltype": "text/Block/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, {"lang": "en-us", "role": "label", "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"}}, {"auth_ref": "r793"}}, {"us_gaap_BasisOfAccountingPolicyPolicyTextBlock", {"xbrltype": "text/Block/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"}, {"lang": "en-us", "role": "label", "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."}}, {"auth_ref": []}, {"glue_CancerResearchTechnologyLimitedMember", {"xbrltype": "domain/ItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "CancerResearchTechnologyLimitedMember", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"}, {"lang": "en-us", "role": "label", "Cancer Research Technology Limited [Member]", "documentation": "Cancer Research Technology Limited."}}, {"auth_ref": []}, {"us_gaap_CapitalExpendituresIncurredButNotYetPaid", {"xbrltype": "monetary/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "order": "credit", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"}, {"lang": "en-us", "role": "label", "Purchases of property and equipment in accounts payable and accrued expenses", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."}}, {"auth_ref": "r22", "r23", "r24"}}, {"us_gaap_CashAndCashEquivalentsAtCarryingValue", {"xbrltype": "monetary/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "order": "debit", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"}, {"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"}, {"lang": "en-us", "role": "label", "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."}}, {"auth_ref": "r21", "r128", "r669"}}, {"us_gaap_CashAndCashEquivalentsAxis", {"xbrltype": "string/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails"}, {"lang": "en-us", "role": "label", "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance."}}, {"auth_ref": "r128"}}, {"us_gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", {"xbrltype": "monetary/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "order": "debit", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"}, {"lang": "en-us", "role": "label", "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "terseLabel": "Total cash, cash equivalents and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}, {"auth_ref": "r21", "r74", "r150"}}, {"us_gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", {"xbrltype": "monetary/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "order": "debit", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"}, {"lang": "en-us", "role": "label", "Not increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}, {"auth_ref": "r0", "r74"}}, {"glue_CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities", {"xbrltype": "monetary/ItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities", "order": "credit", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"}, {"lang": "en-us", "role": "label", "Cash paid for amounts included in the measurement of lease liabilities", "label": "Cash Paid For Amount Included In Measurement Of Lease Liabilities", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"}}, {"auth_ref": []}, {"ecd_ChangedPeerGroupFnTextBlock", {"xbrltype": "text/Block/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, {"lang": "en-us", "role": "label", "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote"}}, {"auth_ref": "r772"}}, {"ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstInCvrdYrMember", {"xbrltype": "domain/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstInCvrdYrMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, {"lang": "en-us", "role": "label", "Change in Fair Value as of Vesting Date of Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"}}, {"auth_ref": "r769"}}, {"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", {"xbrltype": "domain/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, {"lang": "en-us", "role": "label", "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"}}, {"auth_ref": "r767"}}, {"dei_CityAreaCode", {"xbrltype": "normalizedString/ItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentAndEntityInformation"}, {"lang": "en-us", "role": "label", "City Area Code", "label": "City Area Code", "documentation": "Area code of city"}}, {"auth_ref": []}, {"us_gaap_ClassOfStockDomain", {"xbrltype": "domain/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityScheduleOfCommonStockForPotentialConversionOutstandingPreferredStockDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStock"}, {"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParent/ItemType", {"lang": "en-us", "role": "label", "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."}}, {"auth_ref": "r122", "r133", "r134", "r135", "r153", "r172", "r173", "r175", "r177", "r185", "r186", "r232", "r266", "r268", "r269", "r270", "r273", "r274", "r278", "r279", "r282", "r285", "r293", "r418", "r558", "r559", "r560", "r561", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r590", "r612", "r631", "r646", "r647", "r648", "r649", "r650", "r812", "r837", "r844"}}, {"us_gaap_ClassOfStockLineItems", {"xbrltype": "string/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityScheduleOfCommonStockForPotentialConversionOutstandingPreferredStockDetails"}, {"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"}, {"lang": "en-us", "role": "label", "Class Of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}, {"auth_ref": "r133", "r134", "r135", "r185", "r278", "r279", "r280", "r282", "r285", "r291", "r293", "r558", "r559", "r560", "r561", "r670", "r812", "r837"}}, {"us_gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", {"xbrltype": "perShare/ItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": {"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails"}, {"lang": "en-us", "role": "label", "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Pre-funded warrants exercisable, exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding."}}, {"auth_ref": "r294"}}, {"ecd_CoSelectedMeasureAmt", {"xbrltype": "decimal/ItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, {"lang": "en-us", "role": "label", "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount"}}, {"auth_ref": }

“r773” } } , “ecd_CoSelectedMeasureName”: { “xbrltype”: “normalizedStringItemType”, “nsuri”: “http://xbrl.sec.gov/ecd/2024”, “localname”: “CoSelectedMeasureName”, “presentation”: { “http://xbrl.sec.gov/ecd/role/PvpDisclosure” } } , “lang”: { “en-us”: { “role”: { “label”: “Company Selected Measure Name”, “terseLabel”: “Company Selected Measure Name” } } } , “auth_ref”: { “r773” } } , “glue_CollaborationAndLicenseAgreementMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://monterosatx.com/20240930”, “localname”: “CollaborationAndLicenseAgreementMember”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails” } , “http://monterosatx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails” } } , “lang”: { “en-us”: { “role”: { “documentation”: “Collaboration and License Agreement [Member]”, “label”: “Collaboration and License Agreement [Member]”, “terseLabel”: “Collaboration and License Agreement” } } } , “auth_ref”: { } } , “us_gaap_CollaborativeArrangementDisclosureTextBlock”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CollaborativeArrangementDisclosureTextBlock”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements” } } , “lang”: { “en-us”: { “role”: { “terseLabel”: “Collaboration and license agreements”, “label”: “Collaborative Arrangement Disclosure [Text Block]”, “documentation”: “The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.” } } } , “auth_ref”: { “r115”, “r116”, “r121” } } , “us_gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems”: { “xbrltype”: “stringItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails” } } , “lang”: { “en-us”: { “role”: { “label”: “Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]”, “documentation”: “Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.” } } } , “auth_ref”: { “r381” } } , “us_gaap_CommitmentsAndContingencies”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommitmentsAndContingencies”, “crdr”: “credit”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited” } } , “lang”: { “en-us”: { “role”: { “terseLabel”: “Commitments and contingencies (Note 9)”, “label”: “Commitments and Contingencies”, “documentation”: “Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or less frequently, gains, arising from (a) possible claims against a company’s resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.” } } } , “auth_ref”: { “r54”, “r08”, “r526”, “r589” } } } , “us_gaap_CommitmentsAndContingenciesDisclosureAbstract”: { “xbrltype”: “stringItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommitmentsAndContingenciesDisclosureAbstract”, “lang”: { “en-us”: { “role”: { “label”: “Commitments and Contingencies Disclosure [Abstract]” } } } , “auth_ref”: { } } , “us_gaap_CommitmentsAndContingenciesDisclosureTextBlock”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommitmentsAndContingenciesDisclosureTextBlock”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies” } } , “lang”: { “en-us”: { “role”: { “label”: “Commitments and Contingencies Disclosure [Text Block]”, “terseLabel”: “Commitments and Contingencies”, “documentation”: “The entire disclosure for commitments and contingencies.” } } } , “auth_ref”: { “r82”, “r260”, “r261”, “r653”, “r870”, “r872” } } } , “us_gaap_CommonStockCapitalSharesReservedForFutureIssuance”: { “xbrltype”: “sharesItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommonStockCapitalSharesReservedForFutureIssuance”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityScheduleOfCommonStockForPotentialConversionOutstandingPreferredStockDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails” } } , “lang”: { “en-us”: { “role”: { “terseLabel”: “Convertible preferred stock”, “label”: “Common Stock, Capital Shares Reserved for Future Issuance”, “verboseLabel”: “Common stock reserved for future issuance”, “documentation”: “Aggregate number of common shares reserved for future issuance.” } } } , “auth_ref”: { “r58” } } } , “us_gaap_CommonStockMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommonStockMember”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical” } } , “http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited” } } , “lang”: { “en-us”: { “role”: { “terseLabel”: “Common Stock”, “label”: “Common Stock”, “documentation”: “Stock that is subordinate to all other stock of the issuer.” } } } , “auth_ref”: { “r713”, “r714”, “r715”, “r717”, “r718”, “r719”, “r720”, “r839”, “r840”, “r843”, “r905”, “r969”, “r970” } } } , “glue_CommonStockOptionsMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://monterosatx.com/20240930”, “localname”: “CommonStockOptionsMember”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityScheduleOfCommonStockForPotentialConversionOutstandingPreferredStockDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/DisclosureNotLessPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails” } } , “lang”: { “en-us”: { “role”: { “terseLabel”: “Options to purchase common stock”, “label”: “Common Stock Options [Member]”, “documentation”: “Common stock options member.”, “verboseLabel”: “Stock Options to Purchase Common Stock” } } } , “auth_ref”: { } } } , “us_gaap_CommonStockParOrStatedValuePerShare”: { “xbrltype”: “perShareItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommonStockParOrStatedValuePerShare”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical” } } , “lang”: { “en-us”: { “role”: { “verboseLabel”: “Purchase price of stock”, “label”: “Common Stock, Par or Stated Value Per Share”, “terseLabel”: “Common stock, par or stated value per share”, “documentation”: “Face amount or stated value per share of common stock.” } } } , “auth_ref”: { “r58” } } } , “us_gaap_CommonStockSharesAuthorized”: { “xbrltype”: “sharesItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommonStockSharesAuthorized”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical” } } , “lang”: { “en-us”: { “role”: { “label”: “Common Stock, Shares Authorized”, “terseLabel”: “Common stock, shares authorized”, “documentation”: “The maximum number of common shares permitted to be issued by an entity’s charter and bylaws.” } } } , “auth_ref”: { “r58”, “r590” } } } , “us_gaap_CommonStockSharesIssued”: { “xbrltype”: “sharesItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommonStockSharesIssued”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical” } } , “lang”: { “en-us”: { “role”: { “verboseLabel”: “Common stock shares issued”, “label”: “Common Stock, Shares, Issued”, “totalLabel”: “Common Stock, Shares, Issued, Total”, “terseLabel”: “Common stock, shares, issued”, “documentation”: “Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm’s shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.” } } } , “auth_ref”: { “r58” } } } , “us_gaap_CommonStockSharesOutstanding”: { “xbrltype”: “sharesItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommonStockSharesOutstanding”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical” } } , “lang”: { “en-us”: { “role”: { “label”: “Common Stock, Shares, Outstanding”, “periodStartLabel”: “Common Stock, Shares, Outstanding, Beginning Balance”, “periodEndLabel”: “Common Stock, Shares, Outstanding, Ending Balance”, “terseLabel”: “Common stock, shares outstanding”, “documentation”: “Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.” } } } , “auth_ref”: { “r11”, “r58”, “r590”, “r609”, “r970”, “r971” } } } , “us_gaap_CommonStockValue”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommonStockValue”, “crdr”: “credit”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited” } } , “lang”: { “en-us”: { “role”: { “terseLabel”: “Common stock, \$0.0001 par value, 500,000,000 shares authorized, 61,378,108 shares issued and 61,377,484 shares outstanding as of September 30, 2024, and 50,154,929 shares issued and 50,140,233 shares outstanding as of December 31, 2023”, “label”: “Common Stock, Value, Issued”, “totalLabel”: “Common Stock, Value, Issued, Total”, “periodStartLabel”: “Common Stock, Value, Issued, Beginning Balance”, “periodEndLabel”: “Common Stock, Value, Issued, Ending Balance”, “documentation”: “Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders’ equity.” } } } , “auth_ref”: { “r58”, “r529”, “r700” } } } , “us_gaap_CommonStockVotingRights”: { “xbrltype”: “stringItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CommonStockVotingRights”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails” } } , “lang”: { “en-us”: { “role”: { “label”: “Common Stock, Voting Rights”, “terseLabel”: “Common stock, voting rights”, “documentation”: “Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.” } } } , “auth_ref”: { “r31” } } } , “ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://xbrl.sec.gov/ecd/2024”, “localname”: “CompActuallyPaidVsCoSelectedMeasureTextBlock”, “presentation”: { “http://xbrl.sec.gov/ecd/role/PvpDisclosure” } } , “lang”: { “en-us”: { “role”: { “label”: “Compensation Actually Paid vs. Company Selected Measure [Text Block]”, “terseLabel”: “Compensation Actually Paid vs. Company Selected Measure” } } } , “auth_ref”: { “r778” } } } , “ecd_CompActuallyPaidVsNetIncomeTextBlock”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://xbrl.sec.gov/ecd/2024”, “localname”: “CompActuallyPaidVsNetIncomeTextBlock”, “presentation”: { “http://xbrl.sec.gov/ecd/role/PvpDisclosure” } } , “lang”: { “en-us”: { “role”: { “label”: “Compensation Actually Paid vs. Net Income [Text Block]”, “terseLabel”: “Compensation Actually Paid vs. Net Income” } } } , “auth_ref”: { “r777” } } } , “ecd_CompActuallyPaidVsOtherMeasureTextBlock”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://xbrl.sec.gov/ecd/2024”, “localname”: “CompActuallyPaidVsOtherMeasureTextBlock”, “presentation”: { “http://xbrl.sec.gov/ecd/role/PvpDisclosure” } } , “lang”: { “en-us”: { “role”: { “label”: “Compensation Actually Paid vs. Other Measure” } } } , “auth_ref”: { “r779” } } } , “ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://xbrl.sec.gov/ecd/2024”, “localname”: “CompActuallyPaidVsTotalShareholderRtnTextBlock”, “presentation”: { “http://xbrl.sec.gov/ecd/role/PvpDisclosure” } } , “lang”: { “en-us”: { “role”: { “label”: “Compensation Actually Paid vs. Total Shareholder Return [Text Block]”, “terseLabel”: “Compensation Actually Paid vs. Total Shareholder Return” } } } , “auth_ref”: { “r776” } } } , “us_gaap_CompensationAndRetirementDisclosureAbstract”: { “xbrltype”: “stringItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CompensationAndRetirementDisclosureAbstract”, “lang”: { “en-us”: { “role”: { “label”: “Retirement Benefits [Abstract]” } } } , “auth_ref”: { } } } , “us_gaap_ComprehensiveIncomeNetOfTax”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “ComprehensiveIncomeNetOfTax”, “crdr”: “credit”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss” } } , “lang”: { “en-us”: { “role”: { “totalLabel”: “Comprehensive loss”, “label”: “Comprehensive Income (Loss), Net of Tax, Attributable to Parent”, “documentation”: “Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.” } } } , “auth_ref”: { “r19”, “r140”, “r142”, “r146”, “r510”, “r541”, “r542” } } } , “us_gaap_ComputerEquipmentMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “ComputerEquipmentMember”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail” } } , “lang”: { “en-us”: { “role”: { “label”: “Computer Equipment [Member]”, “terseLabel”: “Computer Hardware and Software”, “documentation”: “Long-lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.” } } } , “auth_ref”: { } } } , “us_gaap_ConstructionInProgressMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “ConstructionInProgressMember”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail” } } , “lang”: { “en-us”: { “role”: { “label”: “Construction in Progress [Member]”, “terseLabel”: “Construction in process”, “documentation”: “Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.” } } } , “auth_ref”: { } } } , “us_gaap_ConvertiblePreferredStockMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “ConvertiblePreferredStockMember”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureNotLessPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStock” } } , “lang”: { “en-us”: { “role”: { “label”: “Convertible Preferred Stock [Member]”, “terseLabel”: “Convertible Preferred Stock”, “documentation”: “Preferred stock that may be exchanged into common shares or other types of securities at the owner’s option.” } } } , “auth_ref”: { “r278”, “r279”, “r282”, “r717”, “r718”, “r719”, “r720” } } } , “us_gaap_ConvertiblePreferredStockSharesIssuedUponConversion”: { “xbrltype”: “sharesItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “ConvertiblePreferredStockSharesIssuedUponConversion”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails” } } , “lang”: { “en-us”: { “role”: { “terseLabel”: “Convertible preferred stock converted to common stock”, “label”: “Convertible Preferred Stock, Shares Issued upon Conversion”, “documentation”: “Number of shares issued for each share of convertible preferred stock that is converted.” } } } , “auth_ref”: { “r16”, “r31”, “r57”, “r86”, “r288” } } } , “us_gaap_CorporateDebtSecuritiesMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “CorporateDebtSecuritiesMember”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails” } } , “http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails” } } , “lang”: { “en-us”: { “role”: { “label”: “Corporate Debt Securities [Member]”, “terseLabel”: “Corporate Debt Securities Member”, “documentation”: “Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.” } } } , “auth_ref”: { “r681”, “r683”, “r689”, “r701”, “r712”, “r966” } } } , “dei_CoverAbstract”: { “xbrltype”: “stringItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “CoverAbstract”, “lang”: { “en-us”: { “role”: { “label”: “Cover [Abstract]”, “documentation”: “Cover page.” } } } , “auth_ref”: { } } } , “dei_CurrentFiscalYearEndDate”: { “xbrltype”: “gMonthDayItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “CurrentFiscalYearEndDate”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation” } } , “lang”: { “en-us”: { “role”: { “terseLabel”: “Current Fiscal Year End Date”, “label”: “Current Fiscal Year End Date”, “documentation”: “End date of current fiscal year in the format -MM-DD.” } } } , “auth_ref”: { } } } , “us_gaap_DebtSecuritiesAvailableForSaleRealizedLoss”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “DebtSecuritiesAvailableForSaleRealizedLoss”, “crdr”: “debit”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss” } } , “lang”: { “en-us”: { “role”: { “negatedLabel”: “Unrealized gain on available for sale securities”, “label”: “Debt Securities, Available for Sale, Realized Loss”, “terseLabel”: “Unrealized loss on available for sale securities”, “documentation”: “Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale).” } } } , “auth_ref”: { “r231” } } } , “us_gaap_DebtSecuritiesAvailableForSaleTableTextBlock”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “DebtSecuritiesAvailableForSaleTableTextBlock”, “presentation”: { “http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesTables” } } , “lang”: { “en-us”: { “role”: {

"label": "Debt Securities, Available for Sale [Table Text Block]", "terseLabel": "Summary of Marketable securities", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)" } } , "auth_ref": { "r54": "r55", "r56", "r57", "r58", "r59", "r60", "r61", "r62", "r63", "r64", "r65" } } , "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available for Sale, Unrealized Loss Position, Total", "label": "Debt Securities, Available for Sale, Unrealized Loss Position", "verboseLabel": "Debt Securities, Available for Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) in unrealized loss position without allowance for credit loss." } } } , "auth_ref": { "r109", "r242", "r675" } } , "us-gaap_DeferredRevenue": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role StatementCondensedConsolidatedBalanceSheetsUnaudited" } } , "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, net of current", "label": "Deferred Revenue", "totalLabel": "Deferred Revenue, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } } , "auth_ref": { "r827" } } , "us-gaap_DeferredRevenueCurrent": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role StatementCondensedConsolidatedBalanceSheetsUnaudited" } } , "lang": { "en-us": { "role": { "terseLabel": "Current deferred revenue", "label": "Deferred Revenue, Current", "totalLabel": "Deferred Revenue, Current, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } } , "auth_ref": { "r826" } } , "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent", "crdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role StatementCondensedConsolidatedBalanceSheetsUnaudited" } } , "lang": { "en-us": { "role": { "terseLabel": "Defined benefit plan liability", "label": "Liability, Defined Benefit Pension Plan, Noncurrent", "documentation": "Amount of liability recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan." } } } , "auth_ref": { "r35", "r36", "r53", "r90" } } , "us-gaap_DefinedBenefitPlanOtherChanges": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanOtherChanges", "crdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" } } , "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change", "terseLabel": "Defined benefit plan liability", "negatedLabel": "Defined benefit plan liability", "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other." } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlansScheduleOfDefinedContributionExpenseDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Total company contributions to 401 (k) plan", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "verboseLabel": "Defined contribution expense", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrlytype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Company matching contributions to maximum employees eligible compensation", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrlytype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlanAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Percentage of company's matching contribution with respect to each participant's contribution", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "us-gaap_Depreciation": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation expense", "totalLabel": "Depreciation expense", "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } } , "auth_ref": { "r7", "r26" } } , "gluc_DescriptionOfPreFundedWarrants": { "xbrlytype": "stringItemType", "nsuri": "http://monterosax.com/20240930", "localname": "DescriptionOfPreFundedWarrants", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "documentation": "Description of Pre Funded Warrants", "label": "Description of Pre Funded Warrants" } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role DisclosureStockBasedCompensation" } } , "lang": { "en-us": { "role": { "terseLabel": "Stock Based Compensation", "label": "Share Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement [Abstract]" } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "label": "Dividends Payable", "terseLabel": "Dividends declared", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } } , "auth_ref": { "r50", "r53", "r97", "r721", "r935" } } , "dei_DocumentFiscalPeriodFocus": { "xbrlytype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role DocumentDocumentAndEntityInformation" } } , "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-O or 10-OT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "dei_DocumentFiscalYearFocus": { "xbrlytype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role DocumentDocumentAndEntityInformation" } } , "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "dei_DocumentPeriodEndDate": { "xbrlytype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role DocumentDocumentAndEntityInformation" } } , "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDCAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDCAR submission types of Form N-1A, the filing date; for all other submission types, the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r685" } } , "dei_DocumentQuarterlyReport": { "xbrlytype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role DocumentDocumentAndEntityInformation" } } , "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } } , "auth_ref": { "r728" } } , "dei_DocumentTransitionReport": { "xbrlytype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role DocumentDocumentAndEntityInformation" } } , "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } } , "auth_ref": { "r760" } } , "dei_DocumentType": { "xbrlytype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role DocumentDocumentAndEntityInformation" } } , "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } } , "auth_ref": { "r319", "r323", "r351", "r352", "r354", "r6

"Entity Address, State or Province": "documentation": "Name of the state or province." } } }, "auth ref": [] }, "dei EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10 digit SEC issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth ref": ["r726"] }, "dei EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock Shares Outstanding", "label": "Entity Common Stock Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth ref": [] }, "dei EntityCurrentReportingStatus": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth ref": [] }, "dei EntityEmergingGrowthCompany": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth ref": ["r726"] }, "dei EntityExTransitionPeriod": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth ref": ["r811"] }, "dei EntityFileNumber": { "xbrltype": "fileNumberItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth ref": [] }, "dei EntityFilerCategory": { "xbrltype": "filerCategoryItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth ref": ["r726"] }, "dei EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation State Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two character EDGAR code representing the state or country of incorporation." } } }, "auth ref": [] }, "dei EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth ref": ["r810"] }, "dei EntityRegistrantName": { "xbrltype": "normalizedStringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth ref": ["r726"] }, "dei EntityShellCompany": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth ref": ["r726"] }, "dei EntitySmallBusiness": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth ref": ["r726"] }, "dei EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9 digit value assigned by the IRS." } } }, "auth ref": ["r726"] }, "ecd EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments Footnote", "documentation": "Equity Awards Adjustments Footnote [Text Block]" } } }, "auth ref": ["r765"] }, "ecd EqtyAwrdsAdjExclValRptdInSummryCompstnTblMember": { "xbrltype": "domainItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclValRptdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth ref": ["r806"] }, "ecd EqtyAwrdsAdjisMember": { "xbrltype": "domainItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjisMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments", "documentation": "Equity Awards Adjustments [Member]" } } }, "auth ref": ["r806"] }, "ecd EqtyAwrdsInSummryCompstnTblForAplblyrMember": { "xbrltype": "domainItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblyrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "documentation": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth ref": ["r806"] }, "us-gaap EquityAbstract": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth ref": [] }, "us-gaap EquityComponentDomain": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails"] }, "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentetical", "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" } } }, "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth ref": ["r11", "r124", "r143", "r144", "r145", "r155", "r156", "r157", "r159", "r164", "r165", "r167", "r184", "r233", "r234", "r256", "r295", "r367", "r368", "r374", "r375", "r376", "r378", "r379", "r380", "r389", "r390", "r391", "r392", "r393", "r394", "r397", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r432", "r447", "r539", "r548", "r549", "r550", "r565", "r631"] }, "ecd EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference Footnote", "documentation": "Equity Valuation Assumption Difference Footnote" } } }, "auth ref": ["r775"] }, "ecd ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis", "documentation": "Erroneous Compensation Analysis" } } }, "auth ref": ["r723", "r743", "r753", "r785"] }, "ecd ErrCompRecoveryTable": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery", "documentation": "Erroneously Awarded Compensation Recovery" } } }, "auth ref": ["r730", "r740", "r750", "r782"] }, "ecd ExecutiveCategoryAxis": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category", "documentation": "Executive Category [Axis]" } } }, "auth ref": ["r781"] }, "glue ExpectedRemainingCostWeightedAveragePeriodUnits": { "xbrltype": "durationItemtype", "nsuri": "http://monterosatx.com/20240930", "localname": "ExpectedRemainingCostWeightedAveragePeriodUnits", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Expected remaining cost, weighted average period, units", "documentation": "Expected remaining cost, weighted average period, units" } } }, "auth ref": [] }, "us-gaap FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth ref": ["r405", "r406", "r407", "r408", "r409", "r410", "r413", "r690"] }, "us-gaap FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"] }, "http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails" } } }, "en-us": { "role": { "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": [] }, "us-gaap FairValueByAssetClassAxis": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth ref": ["r405", "r406", "r407", "r408", "r409", "r410", "r413", "r690"] }, "us-gaap FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails"] }, "http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails" } } }, "en-us": { "role": { "terseLabel": "Fair Value By Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth ref": ["r45", "r46"] }, "us-gaap FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth ref": ["r275", "r301", "r302", "r303", "r304", "r305", "r306", "r309", "r401", "r402", "r403", "r404", "r411", "r412", "r414", "r456", "r457", "r458", "r677", "r678", "r681", "r682", "r683", "r689", "r692"] }, "us-gaap FairValueDisclosuresAbstract": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth ref": [] }, "us-gaap FairValueInputsLevel1Member": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth ref": ["r275", "r301", "r306", "r401", "r412", "r456", "r681", "r682", "r683", "r689"] }, "us-gaap FairValueInputsLevel2Member": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth ref": ["r275", "r301", "r306", "r401", "r402", "r412", "r457", "r677", "r678", "r681", "r682", "r683", "r689"] }, "us-gaap FairValueInputsLevel3Member": { "xbrltype": "domainItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth ref": ["r275", "r301", "r302", "r303", "r304", "r305", "r306", "r401", "r402", "r403", "r404", "r412", "r458", "r677", "r678", "r681", "r682", "r683", "r689", "r692"] }, "us-gaap FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": ["http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements"] }, "lang": { "en-us": { "role": { "terseLabel": "Fair value measurements", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or

nonrecursing basis." } } } , "auth ref": { "r94" } } , "us-gaap-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "credit": "debit", "presentation": { "http://monterotsatx.com/20240930/taxonomy/role/Role-DisclosureFairValueMeasurementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "totalLabel": "Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total", "terseLabel": "Measure at fair value, transfers among Level 1, Level 2 or Level 3", "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy." } } } , "auth ref": { "r912", "r914" } } , "us-gaap-FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://monterotsatx.com/20240930/taxonomy/role/Role-DisclosureFairValueMeasurementsSummaryOfFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV (Domain)", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } } , "auth ref": { "r275", "r301", "r302", "r303", "r304", "r305", "r306", "r390", "r401", "r402", "r403", "r404", "r411", "r412", "r414", "r456", "r457", "r458", "r677", "r678", "r681", "r682", "r683", "r689", "r692" } } } , "us-gaap-FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": { "http://monterotsatx.com/20240930/taxonomy/role/Role-DisclosureFairValueMeasurementsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis on Unobservable Inputs", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation (Table Text Block)", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } } , "auth ref": { "r405", "r410", "r413" } } } , "glue-FairValueOfPreferredStockTrancheObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://monterotsatx.com/20240930", "localname": "FairValueOfPreferredStockTrancheObligation", "credit": "debit", "presentation": { "http://monterotsatx.com/20240930/taxonomy/role/Role-DisclosureConvertiblePreferredStockAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Fair Value of Preferred Stock Tranche Obligation", "label": "Fair Value of Preferred Stock Tranche Obligation", "terseLabel": "Fair value of preferred stock tranche obligation." } } } , "auth ref": { } } } , "us-gaap-FeaturesOfConvertiblePreferredStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FeaturesOfConvertiblePreferredStockAbstract", "lang": { "en-us": { "role": { "label": "Features of Convertible Preferred Stock (Abstract)" } } } , "auth ref": { } } , "us-gaap-FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "credit": "debit", "presentation": { "http://monterotsatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Finance Lease, Liability", "totalLabel": "Finance Lease", "terseLabel": "Finance Lease", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } } , "auth ref": { "r434", "r443" } } } , "us-gaap-FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://monterotsatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Financial Instrument (Axis)", "documentation": "Information by type of financial instrument." } } } , "auth ref": { "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r6

loss per share-diluted", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "totalLabel": "Net loss per share attributable to common stockholders-diluted", "terseLabel": "Net loss per share attributable to common stockholders-diluted", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth ref": { "r67", "r147", "r158", "r160", "r161", "r162", "r163", "r164", "r172", "r175", "r176", "r177", "r390", "r398", "r399", "r520", "r939" } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth ref": { "r11", "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesSummarizesLeaseExpenseDetails", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetails", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails", "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth ref": { "r257", "r258", "r259", "r406", "r410", "r413", "r545", "r547", "r615", "r665", "r691", "r940" } } }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesSummarizesLeaseExpenseDetails", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetails", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails", "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth ref": { "r258", "r259", "r406", "r410", "r413", "r545", "r547", "r615", "r665", "r691", "r940" } } }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth ref": { "r11", "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureIncomeTaxes", "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth ref": { "r154", "r359", "r361", "r362", "r363", "r364", "r365", "r366", "r369", "r371", "r372", "r373", "r563", "r696" } } }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "erdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetails", "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "lang": { "en-us": { "role": { "negatedLabel": "Provision for income taxes", "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit) Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth ref": { "r113", "r120", "r166", "r167", "r181", "r190", "r193", "r360", "r361", "r370", "r543", "r686" } } }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "erdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth ref": { "r6", "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "erdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth ref": { "r6", "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "erdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses and obligations classified as other." } } }, "auth ref": { "r834", "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "erdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth ref": { "r666", "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth ref": { "r11", "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "erdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets and operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "verboseLabel": "Decrease in operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth ref": { "r815", "r834", "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherReceivables", "erdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "negatedLabel": "Other receivables", "terseLabel": "Other receivables", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth ref": { "r6", "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "erdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "documentation": "Amount of increase (decrease) in prepaid expenses and assets classified as other." } } }, "auth ref": { "r6", "glue_IncreaseInAnnualBaseRentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "IncreaseInAnnualBaseRentPercentage", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Increase in annual base rent (Percentage)", "label": "Increase in annual base rent (Percentage)", "terseLabel": "Increase in annual base rent (Percentage)" } } }, "auth ref": { "r11", "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual" } } }, "auth ref": { "r737", "r747", "r757", "r781", "r789", "r793", "r801", "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements", "documentation": "Insider Trading Policies and Procedures [Line Items]", "auth ref": { "r729", "r805", "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures", "documentation": "Insider Trading Policies and Procedures [Line Items]", "auth ref": { "r729", "r805", "ecd_InsiderTradingPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted", "documentation": "Insider Trading Policies and Procedures Adopted", "auth ref": { "r729", "r805", "ecd_InsiderTradingPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "documentation": "Insider Trading Policies and Procedures Not Adopted", "auth ref": { "r729", "r805", "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "erdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "lang": { "en-us": { "role": { "label": "Interest Income (Expense) Nonoperating", "terseLabel": "Interest income", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth ref": { "r672", "r832", "r847", "us-gaap_InterestIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeMember", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Interest Income [Member]", "documentation": "Primary financial statement caption in which reported facts about interest income have been included." } } }, "auth ref": { "r11", "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "documentation": "Investments in Debt and Marketable Equity Securities and Certain Trading Assets Disclosure Text Block", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecurities", "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth ref": { "r104", "r123", "r199", "r200", "r416", "r417", "r932", "glue_IssuanceOfCommonStockNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "IssuanceOfCommonStockNetOfIssuanceCosts", "erdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Aggregate net proceeds", "label": "Issuance of common stock, net of issuance costs", "documentation": "Issuance of common stock, net of issuance costs", "auth ref": { "r11", "glue_IssuanceOfCommonStockNetOfIssuanceCostsOf984": { "xbrltype": "monetaryItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "IssuanceOfCommonStockNetOfIssuanceCostsOf984", "erdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentetical", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock, net of issuance costs of \$984", "label": "Issuance of common stock, net of issuance costs of \$714", "terseLabel": "Issuance of common stock, net of issuance costs of \$714", "auth ref": { "r11", "us-gaap_IssuanceOfCommonStockNetOfIssuanceCostsShares": { "xbrltype": "perShareItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "IssuanceOfCommonStockNetOfIssuanceCostsShares", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Common stock shares issued", "label": "Issuance of common stock, net of issuance costs Shares", "documentation": "Issuance of common stock, net of issuance costs Shares", "auth ref": { "r11", "glue_IssuanceOfCommonStockPursuantToTheAtTheMarketSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "IssuanceOfCommonStockPursuantToTheAtTheMarketSalesAgreement", "erdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited", "lang": { "en-us": { "role": { "documentation": "Issuance of Common Stock Pursuant to the At-the-Market Sales Agreement", "label": "Issuance of Common Stock Pursuant to the At-the-Market Sales Agreement", "terseLabel": "Issuance of common stock pursuant to the at-the-market sales agreement", "documentation": "Issuance of common stock pursuant to the at-the-market sales agreement", "auth ref": { "r11", "glue_IssuanceOfCommonStockPursuantToTheAtTheMarketSalesAgreementShares": { "xbrltype": "shareItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "IssuanceOfCommonStockPursuantToTheAtTheMarketSalesAgreementShares", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited", "lang": { "en-us": { "role": { "documentation": "Issuance of Common Stock Pursuant to the At-the-Market Sales Agreement, Shares", "label": "Issuance of Common Stock Pursuant to the At-the-Market Sales Agreement, Shares", "terseLabel": "Issuance of common stock pursuant to the at-the-market sales agreement, Shares", "documentation": "Issuance of common stock pursuant to the at-the-market sales agreement, Shares", "auth ref": { "r11", "glue_IssuanceOfPreFundedWarrantNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "IssuanceOfPreFundedWarrantNetOfIssuanceCosts", "erdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited", "lang": { "en-us": { "role": { "documentation": "Issuance of pre-funded warrant, net of issuance costs", "label": "Issuance of pre-funded warrant, net of issuance costs", "terseLabel": "Issuance of pre-funded warrant, net of issuance costs of \$290", "documentation": "Issued Pre-Funded Warrants", "xbrltype": "shareItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "IssuedPreFundedWarrants", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Issued Pre-Funded Warrants", "label": "Issued Pre-Funded Warrants", "terseLabel": "Purchase of pre-funded warrants shares", "documentation": "Issued Pre-Funded Warrants", "auth ref": { "r11", "glue_JefferiesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "JefferiesLlcMember", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Jefferies LLC [Member]", "label": "Jefferies LLC [Member]", "auth ref": { "r11", "glue_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail", "lang": { "en-us": { "role": { "terseLabel": "Laboratory Equipment", "label": "Laboratory Equipment [Member]", "documentation": "Laboratory equipment [Member]", "auth ref": { "r11", "us-gaap_LandSubjectToGroundLeases": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandSubjectToGroundLeases", "presentation": {

```

http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" }, { "lang": { "en-us": { "role": { "label": "Land Subject to Ground Leases", "terseLabel": "Land Subject to Ground Leases", "documentation": "Area of land subject to a ground lease." } } }, { "auth ref": { "r918" } }, { "glue LeaseCommencementDate": { "xbrltype": "dateItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "LeaseCommencementDate", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" }, { "lang": { "en-us": { "role": { "documentation": "Lease Commencement Date", "label": "Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, { "auth ref": { "r919" } }, { "us-gaap LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crd": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" }, { "lang": { "en-us": { "role": { "label": "Lease Cost", "totalLabel": "Total Lease expense", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, { "auth ref": { "r436", "r699" } }, { "us-gaap LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesTables" }, { "lang": { "en-us": { "role": { "terseLabel": "Component of Lease Expense", "label": "Lease Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, { "auth ref": { "r920" } }, { "us-gaap LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail" }, { "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, { "auth ref": { "r81", "r444" } }, { "us-gaap LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, { "auth ref": { "r921" } }, { "us-gaap LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" }, { "lang": { "en-us": { "role": { "label": "Lessee Lease Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, { "auth ref": { "r435", "r445" } }, { "us-gaap LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" }, { "lang": { "en-us": { "role": { "label": "Lessee Lease Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, { "auth ref": { "r435", "r445" } } }, { "us-gaap LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesTables" }, { "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Payments Under Non-cancelable Operating Leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, { "auth ref": { "r921" } }, { "us-gaap LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crd": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" }, { "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability, to be Paid", "totalLabel": "Total undiscounted minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, { "auth ref": { "r443" } } }, { "us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crd": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee Operating Lease Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, { "auth ref": { "r443" } } }, { "glue LesseeOperatingLeaseLiabilityPaymentsDueThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueThereafter", "crd": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" }, { "lang": { "en-us": { "role": { "documentation": "Lessee Operating Lease Liability Payments Due Thereafter", "label": "Lessee Operating Lease Liability Payments Due Thereafter", "terseLabel": "Thereafter" } } }, { "auth ref": { "r922" } }, { "us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crd": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee Operating Lease Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, { "auth ref": { "r443" } } }, { "us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crd": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee Operating Lease Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, { "auth ref": { "r443" } } }, { "us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crd": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee Operating Lease Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, { "auth ref": { "r443" } } }, { "us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crd": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee Operating Lease Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, { "auth ref": { "r443" } } }, { "us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crd": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" }, { "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee Operating Lease Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, { "auth ref": { "r921" } } }, { "us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crd": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" }, { "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, { "auth ref": { "r443" } } }, { "us-gaap LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" }, { "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMdThnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, { "auth ref": { "r919" } } }, { "us-gaap LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" }, { "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Term of Contract", "terseLabel": "Initial lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMdThnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, { "auth ref": { "r919" } } }, { "us-gaap LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeases" }, { "lang": { "en-us": { "role": { "label": "Lessee Operating Leases [Text Block]", "verboseLabel": "Leases", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, { "auth ref": { "r431" } } }, { "us-gaap Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crd":
```

["http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"](http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails),
"http://monterosatx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Milestone Payments",
"label": "Milestone Payments", "documentation": "Milestone Payments Maximum" } } }, "auth_ref": [] }, "glue_MilestonePaymentsMaximum": { "xbrltype": "monetaryItemType", "nsuri":
"http://monterosatx.com/20240930", "localname": "MilestonePaymentsMaximum" }, "credit": "presentation" }, {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Milestone Payments,
Maximum", "label": "Milestone Payments Maximum", "documentation": "Milestone payments Maximum" } } }, "auth_ref": [], "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://monterosatx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel":
"Minimum [Member]" } } }, "auth_ref": { "r262", "r263", "r264", "r265", "r317", "r356", "r404", "r484", "r544", "r546", "r554", "r580", "r581", "r637", "r639", "r641", "r642", "r644", "r663",
"r664", "r674", "r679", "r684", "r692", "r693", "r697", "r710", "r875", "r925", "r926", "r927", "r928", "r929", "r930" } }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": }, "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": {
"label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": { "r792" } }, "us-
gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOffFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails" }, "lang": { "en-us": { "role":
"label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money market instruments, for example, but not
limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities" } } }, "auth_ref": { "r877" } },
"ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": }, {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of
Trading Arrangement" } } }, "auth_ref": { "r800" } }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NamedExecutiveOfficersFnTextBlock", "presentation": }, { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]",
"terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": { "r774" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by
financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued
operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying
amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit" } } }, "auth_ref": { "r149" } }, "us-
gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing
activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used
in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued
operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive
assets" } } }, "auth_ref": { "r149" } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing
activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating
activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations.
Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities" } } }, "auth_ref": { "r74", "r75", "r76" } }, "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating
activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidityAdditionalInformationDetails",
"http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
"http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net income loss", "totalLabel": "Net
loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent" } } }, "auth_ref": { "r68", "r76", "r103", "r125", "r139", "r141",
"r145", "r153", "r158", "r160", "r161", "r162", "r163", "r164", "r166", "r167", "r174", "r232", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r377", "r380", "r398", "r418",
"r538", "r611", "r620", "r630", "r722", "r873" } }, "glue_NetOfUnderwritingDiscountOnIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri":
"http://monterosatx.com/20240930", "localname": "NetOfUnderwritingDiscountOnIssuanceOfCommonStock", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParental": "lang": { "en-us": { "role": { "documentation": "Net of
underwriting Discount on issuance of common stock", "label": "Net of underwriting Discount on issuance of common stock", "terseLabel": "Underwriter's discount on issuance of common stock
pursuant to the at the market sales agreement" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy
[Policy Text Block]", "terseLabel": "Recently issued accounting pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may
impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact" } } }, "auth_ref": [] }, "glue_NonCancelLeasesMember": { "xbrltype":
"domainItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "NonCancelLeasesMember", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelLeaseOperatingLeasesDetails" }, "lang": { "en-us": { "role": {
"documentation": "Non-cancelable leases [Member]", "label": "Non-cancelable leases [Member]", "terseLabel": "Non-cancelable leases [Member]" } } }, "auth_ref": [] },
"ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": }, {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } },
"auth_ref": { "r773" } }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": }, {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": { "r737", "r747", "r757", "r781",
"r789" } }, "ecd_NonPeeNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoAvgCompActuallyPaidAmt",
"presentation": }, { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO-NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO-NEO
Average Compensation Actually Paid Amount" } } }, "auth_ref": { "r764" } }, "ecd_NonPeeNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonPeeNeoAvgTotalCompAmt", "presentation": }, { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO-NEO Average Total Compensation
Amount", "terseLabel": "Non-PEO-NEO Average Total Compensation Amount" } } }, "auth_ref": { "r763" } }, "ecd_NonPeeNeoMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoMember", "presentation": }, { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO-NEO
[Member]", "terseLabel": "Non-PEO-NEO" } } }, "auth_ref": { "r781" } }, "glue_NonRefundableUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://monterosatx.com/20240930",
"localname": "NonRefundableUpfrontPayment", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Non-Refundable
Upfront Payment", "label": "Non-Refundable Upfront Payment", "documentation": "Non-Refundable Upfront Payment" } } }, "auth_ref": [] }, "glue_NonRule10b51ArrModifiedFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "NonRule10b51ArrModifiedFlag", "presentation": }, { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" },
"lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Modified", "label": "Non-Rule 10b5-1 Arrangement Modified", "documentation": "Non-Rule 10b5-1 Arrangement Modified Flag" } } },
"auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": }, {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement
Adopted" } } }, "auth_ref": { "r800" } }, "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonRule10b51ArrTrmtdFlag", "presentation": }, { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated
[Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r800" } }, "glue_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://monterosatx.com/20240930", "localname": "NoncashLeaseExpense", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Noncash lease expense", "label": "Noncash
Lease Expense", "terseLabel": "Noncash lease expense" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NonoperatingIncomeExpense", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "label": "Nonoperating
Income [Expense]", "totalLabel": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major
activities considered part of the normal operations of the business)" } } }, "auth_ref": { "r70" } }, "glue_NumberOfMarketableSecuritiesHeld": { "xbrltype": "integerItemType", "nsuri":
"http://monterosatx.com/20240930", "localname": "NumberOfMarketableSecuritiesHeld", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Number of marketable
securities held", "label": "Number of marketable securities held", "terseLabel": "Number of marketable securities held" } } }, "auth_ref": [] }, "glue_OneTimeUpfrontPayment": { "xbrltype":
"monetaryItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "OneTimeUpfrontPayment", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "One Time Upfront
Payment", "label": "One Time Upfront Payment", "documentation": "One Time Upfront Payment" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "totalLabel": "Total
operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly
related to production and included in cost of sales or services. Includes selling, general and administrative expense" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "terseLabel":
"Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingIncomeLoss", "credit": "debit", "presentation": }, {
"http://monterosatx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "terseLabel": "Loss
from operations", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating
revenues" } } }, "auth_ref": { "r107", "r671", "r846", "r847", "r848", "r849", "r850" } }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingLeaseCost", "credit": "debit", "presentation": }, { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" },
"lang": { "en-us": { "role": { "label": "Operating Lease Cost", "terseLabel": "Operating lease expense", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost
of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and
accretion of lease liability" } } }, "auth_ref": { "r437", "r699" } }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseExpense", "credit": "debit", "presentation": }, { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesSummarizesLeaseExpenseDetails" }, "lang": { "en-us": { "role": {
"totalLabel": "Total Lease expense", "label": "Operating Lease Expense", "documentation": "Amount of operating lease expense. Excludes sublease income" } } }, "auth_ref": { "r917" } }, "us-
gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncomeTableTextBlock",

"presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Summarizes Lease Expense", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": { "r183": "r446" } }, "us-gaap-OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails": { "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liability", "terseLabel": "Operating lease liability", "verboseLabel": "Total operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r434" } }, "us-gaap-OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r434" } }, "us-gaap-OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r434" } }, "us-gaap-OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "label": "Operating Lease, Right of Use Asset", "terseLabel": "Operating lease right of use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r433" } }, "us-gaap-OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermsAndDiscountRateDetails": { "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r442": "r699" } }, "us-gaap-OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermsAndDiscountRateDetails": { "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PaYnMnDThInMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r441": "r699" } }, "us-gaap-OperatingLeasesFutureMinimumPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsDue", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesUnderNoncancelableDetails": { "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Total future minimum lease payments", "totalLabel": "Total future minimum lease payments", "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter terms in excess of one year." } } }, "auth_ref": { "r110": "r112" } }, "us-gaap-OperatingLeasesFutureMinimumPaymentsDueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesUnderNoncancelableDetails": { "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months", "terseLabel": "2023", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": { "r110": "r112" } }, "us-gaap-OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesUnderNoncancelableDetails": { "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2026", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": { "r110": "r112" } }, "us-gaap-OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesUnderNoncancelableDetails": { "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2025", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": { "r110": "r112" } }, "us-gaap-OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesUnderNoncancelableDetails": { "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2024", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": { "r110": "r112" } }, "us-gaap-OperatingLeasesFutureMinimumPaymentsDueThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesUnderNoncancelableDetails": { "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": { "r110": "r112" } }, "us-gaap-OperatingLeasesFutureMinimumPaymentsRemainderOffiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOffiscalYear", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesUnderNoncancelableDetails": { "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year", "terseLabel": "2022", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": { "r110": "r112" } }, "us-gaap-OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "auth_ref": { "r110": "r112" } }, "us-gaap-OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidity": { "lang": { "en-us": { "role": { "terseLabel": "Description of business and liquidity", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": { "r47": "r93": "r555": "r556" } }, "us-gaap-OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": { "r131" } }, "us-gaap-OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Provision for pension benefit obligation", "label": "Other Comprehensive Income (Expense) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "totalLabel": "Other Comprehensive Income (Expense) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax, Total", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": { "r2": "r3": "r64": "r65": "r539" } }, "us-gaap-OtherComprehensiveIncomeLossTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxAbstract", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Tax [Abstract]", "terseLabel": "Comprehensive loss", "auth_ref": { "r131": "r539": "r673": "r937" } }, "us-gaap-OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r50": "r700" } }, "us-gaap-OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "auth_ref": { "r131": "r539": "r673": "r937" } }, "us-gaap-OtherOwnershipInterestsOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOwnershipInterestsOfferingCosts", "crdr": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Other Ownership Interests, Offering Costs", "terseLabel": "Offering Costs", "documentation": "The cumulative amount of offering costs allocated to the other unit holders." } } }, "auth_ref": { "r89": "r110": "r111": "r112": "r113": "r114": "r115": "r116": "r117": "r118": "r119": "r120": "r121": "r122": "r123": "r124": "r125": "r126": "r127": "r128": "r129": "r130": "r131": "r132": "r133": "r134": "r135": "r136": "r137": "r138": "r139": "r140": "r141": "r142": "r143": "r144": "r145": "r146": "r147": "r148": "r149": "r150": "r151": "r152": "r153": "r154": "r155": "r156": "r157": "r158": "r159": "r160": "r161": "r162": "r163": "r164": "r165": "r166": "r167": "r168": "r169": "r170": "r171": "r172": "r173": "r174": "r175": "r176": "r177": "r178": "r179": "r180": "r181": "r182": "r183": "r184": "r185": "r186": "r187": "r188": "r189": "r190": "r191": "r192": "r193": "r194": "r195": "r196": "r197": "r198": "r199": "r200": "r201": "r202": "r203": "r204": "r205": "r206": "r207": "r208": "r209": "r210": "r211": "r212": "r213": "r214": "r215": "r216": "r217": "r218": "r219": "r220": "r221": "r222": "r223": "r224": "r225": "r226": "r227": "r228": "r229": "r230": "r231": "r232": "r233": "r234": "r235": "r236": "r237": "r238": "r239": "r240": "r241": "r242": "r243": "r244": "r245": "r246": "r247": "r248": "r249": "r250": "r251": "r252": "r253": "r254": "r255": "r256": "r257": "r258": "r259": "r260": "r261": "r262": "r263": "r264": "r265": "r266": "r267": "r268": "r269": "r270": "r271": "r272": "r273": "r274": "r275": "r276": "r277": "r278": "r279": "r280": "r281": "r282": "r283": "r284": "r285": "r286": "r287": "r288": "r289": "r290": "r291": "r292": "r293": "r294": "r295": "r296": "r297": "r298": "r299": "r300": "r301": "r302": "r303": "r304": "r305": "r306": "r307": "r308": "r309": "r310": "r311": "r312": "r313": "r314": "r315": "r316": "r317": "r318": "r319": "r320": "r321": "r322": "r323": "r324": "r325": "r326": "r327": "r328": "r329": "r330": "r331": "r332": "r333": "r334": "r335": "r336": "r337": "r338": "r339": "r340": "r341": "r342": "r343": "r344": "r345": "r346": "r347": "r348": "r349": "r350": "r351": "r352": "r353": "r354": "r355": "r356": "r357": "r358": "r359": "r360": "r361": "r362": "r363": "r364": "r365": "r366": "r367": "r368": "r369": "r370": "r371": "r372": "r373": "r374": "r375": "r376": "r377": "r378": "r379": "r380": "r381": "r382": "r383": "r384": "r385": "r386": "r387": "r388": "r389": "r390": "r391": "r392": "r393": "r394": "r395": "r396": "r397": "r398": "r399": "r400": "r401": "r402": "r403": "r404": "r405": "r406": "r407": "r408": "r409": "r410": "r411": "r412": "r413": "r414": "r415": "r416": "r417": "r418": "r419": "r420": "r421": "r422": "r423": "r424": "r425": "r426": "r427": "r428": "r429": "r430": "r431": "r432": "r433": "r434": "r435": "r436": "r437": "r438": "r439": "r440": "r441": "r442": "r443": "r444": "r445": "r446": "r447": "r448": "r449": "r450": "r451": "r452": "r453": "r454": "r455": "r456": "r457": "r458": "r459": "r460": "r461": "r462": "r463": "r464": "r465": "r466": "r467": "r468": "r469": "r470": "r471": "r472": "r473": "r474": "r475": "r476": "r477": "r478": "r479": "r480": "r481": "r482": "r483": "r484": "r485": "r486": "r487": "r488": "r489": "r490": "r491": "r492": "r493": "r494": "r495": "r496": "r497": "r498": "r499": "r500": "r501": "r502": "r503": "r504": "r505": "r506": "r507": "r508": "r509": "r510": "r511": "r512": "r513": "r514": "r515": "r516": "r517": "r518": "r519": "r520": "r521": "r522": "r523": "r524": "r525": "r526": "r527": "r528": "r529": "r530": "r531": "r532": "r533": "r534": "r535": "r536": "r537": "r538": "r539": "r540": "r541": "r542": "r543": "r544": "r545": "r546": "r547": "r548": "r549": "r550": "r551": "r552": "r553": "r554": "r555": "r556": "r557": "r558": "r559": "r560": "r561": "r562": "r563": "r564": "r565": "r566": "r567": "r568": "r569": "r570": "r571": "r572": "r573": "r574": "r575": "r576": "r577": "r578": "r579": "r580": "r581": "r582": "r583": "r584": "r585": "r586": "r587": "r588": "r589": "r590": "r591": "r592": "r593": "r594": "r595": "r596": "r597": "r598": "r599": "r600": "r601": "r602": "r603": "r604": "r605": "r606": "r607": "r608": "r609": "r610": "r611": "r612": "r613": "r614": "r615": "r616": "r617": "r618": "r619": "r620": "r621": "r622": "r623": "r624": "r625": "r626": "r627": "r628": "r629": "r630": "r631": "r632": "r633": "r634": "r635": "r636": "r637": "r638": "r639": "r640": "r641": "r642": "r643": "r644": "r645": "r646": "r647": "r648": "r649": "r650": "r651": "r652": "r653": "r654": "r655": "r656": "r657": "r658": "r659": "r660": "r661": "r662": "r663": "r664": "r665": "r666": "r667": "r668": "r669": "r670": "r671": "r672": "r673": "r674": "r675": "r676": "r677": "r678": "r679": "r680": "r681": "r682": "r683": "r684": "r685": "r686": "r687": "r688": "r689": "r690": "r691": "r692": "r693": "r694": "r695": "r696": "r697": "r698": "r699": "r700": "r701": "r702": "r703": "r704": "r705": "r706": "r707": "r708": "r709": "r710": "r711": "r712": "r713": "r714": "r715": "r716": "r717": "r718": "r719": "r720": "r721": "r722": "r723": "r724": "r725": "r726": "r727": "r728": "r729": "r730": "r731": "r732": "r733": "r734": "r735": "r736": "r737": "r738": "r739": "r740": "r741": "r742": "r743": "r744": "r745": "r746": "r747": "r748": "r749": "r750": "r751": "r752": "r753": "r754": "r755": "r756": "r757": "r758": "r759": "r760": "r761": "r762": "r763": "r764": "r765": "r766": "r767": "r768": "r769": "r770": "r771": "r772": "r773": "r774": "r775": "r776": "r777": "r778": "r779": "r780": "r781": "r782": "r783": "r784": "r785": "r786": "r787": "r788": "r789": "r790": "r791": "r792": "r793": "r794": "r795": "r796": "r797": "r798": "r799": "r800": "r801": "r802": "r803": "r804": "r805": "r806": "r807": "r808": "r809": "r810": "r811": "r812": "r813": "r814": "r815": "r816": "r817": "r818": "r819": "r820": "r821": "r822": "r823": "r824": "r825": "r826": "r827": "r828": "r829": "r830": "r831": "r832": "r833": "r834": "r835": "r836": "r837": "r838": "r839": "r840": "r841": "r842": "r843": "r844": "r845": "r846": "r847": "r848": "r849": "r850": "r851": "r852": "r853": "r854": "r855": "r856": "r857": "r858": "r859": "r860": "r861": "r862": "r863": "r864": "r865": "r866": "r867": "r868": "r869": "r870": "r871": "r872": "r873": "r874": "r875": "r876": "r877": "r878": "r879": "r880": "r881": "r882": "r883": "r884": "r885": "r886": "r887": "r888": "r889": "r890": "r891": "r892": "r893": "r894": "r895": "r896": "r897": "r898": "r899": "r900": "r901": "r902": "r903": "r904": "r905": "r906": "r907": "r908": "r909": "r910": "r911": "r912": "r913": "r914": "r915": "r916": "r917": "r918": "r919": "r920": "r921": "r922": "r923": "r924": "r925": "r926": "r927": "r928": "r929": "r930": "r931": "r932": "r933": "r934": "r935": "r936": "r937": "r938": "r939": "r940": "r941": "r942": "r943": "r944": "r945": "r946": "r947": "r948": "r949": "r950": "r951": "r952": "r953": "r954": "r955": "r956": "r957": "r958": "r959": "r960": "r961": "r962": "r963": "r964": "r965": "r966": "r967": "r968": "r969": "r970": "r971": "r972": "r973": "r974": "r975": "r976": "r977": "r978": "r979": "r980": "r981": "r982": "r983": "r984": "r985": "r986": "r987": "r988": "r989": "r990": "r991": "r992": "r993": "r994": "r995": "r996": "r997": "r998": "r999": "r1000": "r1001": "r1002": "r1003": "r1004": "r1005": "r1006": "r1007": "r1008": "r1009": "r1010": "r1011": "r1012": "r1013": "r1014": "r1015": "r1016": "r1017": "r1018": "r1019": "r1020": "r1021": "r1022": "r1023": "r1024": "r1025": "r1026": "r1027": "r1028": "r1029": "r1030": "r1031": "r1032": "r1033": "r1034": "r1035": "r1036": "r1037": "r1038": "r1039": "r1040": "r1041": "r1042": "r1043": "r1044": "r1045": "r1046": "r1047": "r1048": "r1049": "r1050": "r1051": "r1052": "r1053": "r1054": "r1055": "r1056": "r1057": "r1058": "r1059": "r1060": "r1061": "r1062": "r1063": "r1064": "r1065": "r1066": "r1067": "r1068": "r1069": "r1070": "r1071": "r1072": "r1073": "r1074": "r1075": "r1076": "r1077": "r1078": "r1079": "r1080": "r1081": "r1082": "r1083": "r1084": "r1085": "r1086": "r1087": "r1088": "r1089": "r1090": "r1091": "r1092": "r1093": "r1094": "r1095": "r1096": "r1097": "r1098": "r1099": "r1100": "r1101": "r1102": "r1103": "r1104": "r1105": "r1106": "r1107": "r1108": "r1109": "r1110": "r1111": "r1112": "r1113": "r1114": "r1115": "r1116": "r1117": "r1118": "r1119": "r1120": "r1121": "r1122": "r1123": "r1124": "r1125": "r1126": "r1127": "r1128": "r1129": "r1130": "r1131": "r1132": "r1133": "r1134": "r1135": "r1136": "r1137": "r1138": "r1139": "r1140": "r1141": "r1142": "r1143": "r1144": "r1145": "r1146": "r1147": "r1148": "r1149": "r1150": "r1151": "r1152": "r1153": "r1154": "r1155": "r1156": "r1157": "r1158": "r1159": "r1160": "r1161": "r1162": "r1163": "r1164": "r1165": "r1166": "r1167": "r1168": "r1169": "r1170": "r1171": "r1172": "r1173": "r1174": "r1175": "r1176": "r1177": "r1178": "r1179": "r1180": "r1181": "r1182": "r1183": "r1184": "r1185": "r1186": "r1187": "r1188": "r1189": "r1190": "r1191": "r1192": "r1193": "r1194": "r1195": "r1196": "r1197": "r1198": "r1199": "r1200": "r1201": "r1202": "r1203": "r1204": "r1205": "r1206": "r1207": "r1208": "r1209": "r1210": "r1211": "r1212": "r1213": "r1214": "r1215": "r1216": "r1217": "r1218": "r1219": "r1220": "r1221": "r1222": "r1223": "r1224": "r1225": "r1226": "r1227": "r1228": "r1229": "r1230": "r1231": "r1232": "r1233": "r1234": "r1235": "r1236": "r1237": "r1238": "r1239": "r1240": "r1241": "r1242": "r1243": "r1244": "r1245": "r1246": "r1247": "r1248": "r1249": "r1250": "r1251": "r1252": "r1253": "r1254": "r1255": "r1256": "r1257": "r1258": "r1259": "r1260": "r1261": "r1262": "r1263": "r1264": "r1265": "r1266": "r1267": "r1268": "r1269": "r1270": "r1271": "r1272": "r1273": "r1274": "r1275": "r1276": "r1277": "r1278": "r1279": "r1280": "r1281": "r1282": "r1283": "r1284": "r1285": "r1286": "r1287": "r1288": "r1289": "r1290": "r1291": "r1292": "r1293": "r1294": "r1295": "r1296": "r1297": "r1298": "r1299": "r1300": "r1301": "r1302": "r1303": "r1304": "r1305": "r1306": "r1307": "r1308": "r1309": "r1310": "r1311": "r1312": "r1313": "r1314": "r1315": "r1316": "r1317": "r1318": "r1319": "r1320": "r1321": "r1322": "r1323": "r1324": "r1325": "r1326": "r1327": "r1328": "r1329": "r1330": "r1331": "r1332": "r1333": "r1334": "r1335": "r1336": "r1337": "r1338": "r1339": "r1340": "r1341": "r1342": "r1343": "r1344": "r1345": "r1346": "r1347": "r1348": "r1349": "r1350": "r1351": "r1352": "r1353": "r1354": "r1355": "r1356": "r1357": "r1358": "r1359": "r1360": "r1361": "r1362": "r1363": "r1364": "r1365": "r1366": "r1367": "r1368": "r1369": "r1370

"totalLabel": "Payments of Dividends, Total", "terseLabel": "Dividends paid", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth ref": "r73" } } }, "us-gaap-PaymentsOfStockIssuanceCosts": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "erdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role- DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://monterosax.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" } } }, "lang": { "en-us": { "role": { "terseLabel": "Payment of common stock issuance costs", "negatedLabel": "Payment of convertible preferred stock issuance costs", "terseLabel": "Payments of stock issuance costs", "label": "Stock issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth ref": "r20" } } }, "us-gaap-PaymentsToAcquireMarketableSecurities": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "erdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" } } }, "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "terseLabel": "Purchases of marketable securities", "negatedLabel": "Purchases of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth ref": "r853" } } }, "us-gaap-PaymentsToAcquirePropertyPlantAndEquipment": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "erdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" } } }, "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, includes cash outflows to pay for construction of self-constructed assets." } } }, "auth ref": "r72" } } }, "ecd-PeerGroupIssuesFnTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuesFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote", "documentation": "The entire disclosure for retirement benefits." } } }, "auth ref": "r772" } } }, "ecd-PeerGroupTotalShareholderRtnAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount", "documentation": "The entire disclosure for retirement benefits." } } }, "auth ref": "r772" } } }, "us-gaap-PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role- DisclosureEmployeeRetirementPlan" } } }, "lang": { "en-us": { "role": { "terseLabel": "Employee Retirement Plan", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth ref": "r298", "r299", "r300", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r683" } } }, "us-gaap-PensionExpense": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionExpense", "erdr": "debit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlansScheduleOfPensionExpenseDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Pension expense", "label": "Pension Cost (Reversal of Cost)", "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits." } } }, "auth ref": "r672" } } }, "glue-PensionPlanAssetsMember": { "xbrlType": "domainItemType", "nsuri": "http://monterosax.com/20240930", "localname": "PensionPlanAssetsMember", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role- DisclosureFairValueMeasurementsSummaryOfFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails" } } }, "lang": { "en-us": { "role": { "label": "Pension Plan Assets [Member]", "documentation": "Pension plan assets Member", "terseLabel": "Pension Plan Assets [Member]" } } }, "auth ref": {} } } }, "ecd-PeoActuallyPaidCompAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth ref": "r764" } } }, "ecd-PeoMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth ref": "r781" } } }, "ecd-PeoName": { "xbrlType": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth ref": "r774" } } }, "ecd-PeoTotalCompAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth ref": "r763" } } }, "glue-PercentageOfCommissionPayableToRelatedParty": { "xbrlType": "percentItemType", "nsuri": "http://monterosax.com/20240930", "localname": "PercentageOfCommissionPayableToRelatedParty", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role- DisclosureEquityAdditionalInformationDetails" } } }, "lang": { "en-us": { "role": { "documentation": "Percentage of Commission payable to Related Party", "label": "Percentage of Commission payable to Related Party", "terseLabel": "Percentage of Commission payable to Related Party" } } }, "auth ref": {} } } }, "us-gaap-PlanNameAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role- DisclosureStockBasedCompensationAdditionalInformationDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth ref": "r878", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903" } } }, "us-gaap-PlanNameDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role- DisclosureStockBasedCompensationAdditionalInformationDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth ref": "r878", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903" } } }, "ecd-PnsnAdjsPrsSvcCstMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth ref": "r765" } } }, "ecd-PnsnAdjsSvcCstMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth ref": "r809" } } }, "ecd-PnsnBnftsAdjFnTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } }, "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth ref": "r764" } } }, "us-gaap-PostemploymentBenefitsPeriodExpense": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PostemploymentBenefitsPeriodExpense", "erdr": "debit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlansScheduleOfDefinedContributionExpenseDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "401(k) expense", "label": "Postemployment Benefits, Period Expense", "documentation": "Period expense related to postemployment benefits." } } }, "auth ref": {} } } }, "glue-PotentialClinicalCommercialAndSalesMilestones": { "xbrlType": "monetaryItemType", "nsuri": "http://monterosax.com/20240930", "localname": "PotentialClinicalCommercialAndSalesMilestones", "erdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Potential clinical, commercial and sales milestones", "label": "Potential Clinical, Commercial And Sales Milestones", "documentation": "Potential Clinical, Commercial And Sales Milestones" } } }, "auth ref": {} } } }, "glue-PotentialPreClinicalClinicalCommercialAndSalesMilestones": { "xbrlType": "monetaryItemType", "nsuri": "http://monterosax.com/20240930", "localname": "PotentialPreClinicalClinicalCommercialAndSalesMilestones", "erdr": "credit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" } } }, "lang": { "en-us": { "role": { "documentation": "Pre-Clinical Milestones", "label": "Pre-Clinical Milestones", "terseLabel": "Pre-clinical milestones" } } }, "auth ref": {} } } }, "glue-PreFundedWarrantsMember": { "xbrlType": "domainItemType", "nsuri": "http://monterosax.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails" } } }, "lang": { "en-us": { "role": { "documentation": "Pre-Funded Warrants [Member]", "label": "Pre-Funded Warrants [Member]", "terseLabel": "Pre-funded warrants" } } }, "auth ref": {} } } }, "glue-PreFundedWarrantsToPurchase": { "xbrlType": "sharesItemType", "nsuri": "http://monterosax.com/20240930", "localname": "PreFundedWarrantsToPurchase", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails" } } }, "lang": { "en-us": { "role": { "documentation": "Pre-Funded Warrants

```

"debit": "presentation", "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Aggregate net proceeds after deducting underwriter discounts and commissions", "terseLabel": "Aggregate gross proceeds", "verboseLabel": "Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount of $20", "documentation": "The cash inflow from the additional capital contribution to the entity", "auth_ref": "r4", "us-gaap-ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan", "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan", "terseLabel": "Proceeds from employee stock purchase plan", "documentation": "Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan", "auth_ref": "r833", "us-gaap-ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosureConvertiblePreferredStockAdditionalInformationDetails", "lang": "en-us", "role": "label", "Gross proceed from issuance of preferred stock", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation", "auth_ref": "r4", "us-gaap-ProceedsFromIssuanceOfWarrants", "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from the issuance of pre-funded warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)", "auth_ref": "r4", "us-gaap-ProceedsFromIssuanceOrSaleOfEquity", "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "lang": "en-us", "role": "label", "Proceeds from Issuance or Sale of Equity, Total", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Gross Proceeds from sale of Common Stock", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity", "auth_ref": "r4", "us-gaap-ProceedsFromSaleAndMaturityOfMarketableSecurities", "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Proceeds from Sale and Maturity of Marketable Securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period", "auth_ref": "us-gaap-ProceedsFromSaleOfPropertyPlantAndEquipment", "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Proceeds from Sale of Property, Plant, and Equipment, Total", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from the sale of property and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale", "auth_ref": "r21", "us-gaap-ProceedsFromStockOptionsExercised", "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Proceeds from exercise of employee stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement", "auth_ref": "r4", "r14", "glue-ProceedsFromUnderwrittenPublicOfferingCost", "xbrlytype": "monetaryItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "ProceedsFromUnderwrittenPublicOfferingCost", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Proceeds from Underwritten Public Offering Cost", "label": "Proceeds from Underwritten Public Offering Cost", "terseLabel": "Proceeds from underwritten public offering cost, net of underwriter's discount of $3,000", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest", "auth_ref": "r125", "r139", "r141", "r148", "r153", "r158", "r164", "r166", "r167", "r232", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r377", "r380", "r382", "r385", "r386", "r398", "r418", "r521", "r537", "r564", "r611", "r620", "r630", "r687", "r688", "r723", "r831", "r873", "us-gaap-PropertyPlantAndEquipmentAbstract", "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": "en-us", "role": "label", "Property, Plant and Equipment [Abstract]", "auth_ref": "us-gaap-PropertyPlantAndEquipmentByTypeAxis", "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail", "lang": "en-us", "role": "label", "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale", "auth_ref": "r8", "r44", "us-gaap-PropertyPlantAndEquipmentDisclosureTextBlock", "xbrlytype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNet", "lang": "en-us", "role": "label", "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections", "auth_ref": "r80", "r117", "r118", "r119", "us-gaap-PropertyPlantAndEquipmentGross", "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail", "lang": "en-us", "role": "label", "Property, Plant and Equipment, Gross", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "terseLabel": "Total property and equipment, at cost", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures", "auth_ref": "r81", "r120", "r535", "us-gaap-PropertyPlantAndEquipmentLineItems", "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail", "lang": "en-us", "role": "label", "Property Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "auth_ref": "r44", "us-gaap-PropertyPlantAndEquipmentNet", "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail", "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "label", "Property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures", "auth_ref": "r8", "r44", "r522", "r535", "r700", "us-gaap-PropertyPlantAndEquipmentTextBlock", "xbrlytype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetTables", "lang": "en-us", "role": "label", "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation", "auth_ref": "r8", "us-gaap-PropertyPlantAndEquipmentTypeDomain", "xbrlytype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation", "http://monterosatx.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail", "lang": "en-us", "role": "label", "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software", "auth_ref": "r81", "r44", "glue-ProvisionForPensionBenefitObligation", "xbrlytype": "monetaryItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "ProvisionForPensionBenefitObligation", "crdr": "credit", "presentation", "http://monterosatx.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "lang": "en-us", "role": "label", "Provision for pension benefit obligation", "label": "Provision For Pension Benefit Obligation", "documentation": "Provision for pension benefit obligation", "auth_ref": "glue-PublicOfferingOfShare", "xbrlytype": "sharesItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "PublicOfferingOfShare", "presentation", "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "lang": "en-us", "role": "label", "Public Offering of Share", "label": "Public Offering of Share", "terseLabel": "Underwritten public offering", "auth_ref": "ecd-PvpTable", "xbrlytype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure", "auth_ref": "r262", "ecd-PvpTableTextBlock", "xbrlytype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "Pay vs Performance [Table Text Block
```

[{"domain": "F", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."}], [{"auth_ref": ["r198", "r308", "r448", "r449", "r525", "r533", "r583", "r584", "r585", "r586", "r587", "r608", "r610", "r636"]}, {"us_gaap_RelatedPartyTransactionsByRelatedPartyAxis": {"xbrl_type": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails"}], "lang": ["en-us"], "role": ["terseLabel", "Related Party", "label", "Related and Nonrelated Parties [Axis]", "documentation"], "information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."}], [{"auth_ref": ["r198", "r308", "r448", "r449", "r525", "r533", "r583", "r584", "r585", "r586", "r587", "r608", "r610", "r636", "r922"]}, {"us_gaap_ResearchAndDevelopmentExpense": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"}], "lang": ["en-us"], "role": ["terseLabel", "Research and development", "label", "Research and Development Expense", "totalLabel", "Research and Development Expense, Total", "documentation"], "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."}], [{"auth_ref": ["r358", "r665", "r672", "r931"]}, {"us_gaap_ResearchAndDevelopmentExpenseMember": {"xbrl_type": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"}, {"http://monterosax.com/20240930/taxonomy/role/DisclosureLeasesSummarizesLeaseExpenseDetails"}, {"http://monterosax.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"}], "lang": ["en-us"], "role": ["label", "Research and Development Expense [Member]", "verboseLabel", "Research and Development", "documentation"], "Primary financial statement caption in which the reported facts about research and development expense have been included."}], [{"auth_ref": []}, {"ecd_RestatementDateAxis": {"xbrl_type": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}], "lang": ["en-us"], "role": ["label", "Restatement Determination Date [Axis]", "terseLabel", "Restatement Determination Date", "dateItem Type", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}], "lang": ["en-us"], "role": ["label", "Restatement Determination Date", "terseLabel", "Restatement Determination Date"]}], [{"auth_ref": ["r731", "r741", "r751", "r783"]}, {"ecd_RestatementDeterminationDate": {"xbrl_type": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}], "lang": ["en-us"], "role": ["label", "Restatement Determination Date", "terseLabel", "Restatement Determination Date"]}], [{"auth_ref": ["r732", "r742", "r752", "r784"]}, {"ecd_RestatementDoesNotRequireRecoveryTextBlock": {"xbrl_type": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}], "lang": ["en-us"], "role": ["label", "Restatement Does Not Require Recovery [Text Block]", "terseLabel", "Restatement does not require recovery"]}], [{"auth_ref": ["r739", "r749", "r759", "r791"]}, {"us_gaap_RestrictedCash": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"}], "lang": ["en-us"], "role": ["label", "Restricted Cash", "terseLabel", "Restricted cash", "totalLabel", "Restricted Cash, Total", "documentation"], "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."}], [{"auth_ref": ["r823", "r836", "r933", "r936"]}, {"us_gaap_RestrictedCashAndCashEquivalents": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidityAdditionalInformationDetails"}], "lang": ["en-us"], "role": ["totalLabel", "Restricted Cash and Cash Equivalents, Total", "label", "Restricted Cash and Cash Equivalents", "terseLabel", "Restricted Cash and Cash Equivalents", "documentation"], "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}], [{"auth_ref": ["r21", "r95", "r128", "r150", "r527"]}, {"us_gaap_RestrictedCashNoncurrent": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"}], "lang": ["en-us"], "role": ["label", "Restricted Cash, Noncurrent", "terseLabel", "Restricted cash, Noncurrent", "documentation"], "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."}], [{"auth_ref": ["r114", "r824", "r836"]}, {"us_gaap_RestrictedStockMember": {"xbrl_type": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsLiabilitiesMeasuredOnRecurringBasisDetails"}], "lang": ["en-us"], "role": ["label", "Cash and Cash Equivalents [Domain]", "documentation"], "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}], [{"auth_ref": ["r128"]}, {"us_gaap_RestrictedCashNoncurrent": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited"}], "lang": ["en-us"], "role": ["label", "Restricted Cash, Noncurrent", "terseLabel", "Restricted cash, Noncurrent", "documentation"], "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."}], [{"auth_ref": ["r114", "r824", "r836"]}, {"us_gaap_RestrictedStockMember": {"xbrl_type": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails"}, {"http://monterosax.com/20240930/taxonomy/role/DisclosureEquityScheduleOfCommonStockForPotentialConversionOutstandingPreferredStockDetails"}, {"http://monterosax.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails"}, {"http://monterosax.com/20240930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardActivityDetails"}, {"http://monterosax.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails"}], "lang": ["en-us"], "role": ["label", "Unvested restricted common stock awards", "terseLabel", "Restricted common stock", "label", "Restricted Stock [Member]", "documentation"], "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."}], [{"auth_ref": ["r25"]}, {"us_gaap_RestrictedStockUnitsRSUMember": {"xbrl_type": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/DisclosureEquityScheduleOfCommonStockForPotentialConversionOutstandingPreferredStockDetails"}, {"http://monterosax.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails"}, {"http://monterosax.com/20240930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitActivityDetails"}, {"http://monterosax.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails"}], "lang": ["en-us"], "role": ["label", "Unvested restricted common stock units", "verboseLabel", "Restricted stock units", "label", "Restricted Stock Units (RSUs) [Member]", "documentation"], "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."}], [{"auth_ref": []}, {"us_gaap_RetainedEarningsAccumulatedDeficit": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidityAdditionalInformationDetails"}, {"http://monterosax.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsUnaudited"}], "lang": ["en-us"], "role": ["label", "Retained earnings accumulated deficit", "verboseLabel", "Retained earnings accumulated deficit", "terseLabel", "Accumulated deficit", "label", "Retained Earnings (Accumulated Deficit)", "totalLabel", "Retained Earnings (Accumulated Deficit), Total", "periodStartLabel", "Retained Earnings (Accumulated Deficit), Beginning Balance", "periodEndLabel", "Retained Earnings (Accumulated Deficit), Ending Balance", "documentation"], "Amount of accumulated undistributed earnings (deficit)."}], [{"auth_ref": ["r60", "r88", "r531", "r551", "r553", "r562", "r591", "r700"]}, {"us_gaap_RetainedEarningsMember": {"xbrl_type": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"}], "lang": ["en-us"], "role": ["label", "Retained Earnings [Member]", "terseLabel", "Accumulated Deficit", "documentation"], "Accumulated undistributed earnings (deficit)."}], [{"auth_ref": ["r124", "r155", "r166", "r157", "r159", "r164", "r165", "r167", "r233", "r234", "r256", "r367", "r368", "r374", "r375", "r376", "r378", "r380", "r389", "r391", "r392", "r394", "r397", "r430", "r432", "r548", "r550", "r565", "r970"]}, {"us_gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [{"http://monterosax.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"}, {"http://monterosax.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"}], "lang": ["en-us"], "role": ["label", "Collaboration Revenue", "label", "Revenue from Contract with Customer, Including Assessed Tax", "documentation"], "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer.

"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": f
"<http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails>" l lang f en-us f role f terseLabel f Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] l label f Antidilutive Security, Excluded EPS Calculation [Table] l documentation f Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS. l auth_ref f r25 l us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableBlock f xbrltype f textBlockItemType nsuri f http://fasb.org/us-gaap/2024 l localname f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareTables" l lang f en-us f role f terseLabel: "Schedule of Antidilutive Securities Excluded from Earnings Per Share Calculation" label f "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" documentation f "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." l auth_ref f r25 l us-gaap ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable f xbrltype f stringItemType nsuri f http://fasb.org/us-gaap/2024 localname f
"ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" l lang f en-us f role f label: "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" documentation f "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue generating activity or operations." l auth_ref f r381 l us-gaap ScheduleOfConversionsOfStockTableBlock f xbrltype f textBlockItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityTables" l lang f en-us f role f label: "Schedule of Conversions of Stock [Table Text Block]" terseLabel: "Common Stock Reserved for Potential Conversion of Outstanding Preferred Stock Vesting of Restricted Stock and Exercise of Stock Options" documentation f "Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction." l auth_ref f r22 r23 r24 l us-gaap ScheduleOfCostsOfRetirementPlansTableTextBlock f xbrltype f textBlockItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfCostsOfRetirementPlansTableTextBlock" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlansTables" l lang f en-us f role f terseLabel: "Schedule of pension expense incurred" label: "Schedule of Costs of Retirement Plans [Table Text Block]" documentation f "Tabular disclosure of the costs related to the various types of retirement plans including defined benefit pension plan cost, defined contribution plan cost, other postretirement benefit plan cost, and net periodic benefit cost." l auth_ref f r9 l us-gaap ScheduleOfDefinedBenefitPlansDisclosuresTextBlock f xbrltype f textBlockItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureEmployeeRetirementPlansTables" l lang f en-us f role f label: "Schedule of Defined Benefit Plans Disclosures [Table Text Block]" terseLabel: "Schedule of defined contribution expense incurred" documentation f "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans." l auth_ref f r9 r37 r38 r39 r40 l
"glue_ScheduleOfDepreciationExpensesTableTextBlock" f xbrltype f textBlockItemType nsuri f
"http://monterosatx.com/20240930" localname f
"ScheduleOfDepreciationExpensesTableTextBlock" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" l lang f en-us f role f documentation f "Tabular disclosure of depreciation expenses." label: "Schedule of Depreciation Expenses [Table Text Block]" terseLabel: "Schedule of Depreciation Expense" l
auth_ref f l us-gaap ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock f xbrltype f textBlockItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareTables" l lang f en-us f role f terseLabel: "Schedule of Earnings Per Share, Basic and Diluted" label: "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" documentation f "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per share computations for income from continuing operations." l auth_ref f r845 l
us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable f xbrltype f stringItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesSummarizesLeaseExpenseDetails" l lang f en-us f role f label: "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" documentation f "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." l auth_ref f r42 l
us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableBlock f xbrltype f textBlockItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" l lang f en-us f role f terseLabel: "Schedule of Stock Based Compensation Expense" label: "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" documentation f "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." l auth_ref f r42 l
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock f xbrltype f textBlockItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" l lang f en-us f role f terseLabel: "Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis" label: "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" documentation f "Tabular disclosure of assets and liabilities, including financial instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." l auth_ref f r907 r908 l
us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable f xbrltype f stringItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfFiniteLivedIntangibleAssetsTable" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" l lang f en-us f role f label: "Intangible Asset, Finite Lived [Table]" documentation f "Disclosure of information about finite lived intangible asset. Excludes indefinite lived intangible asset." l auth_ref f r245 r251 r252 r254 r255 r486 r665 r676 l
us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock f xbrltype f textBlockItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesTables" l lang f en-us f role f label: "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]" terseLabel: "Schedule of Future Minimum Rental Payments for Operating Leases under non-cancelable" documentation f "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date." l auth_ref f r111 l
glue_ScheduleOfLeaseTermsAndDiscountRateTableTextBlock f xbrltype f textBlockItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesTables" l lang f en-us f role f documentation f "Schedule of Lease Terms and Discount Rate Table Text Block" label: "Schedule of Lease Terms and Discount Rate Table Text Block" terseLabel: "Schedule of Lease Terms and Discount Rate" l
auth_ref f l us-gaap_ScheduleOfPropertyPlantAndEquipmentTable f xbrltype f stringItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfPropertyPlantAndEquipmentTable" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail" l lang f en-us f role f terseLabel: "Schedule Of Property Plant And Equipment [Table]" label: "Property, Plant and Equipment [Table]" documentation f "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." l auth_ref f r8 r44 l
us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable f xbrltype f stringItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails" l lang f en-us f role f label: "Schedule of Restricted Stock Award Activity" label: "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]" documentation f "Tabular disclosure of the number and weighted average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." l auth_ref f r91 l
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock f xbrltype f textBlockItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" l lang f en-us f role f terseLabel: "Schedule of Stock Option Activity" label: "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" documentation f "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted average grant date fair value." l auth_ref f r12 r13 r91 l
us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock f xbrltype f textBlockItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" l lang f en-us f role f terseLabel: "Schedule of Restricted Stock Unit Activity" label: "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]" documentation f "Disclosure of the number and weighted average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." l auth_ref f l
us-gaap_ScheduleOfStockByClassTable f xbrltype f stringItemType nsuri f
"http://fasb.org/us-gaap/2024" localname f
"ScheduleOfStockByClassTable" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" l lang f en-us f role f terseLabel: "Security Exchange Name" label: "Security Exchange Name" documentation f "Name of the Exchange on which a security is registered." l
auth_ref f r727 l
srt_SegmentGeographicalDomain f xbrltype f domainItemType nsuri f
"http://fasb.org/srt/2024" localname f
"SegmentGeographicalDomain" presentation f
"http://monterosatx.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" l lang f en-us f role f label: "Geographical [Domain]" l
auth_ref f r195 r196 r488 r489 r490 r491 r492 r493 r494 r495 r496 r497 r498 r499 r500 r501 r502 r503 r504 r505 r506 r507 r508 r509 r510 r511 r512 r513 r514 r515 r516 r517 r577 r578 r579 r638 r640 r643 r645 r652 r654 r655 r656 r657 r658 r659 r660 r661 r662 r667 r680 r702 r703 r704 r705 r706 r707 r708 r709 r711 r715 r876 r899 r941 r942 r943 r944 r945 r946 r947 r948 r949 r950 r951 r952 r953 r954 r955 r956 r957 r958 r959 r960 r961 r962 r963 r964 r965 r967 r968 l
glue_SeriesA2ConvertiblePreferredStockMember f xbrltype f domainItemType nsuri f
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" l lang f en-us f role f label: "Title of 12(b) registered security." l
auth_ref f r725 l
dei_SecurityExchangeName f xbrltype f edgeExchangeCodeItemType nsuri f
"http://xbrl.sec.gov/dei/2024" localname f
"SecurityExchangeName" presentation f
"http://monterosatx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntity

[http://monterotasx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"/>{"en-us":{"role":{"documentation":"Series A 2 Convertible preferred stock","terselabel":"Series A 2 Convertible Preferred Stock","label":"Series A 2 Convertible Preferred Stock \(Member\)"},"authref":\["glue_SeriesBConvertiblePreferredStockMember"\],"xbritelype":"domainItemType","nsuri":"http://monterotasx.com/20240930/localname","SeriesBConvertiblePreferredStockMember","presentation":\["http://monterotasx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"\],"http://monterotasx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"},"en-us":{"role":{"documentation":"Series B Convertible preferred stock","label":"Series B Convertible Preferred Stock \(Member\)","terselabel":"Series B Convertible Preferred Stock"},"authref":\["glue_SeriesCConvertiblePreferredStockMember"\],"xbritelype":"domainItemType","nsuri":"http://monterotasx.com/20240930/localname","SeriesCConvertiblePreferredStockMember","presentation":\["http://monterotasx.com/20240930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"\],"http://monterotasx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"},"en-us":{"role":{"documentation":"Series C Convertible preferred stock","label":"Series C Convertible Preferred Stock \(Member\)","terselabel":"Series C Convertible Preferred Stock"},"authref":\["us-gaap_ShareBasedCompensation"\],"xbritelype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensation","crdr":"debit","presentation":\["http://monterotasx.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfCashFlowsUnaudited"\],"lang":{"en-us":{"role":{"terselabel":"Stock-based compensation expense","label":"Share-Based Payment Arrangement-Noncash Expense","totalLabel":"Share-based Payment Arrangement-Noncash Expense Total","documentation":"Amount of noncash expense for share-based payment arrangement."}}},"authref":\["r65"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod"},"xbritelype":"durationItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod"},"presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails"\],"lang":{"en-us":{"role":{"terselabel":"Vesting term","label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Award Vesting Period","documentation":"Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. In PnYnMndTnInMns format, for example, PLY5M13D represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."}}},"authref":\["r685"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"},"xbritelype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod","presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"\],"lang":{"en-us":{"role":{"negatedLabel":"Number of shares, Forfeited","terselabel":"Number of shares, Forfeited","label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Equity Instruments Other than Options, Forfeited in Period","documentation":"The number of equity-based payment instruments, excluding stock \(or unit\) options, that were forfeited during the reporting period."}}},"authref":\["r340"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"},"xbritelype":"perShareItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue","presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"\],"http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockUnitActivityDetails"},"lang":{"en-us":{"role":{"terselabel":"Weighted average grant date fair value, Forfeited","label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value","documentation":"Weighted average fair value as of the grant date of equity-based award plans other than stock \(unit\) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."}}},"authref":\["r340"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"},"xbritelype":"sharesItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockUnitActivityDetails"\],"lang":{"en-us":{"role":{"terselabel":"Number of shares, Granted","label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Equity Instruments Other than Options, Grants in Period","documentation":"The number of grants made during the period on other than stock \(or unit\) option plans \(for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan\)."}}},"authref":\["r338"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"},"xbritelype":"perShareItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue","presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockUnitActivityDetails"\],"lang":{"en-us":{"role":{"terselabel":"Weighted average grant date fair value, Granted","label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value","documentation":"The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock \(or unit\) option plans \(for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan\)."}}},"authref":\["r338"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"},"xbritelype":"sharesItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber","presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"\],"http://monterotasx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"},"lang":{"en-us":{"role":{"periodStartLabel":"Number of shares, Unvested restricted stock, beginning balance","label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Equity Instruments Other than Options, Nonvested, Number, periodEndLabel":"Number of shares, Unvested, ending balance","documentation":"The number of non-vested equity-based payment instruments, excluding stock \(or unit\) options, that validly exist and are outstanding as of the balance sheet date."}}},"authref":\["r335","r336"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"},"xbritelype":"perShareItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue","presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"\],"http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockUnitActivityDetails"},"lang":{"en-us":{"role":{"label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value","periodEndLabel":"Weighted average grant date fair value, ending balance","periodStartLabel":"Weighted average grant date fair value, beginning balance","documentation":"Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."}}},"authref":\["r335","r336"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"},"xbritelype":"sharesItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod","presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"\],"http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockUnitActivityDetails"},"lang":{"en-us":{"role":{"label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Equity Instruments Other than Options, Vested in Period","terselabel":"Number of shares, Vested","negatedLabel":"Number of shares, Vested","verboselabel":"Number of shares, Vested","documentation":"The number of equity-based payment instruments, excluding stock \(or unit\) options, that vested during the reporting period."}}},"authref":\["r339"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"},"xbritelype":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue","crdr":"debit","presentation":\["http://monterotasx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"\],"lang":{"en-us":{"role":{"terselabel":"Aggregate fair value of restricted stock vested","label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Equity Instruments Other than Options, Vested in Period, Fair Value","documentation":"Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."}}},"authref":\["r342"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"},"xbritelype":"perShareItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue","presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"\],"http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockUnitActivityDetails"},"lang":{"en-us":{"role":{"label":"Share-Based Compensation Arrangement by Share-Based Payment Award-Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value","terselabel":"Weighted average grant date fair value, vested","verboselabel":"Weighted average grant date fair value, Vested","documentation":"The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock \(or unit\) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."}}},"authref":\["r339"\],"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"},"xbritelype":"stringItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems","presentation":\["http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"\],"http://monterotasx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockUnitActivityDetails"},"http://monterotasx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"},"http://monterotasx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"},"lang":{"en-us":{"role":{"terselabel":"Share-Based Compensation Arrangement by Share-Based Payment Award-Line Items","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"authref":\["r320","r322","r324","r325","r326","r327","r328","r329","r330","r331","r332","r333","r334","r335","r336","r337","r338","r339","r340","r341","r342","r343","r344","r345","r346","r347","r348","r349"\]},"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"},"xbritelype":"sharesItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","presentation":\["http://monterotasx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"\],"lang":{"en-us":{"role":{"label":"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number","terselabel":"Number of options, exercisable","documentation":"The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."}}},"authref":\["r329"\]},"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"},"xbritelype":"perShareItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice","presentation":\["http://monterotasx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"\],"lang":{"en-us":{"role":{"terselabel":"Weighted average exercise price, exercisable","label":"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price","verboselabel":"Weighted average exercise price, exercisable","periodStartLabel":"Weighted average remaining contractual term \(years\), balance","documentation":"The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."}}},"authref":\["r329"\]},"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"},"xbritelype":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue","crdr":"debit","presentation":\["http://monterotasx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"\],"lang":{"en-us":{"role":{"terselabel":"Aggregate intrinsic value, exercised","label":"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period](#)

share-units) granted during the period." } } } , "auth ref": { "r331" } } } , "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem Type", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation":
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } } } , "lang": { "en-us": { "role": { "label": "Share Based Compensation
Arrangement by Share Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant fair value, granted",
"documentation": "The weighted average grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } } ,
"auth ref": { "r341" } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItem Type", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "order": "debit", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "label": "Share Based
Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Intrinsic Value", "periodStartLabel": "Aggregate intrinsic value, beginning balance", "periodEndLabel":
"Aggregate intrinsic value, ending balance", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } } ,
"auth ref": { "r41" } } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItem Type", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "periodStartLabel": "Number
of options, beginning balance", "periodEndLabel": "Number of options, ending balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options,
Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } } , "auth ref": { "r327", "r328" } } } } , "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItem Type", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "periodStartLabel": "Weighted
average exercise price, beginning balance", "periodEndLabel": "Weighted average exercise price, ending balance", "label": "Share Based Compensation Arrangement by Share Based Payment
Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock
option plan." } } } , "auth ref": { "r327", "r328" } } } } , "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItem Type", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
"order": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role":
"label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate
intrinsic value, vested or expected to vest", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or
convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance
condition, if forfeitures are recognized when they occur." } } } , "auth ref": { "r344" } } } } , "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItem Type",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "label": "Share Based
Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise
price, vested or expected to vest", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest
exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement
of performance condition, if forfeitures are recognized when they occur." } } } , "auth ref": { "r344" } } } } , "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItem Type", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
"order": "debit", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role":
"label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options
outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance
condition, if forfeitures are recognized when they occur." } } } , "auth ref": { "r343" } } } } , "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItem Type", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "periodEndLabel": "Number of
options, vested or expected to vest", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
"documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for
which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } ,
"auth ref": { "r343" } } } } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
"xbrltype": "perShareItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "periodEndLabel": "Weighted
average exercise price, vested or expected to vest", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Outstanding,
Weighted Average Exercise Price", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options
outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance
condition, if forfeitures are recognized when they occur." } } } , "auth ref": { "r343" } } } } ,
"glue_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInFutureIssuanceReserveShare": { "xbrltype": "sharesItem Type", "nsuri":
"http://monterosatx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInFutureIssuanceReserveShare", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } } } , "lang": { "en-us": { "role": { "label": "Share Based Compensation
Arrangement by Share Based Payment Award Percentage of Increase In Future Issuance Reserve Share", "terseLabel": "Number of share increase", "documentation": "Share based
compensation arrangement by share based payment award percentage of increase in future issuance reserve share." } } } , "auth ref": { } } } } ,
"glue_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInFutureIssuanceReservedShare": { "xbrltype": "percentItem Type", "nsuri":
"http://monterosatx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInFutureIssuanceReservedShare", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } } } , "lang": { "en-us": { "role": { "documentation": "Share Based
Compensation Arrangement by Share Based Payment Award Percentage Of Increase In Future Issuance Reserved Share", "label": "Share Based Compensation Arrangement by Share Based
Payment Award Percentage Of Increase In Future Issuance Reserved Share", "terseLabel": "Increase in share percentage" } } } , "auth ref": { } } } } , "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItem Type", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
"http://monterosatx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails",
"http://monterosatx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockUnitActivityDetails",
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } } , "lang": { "en-
us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } } , "auth ref": { "r324", "r325", "r326",
"r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349" } } } } , "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItem Type", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "terseLabel": "Weighted
average exercise price, exercised", "label": "Share Based Compensation Arrangements by Share Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
"documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } } , "auth ref": { "r332" } } } } , "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItem Type", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "terseLabel": "Weighted
average exercise price, forfeited", "label": "Share Based Compensation Arrangements by Share Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } } , "auth ref": { "r333" } } } } , "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItem Type", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "terseLabel": "Weighted
average exercise price, granted", "label": "Share Based Compensation Arrangements by Share Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } } , "auth ref": { "r331" } } } } , "us-gaap_SharePrice": {
"xbrltype": "perShareItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails" } } } , "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Common stock price",
"documentation": "Price of a single share of a number of saleable stocks of a company." } } } , "auth ref": { } } } } , "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItem Type", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "order": "debit", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "label": "Share Based
Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, exercisable", "documentation": "Amount of
difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } } , "auth ref": { "r41" } } } } ,
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItem Type", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"presentation": { "http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "label":
"Share Based Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining
contractual term (years), balance", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'PIY5M13D',
represents the reported fact of one year, five months, and thirteen days." } } } , "auth ref": { "r92" } } } } , "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype":
"durationItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "label": "Share Based
Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted
average remaining contractual term (years), exercisable", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible
options, in 'PnYnMnDnTnHnMnS' format, for example, 'PIY5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for
which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } ,
"auth ref": { "r344" } } } } , "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype":
"durationItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": {
"http://monterosatx.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" } } } , "lang": { "en-us": { "role": { "terseLabel": "Weighted
average remaining contractual term (years), vested or expected to vest", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to
Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding,

PnYmMndTnHnMns format, for example, "P1Y5M13D" represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } }, "auth_ref": { "r2432" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares": { "xbrlType": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails": { "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Options Vested Number of Shares", "terseLabel": "Number of options vested or expected to vest", "documentation": "Number of options vested." } } }, "auth_ref": { "r1": "us-gaap-SharesIssued": { "xbrlType": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "SharesIssued", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Shares Issued", "terseLabel": "Shares Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": { "r11": "us-gaap-SharesIssuedPricePerShare": { "xbrlType": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "SharesIssuedPricePerShare", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Shares Issued Price Per Share", "terseLabel": "Share exercise price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": { "r1": "us-gaap-ShortTermLeaseCost": { "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShortTermLeaseCost", "crdr": "debit", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Short Term Lease Cost", "terseLabel": "Short Term Lease", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": { "r438": "r699" } }, "us-gaap-SignificantAccountingPoliciesTextBlock": { "xbrlType": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://monterosax.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Summary of significant accounting policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r77": "r151" } }, "us-gaap-StatementClassOfStockAxis": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "StatementClassOfStockAxis", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEquityScheduleOfCommonStockForPotentialConversionOutstandingPreferredStockDetails": { "http://monterosax.com/20240930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntidilutiveSharesExcludedFromEarningsPerShareCalculationDetails": { "http://monterosax.com/20240930/taxonomy/role/Role-DisclosureConvertiblePreferredStock": { "http://monterosax.com/20240930/taxonomy/role/Role-DisclosureConvertiblePreferredStockAdditionalInformationDetails": { "http://monterosax.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical": { "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r122": "r133": "r134": "r135": "r153": "r172": "r173": "r175": "r177": "r185": "r186": "r232": "r266": "r268": "r269": "r270": "r273": "r274": "r278": "r279": "r282": "r285": "r293": "r418": "r558": "r559": "r560": "r561": "r565": "r566": "r567": "r568": "r569": "r570": "r571": "r572": "r573": "r574": "r575": "r576": "r590": "r612": "r631": "r646": "r647": "r648": "r649": "r650": "r812": "r837": "r844" } }, "us-gaap-StatementEquityComponentsAxis": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "StatementEquityComponentsAxis", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails": { "http://monterosax.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical": { "http://monterosax.com/20240930/taxonomy/role/StatementCondensedCombinedAndConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r11": "r58": "r61": "r62": "r124": "r143": "r144": "r145": "r155": "r156": "r157": "r159": "r164": "r165": "r167": "r184": "r233": "r234": "r256": "r295": "r367": "r368": "r374": "r375": "r376": "r378": "r379": "r380": "r389": "r390": "r391": "r392": "r393": "r394": "r397": "r423": "r424": "r425": "r426": "r427": "r428": "r430": "r432": "r447": "r539": "r548": "r549": "r550": "r565": "r631" } }, "st-StatementGeographicalAxis": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/st/2024", "localName": "StatementGeographicalAxis", "presentation": { "http://monterosax.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Geographical Axis", "documentation": "Information by geographical area." } } }, "auth_ref": { "r105": "r106": "r488": "r489": "r490": "r491": "r492": "r493": "r494": "r495": "r496": "r497": "r498": "r499": "r500": "r501": "r502": "r503": "r504": "r505": "r506": "r507": "r508": "r509": "r510": "r511": "r512": "r513": "r514": "r515": "r516": "r517": "r577": "r578": "r579": "r638": "r640": "r643": "r645": "r652": "r654": "r655": "r656": "r657": "r658": "r659": "r660": "r661": "r662": "r667": "r680": "r702": "r703": "r704": "r705": "r706": "r707": "r708": "r709": "r711": "r715": "r716": "r717": "r718": "r719": "r720": "r721": "r722": "r723": "r724": "r725": "r726": "r727": "r728": "r729": "r730": "r731": "r732": "r733": "r734": "r735": "r736": "r737": "r738": "r739": "r740": "r741": "r742": "r743": "r744": "r745": "r746": "r747": "r748": "r749": "r750": "r751": "r752": "r753": "r754": "r755": "r756": "r757": "r758": "r759": "r760": "r761": "r762": "r763": "r764": "r765": "r766": "r767": "r768": "r769": "r770": "r771": "r772": "r773": "r774": "r775": "r776": "r777": "r778": "r779": "r780": "r781": "r782": "r783": "r784": "r785": "r786": "r787": "r788": "r789": "r790": "r791": "r792": "r793": "r794": "r795": "r796": "r797": "r798": "r799": "r800": "r801": "r802": "r803": "r804": "r805": "r806": "r807": "r808": "r809": "r810": "r811": "r812": "r813": "r814": "r815": "r816": "r817": "r818": "r819": "r820": "r821": "r822": "r823": "r824": "r825": "r826": "r827": "r828": "r829": "r830": "r831": "r832": "r833": "r834": "r835": "r836": "r837": "r838": "r839": "r840": "r841": "r842": "r843": "r844": "r845": "r846": "r847": "r848": "r849": "r850": "r851": "r852": "r853": "r854": "r855": "r856": "r857": "r858": "r859": "r860": "r861": "r862": "r863": "r864": "r865": "r866": "r867": "r868": "r869": "r870": "r871": "r872": "r873": "r874": "r875": "r876": "r877": "r878": "r879": "r880": "r881": "r882": "r883": "r884": "r885": "r886": "r887": "r888": "r889": "r890": "r891": "r892": "r893": "r894": "r895": "r896": "r897": "r898": "r899": "r900": "r901": "r902": "r903": "r904": "r905": "r906": "r907": "r908": "r909": "r910": "r911": "r912": "r913": "r914": "r915": "r916": "r917": "r918": "r919": "r920": "r921": "r922": "r923": "r924": "r925": "r926": "r927": "r928": "r929": "r930": "r931": "r932": "r933": "r934": "r935": "r936": "r937": "r938": "r939": "r940": "r941": "r942": "r943": "r944": "r945": "r9

rs92", "r609", "r632", "r633", "r700", "r724", "r838", "r869", "r916", "r970"] } } , "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } } } , "auth-ref": { "us-gaap-StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquity": { "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Equity", "documentation": "The entire disclosure for equity." } } } } , "auth-ref": { "r84", "r152", "r277", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r292", "r295", "r306", "r634", "r635", "r651" } } } , "us-gaap-SubsequentEventInclItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventInclItems", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } } } , "auth-ref": { "r429", "r451" } } } , "us-gaap-SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Subsequent Event [Type]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } } , "auth-ref": { "r429", "r451" } } } , "us-gaap-SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } } } , "auth-ref": { "r429", "r451" } } } , "us-gaap-SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } } , "auth-ref": { "r429", "r451" } } } , "us-gaap-SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } } , "auth-ref": { "r429", "r451" } } } , "us-gaap-SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } } , "auth-ref": { "us-gaap-SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureSubsequentEvents": { "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } } } , "auth-ref": { "r450", "r452" } } } } , "us-gaap-SubsidiaryOrEquityMethodInvesteeInclItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeInclItems", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndLiquidityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Subsidiary Or Equity Method Investee [Line Items]", "label": "Subsidiary or Equity Method Investee [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } } , "auth-ref": { "us-gaap-SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Subsidiary Sale Of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } } } , "auth-ref": { "us-gaap-SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of noncash items", "label": "Supplemental Cash Flow Information [Abstract]" } } } } , "auth-ref": { "ecd-TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } } } , "auth-ref": { "r780" } } } , "glue-TdSecuritiesUsaLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://monterosatx.com/20240930", "localname": "TdSecuritiesUsaLlcMember", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/DisclosureEquityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "TD Securities USA LLC Member", "label": "TD Securities USA LLC [Member]", "terseLabel": "TD Securities (USA) LLC [Member]" } } } } , "auth-ref": { "us-gaap-TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock, Par or Stated Value Per Share", "label": "Convertible preferred stock, par or stated value per share", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } } } , "auth-ref": { "r16", "r28" } } } , "us-gaap-TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesAuthorized", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Authorized", "terseLabel": "Convertible preferred stock, shares authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } } } , "auth-ref": { "r56" } } } , "us-gaap-TemporaryEquitySharesIssued": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesIssued", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Issued", "terseLabel": "Convertible preferred stock, shares issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } } } , "auth-ref": { "r56" } } } , "us-gaap-TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": { "http://monterosatx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Convertible preferred stock, shares outstanding", "periodEndLabel": "Balance (in shares) period end", "periodStartLabel": "Balance (in shares) beginning", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } } } , "auth-ref": { "r56" } } } , "ecd-TotalShareholderRtnAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } } } , "auth-ref": { "r772" } } } , "ecd-TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[210.12-29\(Column A\)\(Footnote 4\)\)](#), "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479628/948-310-S99-1](\"https://asc.fasb.org/1943274/2147479628/948-310-S99-1\")", "r653": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478522/954-40-50-1](\"https://asc.fasb.org/1943274/2147478522/954-40-50-1\")", "r654": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478979/970-360-S99-1](\"https://asc.fasb.org/1943274/2147478979/970-360-S99-1\")", "r655": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478979/970-360-S99-1](\"https://asc.fasb.org/1943274/2147478979/970-360-S99-1\")", "r656": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478979/970-360-S99-1](\"https://asc.fasb.org/1943274/2147478979/970-360-S99-1\")", "r657": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478979/970-360-S99-1](\"https://asc.fasb.org/1943274/2147478979/970-360-S99-1\")", "r658": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478979/970-360-S99-1](\"https://asc.fasb.org/1943274/2147478979/970-360-S99-1\")", "r659": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478979/970-360-S99-1](\"https://asc.fasb.org/1943274/2147478979/970-360-S99-1\")", "r660": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478979/970-360-S99-1](\"https://asc.fasb.org/1943274/2147478979/970-360-S99-1\")", "r661": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478979/970-360-S99-1](\"https://asc.fasb.org/1943274/2147478979/970-360-S99-1\")", "r662": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478979/970-360-S99-1](\"https://asc.fasb.org/1943274/2147478979/970-360-S99-1\")", "r663": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477332/976-310-50-1](\"https://asc.fasb.org/1943274/2147477332/976-310-50-1\")", "r664": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479230/978-310-50-1](\"https://asc.fasb.org/1943274/2147479230/978-310-50-1\")", "r665": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481283/985-20-50-2](\"https://asc.fasb.org/1943274/2147481283/985-20-50-2\")", "r666": { "role": "[http://www.xbrl.org/2003/role/exampleRef](\"http://www.xbrl.org/2003/role/exampleRef\")", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482740/230-10-45-28](\"https://asc.fasb.org/1943274/2147482740/230-10-45-28\")", "r667": { "role": "[http://www.xbrl.org/2003/role/exampleRef](\"http://www.xbrl.org/2003/role/exampleRef\")", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480046/944-40-55-13H](\"https://asc.fasb.org/1943274/2147480046/944-40-55-13H\")", "r668": { "role": "[http://www.xbrl.org/2003/role/exampleRef](\"http://www.xbrl.org/2003/role/exampleRef\")", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483467/210-10-45-1](\"https://asc.fasb.org/1943274/2147483467/210-10-45-1\")", "r669": { "role": "[http://www.xbrl.org/2003/role/exampleRef](\"http://www.xbrl.org/2003/role/exampleRef\")", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480678/235-10-S99-1](\"https://asc.fasb.org/1943274/2147480678/235-10-S99-1\")", "r670": { "role": "[http://www.xbrl.org/2003/role/exampleRef](\"http://www.xbrl.org/2003/role/exampleRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-30](\"https://asc.fasb.org/1943274/2147482810/280-10-50-30\")", "r671": { "role": "[http://www.xbrl.org/2003/role/exampleRef](\"http://www.xbrl.org/2003/role/exampleRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-31](\"https://asc.fasb.org/1943274/2147482810/280-10-50-31\")", "r672": { "role": "[http://www.xbrl.org/2003/role/exampleRef](\"http://www.xbrl.org/2003/role/exampleRef\")", "Topic": "2

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

~!F3N=&R!_V2TYOA*8S25_2/JPM@F-UN777JIS,ICPU0KT,MFOOPFVINC)-KLVMM&0\$U^OKKM=I-E-G*0J/WC5>?3G%_K<<1EH?DC,MKGK5?R5E<-SIV?TJ+TfW&0\$=-@_2Z5+!A6#-3+FPWZ,AV!SG8!NOQT,MF0E?ZKJF,K4DAW,R3/BH_K!P2WZCOWG24CW!H!BEBTNY=,/_D,=1Y!@0#2G,M!>JUF=D=-A-E?M-U!@QM;(:/6NMfP2&+0/\$~"VC_VJHVWTF->TZ-M*O-O-KA:PISC+Y+V+1\$>?X2N!E-._HYU-U+O=U16E9G!@O,MR,N2G_C_M3YV+(:/65V2TF9JEX?7D\$!-S!H-6_2AR-HN9Q5&N!\$N_~2,O?TQ9?P-MP?TEAR&~!N!16:G!PVZ>U!Y1+2?G,C32@T,F+BF@Q+!DBD6E!92&2!_D2_MX8SG6!_AHB9F?L-5FE&K,G+!"/R/_L=6!\$B5QD!@G-M-WLRD,9QOE,M0P>6\$;J+6+FIH!Q!0,2\$@#N!#=#G/_@_P2P\$IRFE@-./J+TR+P+*M:PVTW83Z?L_YG,VZD7?L\$JVG2_7VNWH!V4-YVQ!U+5_AJG9WG2C-M+5YU\$E_JXQF!V+90=N_~Z+!T\$MD4XW&+!A#RD7!K&VYXKRP!XEF+?M2?29!@HMCV!)_MHA_X\$84BZDFZ>LZ@E4M%=-X=2%1BQ(FB2!FJ2BMS&CNO!5KMV08-(C)!@H!M+0+U!(-H=IS!P!V!W02BF=-DG>I2&C!ARHVE+V-M+INXVY!N!N!@!B+!E9!V6-M!>S>?748X=R?OM!P!@!PRY;SPHF;W!L\$;X!51V@!@PAM3!+L4>4!@+C!M&CZ%_GUVQ6!TK3!6!K8-S!P!@1P!6P15<3!E)-S+!FGW!MF=U!C!@!Y!%CM_N0!HUT!M!H!L_KV,~!<5>C"!F"?R+!UB7WQD!5\$~5!5&!)V\$!\$2!4!2!P!5D!5MGR_~VWDK!M!FNU!QWGU+JURY-JY-JW\$84G;PY!BNTD?2_0?Q+Q@2!B3!MM>*!~DW&=6MOBK!U!ZK~!+WOA!0\$*~NU94R!@Q@E!DFV!P!L!H25!H1?C_VD-D/Y&Y!7!F0!M!CWV,3!L!2!Z>OGAT0,(YV6+4!R!H!T066:BIE\$AMOV0?@!J+O!O!O!M!&BMX&2E!V!70C&Y+ITfV!_XG!OD+!+ZVW!~M!SM&8;S!+*Z_Q15P_L@+M2!L!Y0D& (5!H,0Z_FJWE6ZNGE!UD6=@ZU?M!F!WROHMV3<=I2!94+V6_M!(\$S?Z_&4/Z^QX<6!NH_Y8BX_M!C\$B!8L@XO2H!\$!7!OE!>DD!F!F;NV@9_K!6QX!X!@2Q42!\$!N!U!H!>Z6(!+!H!E2!@!TPX_M!R>=!ZYO_M!>S\$96?T!PH0\$~2K!&K!+1>1=8\$4%_QUJNQ1.GN\$?)>4X%Y\$MAYC_M8L><1!C#>R@!#Y&C_&?S9W>3C!Y\$Y\$V!VH\$!#8790PN\$K075?E~Q!>D M!@!N!<+!4N0_*J~R=(AR_N!YPHW!UD_0!6D7Y:49450E+0P!0!E!E!)M!EDK\$5?_0!@K!X3?R!6P!68!2!IC12?7909NCSV7\$-!HQ3\$=B9H0!MN!K4!V!9HS3=-!R8>?FGZ_AZ#Y;&DYD\$!R8\$-!4+!\$&U!@~L60A=B-R5\$Y_M>^7W+SRU;U!G\$;YX!MFF04WVH&J!0!0&_C!X\$~!X?&#XZP~RK4B_Q45~KMRCB_74PD!P@~0!6\$KTU!_?Y!9!N+!(F!C!B!W!K!M!E,ZDAZ!@!WP2BH?D8H(X+@5!)@BP/>A!VX!X!Y08H!0!1!2-B6!0!V~6~6@+!M5M6;F;_!S;#_S?H24.R3P03?#0!2!@)!)M~%EV~6L!EL!\$+N!K&=&M_M!B!B=-%+!%>+!<5>2!2!0Z\$VN,(RH;E!)L_BRF!A!O!QZY~O?>7>+~!%2@!L!R!V!>N!>Y!>1!MTQ@Y=U!Y!A!0!JMG!6!U!_!Y!Y!X!L!C!&5!57!/_L!XO!0!U!G!Z_&MO!K4!9S_M!_GWD!13!R!>7!>=W!@!B!DZ!X6!+!E!H0!M!D!_!CF5=+!%NV_VHY!L!2!GP2Y!M!_0!H!D8P!N!U!VW!D!Y!V63_V!>4!&CLMG!G!_@390!104\$!>~!R_0\$Z!M!Y!E!CPL+4!9!>6!TK!>L!N!F!AM!S!QF6A@P!<+!&T!F!WZ!XW_M!@7@_863F*7E8!6N!QRA0!@QX<!Q+7!2@=<GL!A!3!59H!D!>7%2!HEK!<F!E_M0!P!P+O!<K!>SZ_V!33M!>_B9=<6!^00!DG<=Y!@F>50R&P!KE!L3!0%2&I!M3K!O_P7N2!HA0LRW3!0!60M/75!F!U!P,X3!E!H!HAJ;M!TQ?VP0A,2!T>=<M0!X\$5!LVY_O!C~R?G!Y?%)K\$5YH!4Y6\$-!/_FZKY+W!B!/_SH!@!X!8_MJC**0!58Z!_R!>J!>SOP!%2!%!DB-&ZQ~!>@!<5!+P!F!CH_4!H!>1!>G:2_M-MU_7!P!EW6!NRDN;99@=<Z?_H!G!H?Q?#P!P!V!R!A!Z!\$MAKEXBG!@!>6!M!L!>R@S_Q!H!<F!>D>2_XYV!ARFP**Z(2!6)!5+><6!U=&4R!0!E!W!4_T_VTX!X!ZK!P!<J!<H_MQEY!C!>C63!0W_!_MEHNAP7!TPK!ITFV!>+!LXU!IT!D2!2%0!2TC!_H!Z&L!T\$MB4PZ!37E!<K!XT!T_<Q\$>XPD!<Q\$>9YB!J!54!<I!C!0D!1\$!HPV!>0!K!J!B!MD_80V?E_G!66\$!5B!BLH_2!U6!AE!L&2C!E!G!&2!X4,BNR<27!MB!\$*8!M!>Y!T!M!>7!W!G!G&9>@W!A!F!2RBB!K!<Y_L!B!>H!H!FTM!>@F!X!A!O!V!D?_AY9>S=V5\$M4@ZC\$~_XB!Q!H_Y!<I02!LV3\$4!>C!<2RZ4C<J4N\$4!>XV!2!>+<S-R7X@?2!G8!E!<@Y\$A*6!I!M2?9!>4!H32!DZ!3!1T!>?<A>Y!L6!>A!B0!SGTW!>MW&@O_*C!F3<8N!M9!M_ML1=-!-(0003!U!H!_UH!H=-(P)!O!A!O!Z=2%N!Q!S*6!4M7+!#!%D7!@BB_!09_M!<5!9!%6!G!<@<5_R!R>K8!J=2\$!>9!R!J@?2!U!P!<4!>OMQ!A4?_7Q&0\$!>1!>6!&4!1!M7!P!<#3?>6!<+W_MG@8!>I2>GT_KZ!RM_50_NH6?S!OY!M!VX<?&S!AW-!?TC7>XRS6!>JAB!U\$<M3_@!%1%Y!>2H!4&2_3!>D!MHN!P6!TG!2!>I!>F!BGC!<F_&F!M8\$4!2!2F?Z_&G!3WY!>252!H!>/_UR~Y~2!NSH!L!KGS7>_!NM8!_ACX!T!+!MZ_!L!COP!\$%1!>KH!H5!>R!F!D!_!L0X!J!U!J!H!M!>L!O_G_M_2!H!H!5!K!\$!T!\$T!>U8C!G!WZ!>L!\$B!>B?Z!>2!M!_2!K!P!K!>13!P!>N!U!<6!5!4!P!P!9_VYOP@S_D20K\$5A0K!9B4!&6E@~%0!>X_MMU!H5!>4C_!WPGZ!Z!<3!NTO!Z!H!>2!>1>Z69!3Z_!C!Z!M32!>0>_!M=N!F4!&19%Y!V96;SWX!YV_YBM_H89!16FAET!>1!DD0!13!(M3Y_ZH<?2\$Y_M!<8R7Z!B5!GQ!<1+3!<^6?+OAK!>1!9!L\$%&2\$!>3!B0!>1!>DDH!F\$>S+7!M4!9!1!5\$R!>G+!+O=V!L!M5!2!>1!E2O!C!N!C!W!<F!>9>RX&K=S65?7M!>S!&M2!H!EVB6+MX<+!E&82!(08P!P!D!KX!H!>2!>1!X!H!>9!N!U!>Z_O!KQO!>M=7#F!2!3!N!0!K!J\$!>99NR!+0!P!>#!+!>1S>13\$>4X<Q>?<CNCL_8!%0!P!X!>M!M2Y!H89X!3!<R!M!F!M!<T!<L!<C&AP83=A=@~_!R!>8>G!T!D!<@<G;2!M!MD!<E9!52T\$>F!H4Q!DD!R!<G!<M!Z!U!Q!<6C!9Q!XG2!T!5!E!L!X!B!XW!H!>@!<L!<@!MX!<6!<XV!>U!>2!>@!B!<X!<6\$>4!>3!>4E!<6P_W!<K!<6!2!>

[illegible][illegible]

[illegible][illegible]

[illegible]

[The content of this block is extremely dense and appears to be a corrupted or heavily obfuscated version of a document. It contains numerous non-standard characters, symbols, and sequences that do not form recognizable words or sentences. The text is largely illegible due to the level of corruption.]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[Home](#) | [About Us](#) | [Contact Us](#) | [Privacy Policy](#) | [Terms & Conditions](#) | [Sitemap](#)

[illegible]

[illegible]

[illegible]

[illegible]

family:Arial,min-width:fit-content; > Unvested restricted stock units as of September 30, 2024</div><div id=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]